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Abstract
The ability to introduce a synthetic amino acid into a fully folded protein allows the
full power of organic chemistry to be applied to protein biochemistry.  Any
functionalized amino acid which can be incorporated by the ribosomal machinery may be
site-specifically introduced.  Through the application of chemical creativity, mimicry of
the natural behavior of protein side chains and the introduction of novel function may
both be attained.
As a class, integral membrane proteins require advanced biochemical tools for their
characterization, since many of the classical methods of biochemistry are not applicable.
These molecules represent an opportunity for the acquisition of unique information
through the use of unnatural amino acid mutagenesis.
Cell-cell communication is fundamental to neurobiology, and leads ultimately to the
phenomenon of consciousness.  The receipt of extracellular stimuli relies on integral
membrane proteins, and membrane-bound ion channels and receptors are the central
proteins of molecular biology.  Just as integral membrane proteins are well-suited to
investigation by unnatural amino acid mutagenesis, molecular neurobiology is an
excellent area for the application of this technology.
In the work presented here, tools for the measurement of physical organic parameters
associated with molecular recognition events and conformational changes of proteins are
developed and implemented in functioning neuroreceptors.  In addition, analytical tools
are introduced and deployed to investigate the real-time modulation of ion channel
function in living cells.
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After the work is introduced in Chapter 1, experiments on the use of fluorinated
tryptophan analogs to serially modulate the electrostatics of particular amino acid side
chains are presented in Chapter 2.  The goal of these investigations is to understand an
interaction between nicotine and tryptophan residues in the nicotinic acetylcholine
receptor.  Nicotine is shown not to experience a cation-π interaction with the side chain
that mediates this interaction between the receptor and its natural agonist, acetylcholine.
Additional studies on analogs of both nicotine and acetylcholine are presented, along
with attempts to extend the fluorinated tryptophan methodology to neuronal receptors of
the same class.
A series of dynamic amino acids are presented in Chapter 3.  The overarching goal of
these studies is to obtain information on ion channel conformation, both in situ and
subsequent to isolation.  A photoactive amino acid which induces proteolysis at the site
of its incorporation is shown to have significant effects on the nicotinic acetylcholine
receptor.  Efforts to extend this methodology to biochemically detect backbone cleavage
in the functionally affected receptors are also presented in this chapter.  Also, the
hydrolysis of an ester linkage introduced by the incorporation of a hydroxy acid in place
of a natural amino acid is attempted to identify the disulfide connectivity of rat P2X2
receptors.  Finally, attempts to utilize photoreactive amino acid side chains to both
crosslink adjacent subunits of the nicotinic acetylcholine receptor and to induce local
conformational perturbations in the transmembrane regions of this receptor are detailed.
In Chapter 4, tyrosine containing a photo-removable protecting group is introduced in
place of a particular tyrosine residue on which the modulation of Kir2.1 channel function
depends.  By this means, experimental control is gained over the chemical identity of this
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side chain.  As introduced, it is neither a substrate for tyrosine kinases nor for protein-
protein interactions.  However, once photolysis has revealed the wild-type residue, these
interactions may occur.  Co-injection of the tyrosine kinase v-Src along with the
irradiation of cells expressing Kir2.1 containing this caged tyrosine residue at position
242 produces a 50% current reduction over a time course of approximately ten minutes.
The roles of phosphorylation and endocytosis in causing this reduction were extensively
investigated.
The final chapter presents progress toward controlling the in situ phosphorylation
state of particular residues in a protein.  A general method for synthesis of caged
phosphoamino acids is developed and applied to the synthesis of analogs of serine,
threonine, and tyrosine.  A variety of routes toward caged non-hydrolyzable
phosphoamino acid analogs are shown, along with the preparation of important synthetic
intermediates.
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1Chapter 1. Unnatural amino acid mutagenesis in molecular neurobiology
1.1 The nature of the interface between chemistry and biology
The smallest meaningful unit of a biological system is probably the molecule.
Chemists working in the life sciences thus represent the reductionist extreme of biology.
Interestingly, biological molecules appear enormous and complex to chemists, and are
closer to the holistic end of our intellectual spectrum.  The individual biochemist, then,
seeks to publish in an environment where both reductionist and holistic thinking count.
The general tenor of biological investigation is less reductionist than our usual work, and
the viewpoint of most chemists is more so.  Thus, the challenge of biochemistry is often
pinpointing the specific interactions that interest us as chemists and yet putting them in
the perspective of their effect on organisms as a whole.  This increased level of generality
in biological chemistry often arises through method development.  To take a well-known
example, the 1991 Nobel Prize in chemistry rewarded the development of two general
methods, site-directed mutagenesis and PCR, which have driven much of the biology of
the last two decades.
The work presented in this thesis focuses in detail on a number of different proteins
and a variety of scientific questions.  Following the strategy suggested above, the
common theme is a technique.  The general method that unites the disparate elements of
this thesis is unnatural amino acid mutagenesis, performed on integral membrane
proteins, in living cells.
21.2 Nonsense suppression and molecular neurobiology – a felicitous combination
Actually, there is a common intellectual theme as well.  All of the questions
addressed in this work, though they may differ from the perspective of biochemistry, are
questions about neuroreceptors.  Molecular neurobiology is a science which has arisen in
the latter half of the 20th century.  The seminal predictions of Hodgkin, Huxley, and Katz
that ion permeability was responsible for the unique behavior of neurons and that
dynamic ion channels must account for electronic excitability, action potentials, and the
propagation of nerve signals were made largely from 1930-50.  In the latter decades of
the century, the molecules responsible for neural excitability began to be characterized at
the atomic level.
Ion channels and neuroreceptors are molecules like any other, and the full range of
techniques of molecular biology and biochemistry is available for their study.  They are
integral membrane proteins, however, and are thus refractory to many of the
manipulations available to soluble proteins.  However, they have a remarkable property
unavailable to other biological molecules.  Unique to these membrane-bound receptors is
the ability to regulate the flow of ions across cellular membranes.  This ion flux can be
very readily measured, and physiologists have developed sophisticated methodology for
studying this phenomenon.   In addition to making up in some ways for their challenging
biochemistry, the electrophysiological response of neuroreceptors is a very sensitive
technique.  Chemists are generally unused to being able to measure single-molecule
events, but the patch clamp permits the electrophysiology of single channels to be
measured.  If electrophysiology provides a sensitive means to detect the activity of ion
3channels, unnatural amino acid mutagenesis provides a sensitive method for manipulating
them.
The introduction of unnatural amino acids into proteins may be accomplished by
nonsense suppression.1-5  The particular codon in a gene which encodes the amino acid to
be replaced is changed to a non-coding, or ‘nonsense’ codon.  Typically, this is a stop
codon.  The conversion of a coding codon to a stop codon normally induces termination
of translation and a protein truncated at the position of stop codon introduction.  If,
however, the cell has also been supplied with tRNA molecules modified to recognize this
stop codon and carrying an amino acid at their 3’ end, translation continues apace.  The
suppression of the phenotype arising from the presence of a truncated protein in the cell,
caused by a nonsense codon, is what gives this phenomenon its name.  Nonsense
suppression may easily be achieved in an organism by the simple molecular biological
manipulation of mRNA and tRNA.
Nonsense suppression is used to introduce unnatural amino acids by charging the
suppressor tRNA with a synthetic amino acid.  It has been observed that the ribosome,
which is responsible for translating mRNA into proteins, is rather tolerant in its
accommodation of amino acid side chains.  In addition to the natural 21 amino acids
which are genetically encoded, the ribosome will accept quite a large number of
unnatural amino acids.  Thus, if a cell can be provided with two materials, an mRNA
altered to contain a stop codon and a tRNA engineered to recognize the stop codon and
carrying a synthetic amino acid at its 3’end, it is possible to introduce an unnatural amino
acid into a protein by nonsense suppression.  (Figure 1.1)  In this work, the nomenclature
4of nonsense suppression and unnatural amino acid mutagenesis will be used
interchangeably.
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Figure 1.1  Schematic of the components necessary for unnatural amino acid mutagenesis.  Left:
Unnatural amino acid, C-terminally activated as the cyanomethyl ester for chemical conjugation to
tRNA, and N-terminally protected for stability.  Center:  Suppressor tRNA (anticodon indicated in
red) and mRNA containing a stop codon (also red) at the site of desired synthetic amino acid
insertion.  Right:  Ribosomal translation, using the synthetically aminoacylated tRNA (blue) and
stop codon-containing mRNA (green) to generate a protein containing an unnatuaral amino acid.
The marriage of ion channel electrophysiology and unnatural amino acid mutagenesis
is consummated in the cells of a South African clawed frog.  The oocyte of Xenopus
laevis has been discovered to be an excellent vehicle for the functional expression of
a wide variety of molecules fundamental to molecular neurobiology.6 (Figure 1.2)
2 4 -72 hrs
mRNA + tRNA
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100 ms
uninjected oocytes oocytes injected
(Kir2.1 mRNA)
Figure 1.2  Xenopus oocytes are utilized in molecular neurobiology for the heterologous
expression of ion channel proteins.  Left:  Xenopus oocytes at 1x magnification.  Center:
Schematic showing the microinjection of mRNA and tRNA into oocytes, followed by the
expression of receptors (not to scale) at the cell surface.  Right:  Example of electrophysiological
data obtained by two-electrode voltage clamp from oocytes expressing a potassium channel Kir2.1
arising from nonsense suppression.
Physical injection of mRNA into oocytes (these are very large cells, approximately 1
mm in diameter, which is why they were selected for this purpose) usually results in the
expression of functional proteins.  In addition, it was demonstrated in our laboratory in
1995 that these cells may accommodate also the co-injection of synthetically charged
5suppressor tRNA, which results in the plasma membrane expression of ion channels
containing synthetic amino acids.7  Thus, in living Xenopus oocytes, unnatural amino
acids are introduced site-specifically into functioning ion channels.7-10  The behavior of
these channels may be measured using electrophysiology.
1.3 Implementation of the suppression method in molecular neurobiology
1.3.1 tRNA synthesis
The organic chemistry required to synthesize amino acids is clearly well-established.
However, the requirement to specifically attach a synthetic amino acid to a full-length
tRNA is potentially a much bigger synthetic challenge.11  A fundamental step in the
development of the unnatural amino acid mutagenesis methodology was the realization
that this synthesis may be largely avoided.12  The bulk of the tRNA may be prepared
using molecular biology.  Only a small piece is chemically synthesized, the dinucleotide
corresponding to the 3’ end of the tRNA.  The desired amino acid is chemically coupled
to this dCA dinucleotide (the cytosine 2’ hydroxyl is not necessary for translation, so dC
is used instead of C for ease of specific aminoacylation).  Then, the dCA-amino acid is
attached to body of the tRNA by enzymatic ligation.  The tRNA body itself is prepared
by runoff transcription from a plasmid template, a very standard molecular biology
procedure.
61.3.2 General considerations
1.3.2.1 Variability in suppression efficiency
The choice of which residue to replace clearly depends on the experiment.  This is
sometimes complicated by the fact that suppression efficiency is also highly variable
from residue to residue.  Some amino acids may not be readily replaced, or may be
replaceable by some unnatural side chains but not others.  In practice, we have identified
no reliable guidelines for predicting which sites will work well.  There is no substitute for
simply attempting incorporation of the desired amino acid at the desired position.
Fortunately, trying several different sites is a matter of fairly routine mutagenesis, so trial
and error is not terribly time-consuming.  There are a number of factors which may
account for the observed variability in suppression efficiency.
1.3.2.2 Optimizing translational efficiency
Factors associated with translation include codon context, read-through of the stop
codon, and effects from truncated proteins.  First, the 5' and 3' nucleotide sequence
around a stop codon can govern the efficiency with which it is suppressed by suppressor
tRNA's.13-16  Since some amino acids may be coded for by codons in unfavorable
contexts, suppression at these positions may be difficult.  It should be mentioned,
however, that we have never observed a clear correlation between suppression efficiency
and codon context, despite the large body of literature on the subject.  It could be that
trends are confounded by post-translational effects of incorporating unnatural side chains,
some of which are discussed below.  In any case, an unfavorable codon context can
sometimes be ameliorated via silent mutations around the desired site.  Codon bias,
7where a heterologous expression system may translate mRNA poorly because their native
codons represent rare tRNA's in the heterologous system, may be addressed similarly.17-20
A second difficulty which may arise at the translational level is read-through of the
stop codon.21  We use the term generally here to mean any process by which full-length
protein is produced which does not contain the desired unnatural amino acid at the
appropriate position.  This may occur if a) the stop codon is recognized by an endogenous
tRNA even without a perfect codon:anticodon match, or b) if the exogenously applied
tRNA loses its unnatural amino acid and an endogenous synthetase replaces it with a
natural amino acid, or c) if the anticodon is skipped to generate a mutant protein with a
deletion at the desired incorporation site.  Again, it has proven difficult to generate formal
rules for predicting the likelihood of these events.  Typically, the amount of injected
mRNA or, if applicable, the ratio of subunits to each other can be altered to reach a
regime where there is reasonable expression with little evidence of read-through.
Finally, suppression efficiency is far from quantitative, so translation frequently
terminates at the introduced stop codon.  When this occurs, the truncated protein which
forms must be checked for its ability to function, any deleterious effect on cell health, or
possible dominant negative effects.22,23  Particularly with suppression near the C-terminus
of polytopic membrane proteins such as receptors, partial-length proteins may be
trafficked to the surface and interfere with certain experiments.  Again, the best
experimental recourse might be to adjust the amounts of mRNA involved.
1.3.2.3 Efficiency of folding and assembly
A second class of complications has to do with folding, assembly, and trafficking of
proteins containing mutant side chains subsequent to translation.24-26  Once again, it is
8difficult to predict the side chains and sites at which this will be problematic.  Also, it can
be difficult to distinguish between improper folding and loss of function as a result of
unnatural amino acid incorporation.  These two scenarios, and also whether a problem is
translational or post-translational, may sometimes be distinguished by SDS-PAGE.
Separation of cytosolic from surface proteins followed by PAGE will reveal a) whether
or not full-length protein is being produced by the cell, and b) whether or not the receptor
is making it to the cell surface.
1.3.3 Essential controls
As a result of the translation and post-translational complications associated with the
nonsense suppression methodology, it is absolutely essential to perform the requisite
controls.  The incorporation of caged side chains has the benefit of conferring chemical
reactivity unavailable to the twenty naturally occurring amino acids, so it is usually
straightforward to distinguish between proteins containing caged amino acids and those
which do not.  Nonetheless, the following controls are necessary each time suppression is
attempted in a new receptor, at a new residue, or with a new amino acid analog.
1.3.3.1 mRNA only
Injection of the stop codon-containing mRNA without exogenous tRNA is a simple
experiment which controls for a number of outcomes.  If truncated protein is functional,
this control should reveal it.  Likewise, if read-through of the stop codon is occurring, it
will be evident.  The mRNA-only control with ion channels in Xenopus oocytes
frequently gives rise to measurable currents, for instance.  If a dominant negative effect
from truncated protein is suspected, it is again a simple matter to co-inject mutant mRNA
9with wild-type mRNA to see if the presence of the mutant RNA decreases the expression
of functional protein.
1.3.3.2 mRNA with uncharged suppressor tRNA
Even if read-through of the mRNA alone is not occurring, the presence of uncharged
exogenous tRNA frequently leads to full-length protein.  Presumably, the exogenous
tRNA is being recognized by endogenous synthetases or the suppressor tRNA facilitates
skipping of the stop codon to generate a deletion mutant.  Again, this problem can be
addressed by decreasing the amount of mRNA injected into the cell to find a
concentration which gives reasonable expression without measurable read-through.  In
this control, mutant mRNA is injected with 74mer tRNA enzymatically ligated to dCA.
Alternatively, mutant mRNA is injected with 74mer tRNA.  Eukaryotic cells transcribe
tRNA in a truncated form and enzymatically add the final CCA bases to the 3' end.  In
oocytes, the 74mer often gives rise to greater read-through currents than full-length tRNA
generated by ligating dCA to the 74mer.  This confirms that oocytes are capable of
completing truncated tRNA and suggests that perhaps dC at position 75 is a poorer
substrate for endogenous synthetases than C, or that interaction with the ribosome is
weaker, resulting in less full-length protein being produced.
1.4 Uses of unnatural amino acid suppression in molecular neurobiology
1.4.1 Structure-function studies
Because of the site-specificity of unnatural amino acid mutagenesis, it is an excellent
tool for determining the functional role and structural context of particular side chains.
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Since the range of amino acid side chains tolerated by the ribosome is rather generous, a
number of functional and structural probes may be introduced.1-5
Chapter 2 presents an example of such a use of unnatural amino acids.  This work
follows the initial observation by Wenge Zhong that nicotine appears to bind the nicotinic
acetylcholine receptor (nAChR) differently from either its natural ligand acetylcholine
(ACh) or the weak agonist tetramethylammonium (TMA).27   The chapter is largely based
on a Biochemistry paper written in collaboration with Darren Beene, who performed an
enormous amount of work on the neurotransmitter serotonin (5-hydroxytryptamine, or 5-
HT) and its receptor, 5-HT3AR.28  Valuable synthetic assistance was also provided by Niki
Zacharias, who prepared an N-alkylated analog of nicotine used in these studies.  The
second section of this chapter describes attempts to extend the use of our structure-
function probe to a class of nAChR found in the central nervous system (CNS).  Much of
this work was carried out with great persistence and skill by Lisa Turner, during the
summers of 1999 and 2000.
1.4.2 Dynamic in situ manipulation of ion channels
In addition to their use as probes, unnatural amino acids may be used to exert control
over biological molecules while they are functional and in their native environment.  This
ability is actually almost without precedent, and could conceivably be used to carry out
experiments which have no counterpart outside the realm of unnatural amino acid
mutagenesis.  Thus, there is undoubtedly information which could be supplied by these
techniques which would be of great interest to the biological community.  However,
experiments of this nature remain technically challenging, as can be seen in Chapters 3-5.
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1.4.2.1 Conformational studies
In Chapter 3, a number of experimental approaches to understanding details of the
conformation of ion channels are presented.  The first deals with attempts to site-
specifically cleave the backbone of a functioning ion channel.  This work is based on
imaginative chemistry developed by Dr. Pam England in this laboratory in 1997.29  The
experiments presented herein were carried out with a great deal of useful assistance from
her, and many of the ideas were developed with her guidance.  The second area treated in
this chapter is site-specific photocrosslinking.  This work mirrors conventional
photoaffinity labeling with the added benefit that the label may be introduced site-
specifically.  The experiments described in the section were carried out in collaboration
with Justin Gallivan, who prepared the unnatural amino acid used in the studies and
performed some of the electrophysiology.30  Thirdly, a method for determining disulfide
connectivity in folded, native proteins is presented.  This section is also based on a
method developed by Pam England.31  Experiments to determine the cysteine topology of
the ATP receptor P2X2 were carried out with intellectual input from her and both
intellectual and material collaboration with the knowledgeable and hard-working Dr.
Baljit Khakh.   Finally, a technique for dynamically altering the local conformation of a
native protein the vicinity of a particular residue is presented.  This work was carried out
almost entirely by Dr. Ken Philipson, who generously shared authorship on a paper in the
American Journal of Physiology for my assistance with the early phases of the project.32
1.4.2.2 Controlling protein-protein interaction and post-translational modification
The ability to introduce photoreactive amino acid side chains permits some control
over the chemical identity of particular residues.  Prior to photolysis, one chemical
12
species is present, while after photoinduced reaction an altogether different compound
may be present.  In Chapter 4, the photochemical conversion of a tyrosine analog to
tyrosine itself is presented as a means of controlling interactions involving a particular
Tyr residue.  This chapter is based in its entirety on a paper in the Journal of General
Physiology written in collaboration with Dr. Yanhe Tong, whose dedication in the face of
an extremely difficult and complex problem was necessary to shepherd the project to a
favorable conclusion.33  He was responsible for all of the electrophysiology reported in
this chapter, with the exception of the single-channel recordings, which were performed
by George Shapovalov.  Fluorescence assays were carried out with the able assistance of
Dr. Ming Li.  The introduction includes portions of an invited review in Methods in
Enzymology.34  The text is my own, written under the guidance of James Petersson and
with additional editorial assistance from Niki Zacharias.
In Chapter 5, a similar strategy of photoreaction is introduced as a means of
controlling phosphorylation, arguably the single most important biological regulatory
pathway acting at the protein level.  Where the work of Chapter 4 is based on revealing
wild-type tyrosine, the experiments in this chapter represent progress toward developing
a technique to reveal phosphoamino acids and their non-hydrolyzable analogs.  The
synthesis of these compounds was performed with the valuable help of Anita Choi, who
prepared caged threonine and the important synthetic intermediate nitrobenzyl
bromodifluorophosphonate, during the summer of 2002. Caged serine and threonine,
mentioned in this chapter, were synthesized earlier in this laboratory by Justin Gallivan.30
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Chapter 2. Cation-π analysis using fluorinated Trp derivatives
2.1 Introduction
From the perspective of the participating molecules, the lock-and-key analogy for the
binding of a neurotransmitter to its receptor is a rather optimistic description.  In fact, the
small molecule is tumbling, colliding with solvent molecules, spastically sampling
different conformations as it diffuses through the medium.  Upon entering the
electrostatic field of its receptor, it's violently jerked this way and that by the protein's
charged residues and hydrophobic cavities.  Likewise, the multi-subunit receptor
undergoes massive breathing motions on the timescale of the neurotransmitter's approach.
Obtaining atomic-scale information about a binding event in the midst of this chaos is not
easy.  Everything depends on having a probe in the right place at the right time.
Classically, probe introduction has been accomplished in two rather different ways.
Affinity labeling places the probe on the ligand and allows the receptor to position it
accordingly.  Any modification to the ligand which still allows binding may be
introduced, including reactive groups for photoaffinity labeling, for example.  The second
means of obtaining structural information about ligand binding has been site-directed
mutagenesis.  The desirable aspect of this technique is the ability to precisely target
single residues with discrete spatial locations.  However, only the chemistry available to
the natural amino acids may be utilized, such as disulfide formation using cysteine
residues.  As mentioned in the previous chapter, the extension of site-directed
mutagenesis to accommodate synthetic amino acids has led to entirely new kinds of
structural probes.  For instance, a series of fluorinated tryptophan analogs has been used
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in this laboratory as a sensitive probe of the role of side chain electrostatics in ligand
binding.1
Ligand binding is a central event in almost every aspect of biology, and molecular
neuroscience is no exception.  The binding of small molecule neurotransmitters to
membrane-bound receptors is the process which drives synaptic transmission.  The
advent of widespread cloning efforts in the past two decades or so has revealed the
primary sequence of a large number of neurotransmitter receptors.   Among the first of
these was the nicotinic acetylcholine receptor (nAChR).2  Attempts to understand the
principles of molecular recognition by which the nAChR binds its agonist initially
centered on attempting to reconcile the known amino acid sequence of the receptor with a
variety of biochemical, electrophysiological, and pharmacological experiments, the
conclusions of which have been extensively reviewed.3-9  Muscle preparations and the
electroplax organs of electric rays, which contain exceptionally dense clusters of nicotinic
receptors, were used to conduct these experiments before advances in molecular biology
made heterologous expression of the nAChR routine.  Physiological experiments
revealed that the nAChR is a cation channel which opens in response to acetylcholine, as
well as nicotine.  Furthermore, the apparent cooperativity of opening implied the
presence of at least two agonist binding sites.  Biochemical experiments involving
photoaffinity labeling had identified a number of aromatic residues, both tyrosine and
tryptophan, in the binding site.  The observation that nAChR agonists are uniformly
cationic had led to the expectation that anionic residues in the binding site would provide
the necessary electrostatic attraction to draw neurotransmitters into the binding site.
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However, it was also appreciated, particularly in this laboratory, that the aromatic
residues identified by labeling studies could stabilize agonist binding through cation-π
interactions.10  Based on studies of molecular recognition of cationic substrates by
synthetic hosts in water, the role of aromatic residues in binding acetylcholine was
proposed in 1990.11 In the absence of structural data on the nAChR, this proposal
remained an attractive hypothesis until 1998, when the interaction was demonstrated
directly.1 In this set of experiments, the series of fluorinated Trp analogs alluded to above
was introduced into the nAChR binding site by unnatural amino acid mutagenesis in
Xenopus oocytes.  At a single position in the binding site, a strict dependence on the
negative electrostatic potential on the surface of the aromatic side chain was observed.1
This dependence pointed to the role of Trp149 in ACh binding, via a cation-π interaction.
This assessment was subsequently confirmed in 2001 by the crystallization of a
soluble acetylcholine-binding protein from the snail Lymnaea helicalis.12 This
crystallography represents a watershed event in structural analysis of ligand-gated ion
channels, because the ACh binding protein (AChBP) is highly homologous to the
extracellular portion of the nAChR.  It is widely believed that structural insights gained
from the AChBP crystal structure will be transferable to the extracellular domain of the
receptor itself.  One small detail of the crystal structure was quite gratifying to this
laboratory.  Cationic HEPES molecules from the crystallization buffer were reported to
be bound to the face of the tryptophan homologous to the muscle Trp149 identified by
Zhong et al. in 1998.12
Some of the structural detail revealed by the crystal structure is shown in Figure 2.1.
Much of the gross structure had been previously gleaned from the physiological and
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biochemical experiments mentioned above, along with primary sequence analysis and
electron tomography.9  The receptor is a pentamer, composed of five subunits around a
central pore, which contains the ion channel region.
} membrane
Figure 2.1   Views of the nAChR based on X-ray crystallography of the highly homologous snail
acetylcholine binding protein.12 Top left:  Receptor electron density from electron
cryomicroscopy,9 superimposed over a ribbon diagram of AChBP, which corresponds to the
extracellular domain of the receptor.  Approximate location of bound agonist is indicated by the
red sphere.  Top right:  Detailed view of the binding site, showing the arrangement of aromatic
residues around the quaternary ammonium of the agonist.  Bottom:  Side and top views of the
receptor with binding site residues in the subunit highlighted in red rendered as stick diagrams.
The muscle receptor is made up of four different subunits, denoted α, β, γ, and ε.  The
fetal form of the receptor, however,  contains α, β, γ, and δ subunits, and it is this murine
embryonic receptor used in the experiments below.  In addition to the muscle-type
receptor, found at neuromuscular junctions, there are neuronal forms of the receptor.5,7,8
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Here, the subunit nomenclature differs somewhat.  One class of subunits, which are
identified by the presence of a vicinal Cys disulfide loop, is known as α.  The muscle α is
α1, and α2-9 are the neuronal isoforms.  All other nicotinic subunits in the CNS are
referred to as β, of which there are four known.  Again, β1 is the muscle subunit and β2-4
are neuronal subunits.
The pore region of the nAChR is made up primarily of the second transmembrane
region, known as M2.  The conformational changes accompanying agonist binding are
communicated to this transmembrane region, thus opening the channel.  Previous work in
this and other laboratories has identified mutations in the central region of this domain
which confer greater sensitivity to agonists.13-16 One of these mutations, Leu258Ser (also
called L9’S, using commonly accepted nAChR nomenclature), will be utilized in the
work below.
The binding domain, for which the structural information obtained from the AChBP
applies, is the focus of the work presented below.  The same series of fluorinated
tryptophan analogs that was used to identify Trp149 as the cation-π binding site of ACh
was employed to study the binding of a variety of agonists, revealing varying degrees of
interaction with aromatic residues in the binding site.  The behavior of nicotine was
extensively characterized, along with a number of related nAChR agonist analogs.  In
addition, the technique was extended to a related serotonin receptor, the neuronal 5-
HT3R.6,17  Unlike crystallography, this combination of unnatural amino acid mutagenesis
and pharmacology is able to give information from only a single residue, so it lacks the
scale of a crystal structure.  However, it has the advantage over a crystal structure in that
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it reports on the structure and function of residues in fully functioning ion channels in the
plasma membrane of living cells.
2.2 Results
2.2.1 Nicotine dose-response to Fx-Trp at α149
The response of nAChR to nicotine was measured by two-electrode voltage clamp of
oocytes expressing murine embryonic muscle nAChR.  These receptors contained a pore
mutation in the beta or gamma subunits, in order to reduce the EC50 and avoid channel
block at higher agonist concentrations.  Each L9'S mutation lowers EC50 by
approximately a factor of ten relative to wild type.  The effects of this mutation on EC50
are well-characterized, and it is expected not to alter agonist binding.14,15,18 Dose-response
curves for βL9'S receptors were collected by Wenge Zhong.19 When a L9'S mutation is
present in the β subunit, EC50 for otherwise wild-type nAChR is 45.3±0.6µM.  If a
single fluorine is added to the tryptophan ring by incorporating F-Trp at position 149, the
EC50 rises to 129.8±4.8µM.  This increase of almost threefold is comparable to the
fourfold increase observed with ACh.  What is observed, though, is that further
fluorination does not lead to a significant further increase the EC50.  A small increase is
noted for F2-Trp, as the EC50 is 172.3±5.7µM.  However, this is much smaller than the
factor of four which characterizes the ACh interaction with Trp analogs at α149.
Continuing in this vein, F3-Trp gives an EC50 of 187.8±11.4µM and F4-Trp produces a
receptor with an EC50 of 136.4±5.0µM.  Again, this increase is significantly less than
that observed for ACh, implying that nicotine may not interact with Trp149 through a
cation-π interaction.
21
The trend of these results was largely replicated in the receptor containing two L9'S
mutations, as seen in Table 2.1.  In this βγL9'S receptor, the EC50 for nicotine is 1.31 ±
0.45 µM.  Introduction of F-Trp at position α149 causes a small increase to 4.19± 1.00
µM.  However, further fluorination of the ring leads to little significant increase relative
to the tenfold increase seen with acetylcholine.  For F2-Trp, the value is 5.43±0.74 µM,
increasing slightly to 12.56±2.10 µM for F3-Trp and to 10.93 for F4-Trp.
L9’S Residue EC50 (µM) SEM nH SEM
β Trp 45.3 ± 0.6
β F-Trp 129.8 ± 4.8
β F2-Trp 172.3 ±5.7
β F3-Trp 187.8 ± 11.4
β F4-Trp 136.4 ± 5.0
βγ Trp 1.31 ± 0.32 2.92 ± 1.47
βγ F-Trp 4.19 ± 0.71 1.57 ± 0.09
βγ F2-Trp 5.43 ± 0.52 1.53 ± 0.08
βγ F3-Trp 12.56 ± 1.49 1.13 ± 0.07
βγ F4-Trp 10.93 1.28
Table 2.1  Nicotine dose-response data for oocytes expressing β and βγ L9’S nAChR suppressed
with the indicated residue at α149.
As an additional test that pore mutations exert their effects independently of binding
interactions between agonists and Trp149, the response of ACh to fluorinated Trp
analogs was measured in nAChR containing two L9’S mutation, in the beta and gamma
subunits.  (Table 2.2) These data replicate the trend observed for β L9’S by Zhong et
al.1,19
Residue EC50 (µM) nH
Trp ND ND
F-Trp 0.04 1.46
F2-Trp 0.13 1.49
F3-Trp 0.45 1.05
F4-Trp 0.86 1.06
Table 2.2 ACh dose-response data for oocytes expressing βγ L9’S nAChR suppressed with the
indicated residue at α149.
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2.2.2 Nicotine dose-response to fluorination at other binding site Trp residues
The above results raise the question of how nicotine is binding to the receptor, if it
does not rely on a cation-π interaction with Trp149.  One possibility is that it retains the
interaction, but with an aromatic residue other than Trp149.  In order to test this
hypothesis, a separate line of experimentation was undertaken involving probing other
aromatic residues in the binding site for cation-π interactions.  Initially, we focused on
tryptophan residues implicated in nicotine binding by mutagenesis and photoaffinity
labeling studies from other labs.3-6 As in previous work with acetylcholine, these residues
included αTrp86, αTrp184, γTrp55, and δTrp57.  However, while this work was
underway, the crystal structure of AChBP was published.  From the crystal structure, it
appears that of these four residues, only the γ55/δ57 pair are part of the agonist binding
site around Trp149.12 Because of this, only α184 and γ55/δ57 were tested.
The experimental procedure for this test was reported earlier.1 In brief, 5-CN-Trp or
5-Br-Trp is incorporated into the receptor at the position of interest.  Both these
substituents withdraw electron density from the tryptophan ring, but the cyano group is
much stronger in this regard than bromine, even though the two are similar in size.  The
calculated cation-π binding energy for 5-CN-Trp is 21.5 kcal/mol, relative to 27.8
kcal/mol for 5-Br-Trp.  The expectation is that an agonist binding to the face of an
aromatic ring at this position would be dramatically affected by the presence of 5-CN-Trp
at this position and less by 5-Br-Trp.  In the case of ACh at position 149, for example,
there is an approximately 50-fold difference between 5-CN-Trp and 5-Br-Trp.19 On the
other hand, if binding to the face of an aromatic at this position is not important, little
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difference between the two will be observed.  At position α184, for instance, the ratio
between 5-CN-Trp and 5-Br-Trp for ACh is 0.96.
As shown in Figure 2.2, nicotine shows no marked reliance on the aromatic face of
side chains at α184 or γ55/δ57.  At α184, the EC50 of receptors containing 5-CN-Trp is
nearly identical to that of those containing 5-Br-Trp, which is no surprise if the AChBP
structure reflects the actual structure of the nAChR binding site.  At  γ55/δ57, there is a
slightly larger effect.  EC50 for 5-CN-Trp is 1.43±0.18µM and 3.04±0.45µM for 5-Br-
Trp.  However, the ratio is approximately 0.5, well below that expected for an agonist
relying on the energetics of a cation-π interaction for binding and, in fact, in the opposite
direction.
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Figure 2.2  Nicotine dose-response for oocytes expressing nAChR suppressed at position α184
(left) and γ55/δ57 (right) with Trp (green), 5-CN-Trp (blue), and 5-Br-Trp (red).  Receptors
suppressed at α184 contain βγ L9’S mutations, while those suppressed at γ55/δ57 contain α L9’S.
From these data, we conclude that nicotine does not bind nAChR via a cation-π
interaction at any of the sites tested.  Most surprisingly, there is no apparent interaction
with Trp149, at which cation-π interactions were observed for ACh and for serotonin at
the homologous residue in the 5-HT3R.  In light of photoaffinity labeling of γ55 by
nicotine in experiments by Jonathan Cohen's lab, it is perhaps also surprising that the
cation of nicotine does not apparently interact with γ55/δ57.20,21
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2.2.3 N-methyl-nicotinium dose-response
One way in which protonated tertiary cations differ from quaternary cations is in their
charge density and ability to benefit from cation-π interaction with aromatic systems.
However, an equally important difference is that the protonated tertiary amine may lose
its proton and revert to neutrality, presumably resulting in a non-binding form of the
agonist.  This is in contrast to the quaternary ammonium center, which is permanently
charged under normal physiological conditions.  In the case of nicotine, the pKa of the
pyrrolidinium nitrogen is 7.8, quite close to physiological pH.22 Thus, it is quite
reasonable to suppose that the microenvironment at the nAChR binding site might be
sufficiently basic to induce deprotonation.  Further, it is reasonable to suppose that
perturbing the electrostatics of the side chain at α149 might alter the electrostatics of the
binding site in such a way as to promote or hinder deprotonation.  In order to test the
hypothesis that fluorination affects not only the cation-π binding ability of the residue at
α149 but also the protonation state of nicotine, a quaternary analog of nicotine, N-
methyl-nicotinium, was prepared by Niki Zacharias.22
Sterically, N-methyl-nicotinium is bulkier than nicotine, as a result of the additional
N-methyl group.  As discussed, the relatively diffuse charge density decreases the ability
of this quaternary cation to interact with the face of an aromatic residue relative to
nicotine.  Finally, the quaternary analog of nicotine is unable to undergo deprotonation
and thus serves as a test for the hypothesis that fluorination at α149 promotes
deprotonation and results in an apparent decrease in agonist affinity.  As shown in Table
2.3, the EC50 for N-methyl-nicotinium in βγL9’S nAChR is 0.77±0.14µM, quite similar
to that that of nicotine.  (Table 2.1)  In response to F-Trp, the EC50 increases fivefold to
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4.23±0.44µM.  Like nicotine, N-methyl-nicotinium does not respond significantly to
further increases in fluorination.  F2-Trp gives rise to an EC50 of 5.70±0.76µM, F3-Trp
to 3.27±0.44µM, and F4-Trp to 4.56±1.01µM.  Thus, it seems that changes in
protonation state do not account for the increased EC50 of Fx-Trp.  Furthermore,
quaternized nicotine does not appear to acquire a cation-π interaction.
Residue EC50 (µM) SEM nH SEM
Trp 0.77 ± 0.14 1.34 ± 0.07
F-Trp 4.23 ± 0.44 1.44 ± 0.08
F2-Trp 5.70 ± 0.76 1.42 ± 0.09
F3-Trp 3.27 ± 0.44 1.33 ± 0.07
F4-Trp 4.56 ± 1.01 1.05 ± 0.13
Table 2.3 N-methylnicotinium dose-response data for oocytes expressing βγ L9’S nAChR
suppressed with the indicated residue at α149.
2.2.4 Noracetylcholine dose-response
A complementary line of experimentation analyzed the behavior of a tertiary analog
of ACh.  The expectation, strictly on charge-density considerations, is that this agonist
should show a steeper slope in the plot of EC50 versus cation-π binding ability of α149.
However, the data do not conform to this expectation (Table 2.4).
Residue EC50 (µM) SEM nH SEM
Trp 22.75 ± 6.45 2.62 ± 1.00
F-Trp 161.03 ± 9.31 1.92 ± 0.26
F2-Trp 225.46 ± 27.92 1.62 ± 0.04
F3-Trp 326.59 ± 18.16 1.62 ± 0.03
F4-Trp 152.24 ± 4.31 1.53 ± 0.03
Table 2.4 NorACh dose-response data for oocytes expressing βγ L9’S nAChR suppressed with
the indicated residue at α149.
Noracetylcholine is vastly inferior to the natural agonist, with an EC50 of
22.75±6.45µM in the βγL9’S receptor.  Interestingly, the tertiary analog of ACh shows
a trend which is ambiguous as to whether or not it implies a cation-π interaction with
α149.  The EC50 for norACh in receptors containing F-Trp is 161.03±9.31µM, a
sevenfold increase.  However, EC50 with F2-Trp at α149 is 225.46±27.92µM, F3-Trp is
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326.59±18.16µM, and F4-Trp is 152.24±4.31µM.  As with nicotine, there is a formal
possibility that norACh is being deprotonated in the binding site, although the pKa of this
amine is greater (8.3).23
2.2.5 Variation of pH with tertiary ACh
Work by James Petersson in this laboratory has shown that the apparent local pKa of
amine-containing compounds in the muscle receptor binding site differs dramatically
from their behavior in bulk solvent.24 We reasoned that it may be such a distinction which
accounts for the marked difference in response to ACh and the very similar compound
norACh.  To provide an initial test of this hypothesis, the trend of activation by norACh
with varying pH was investigated.  (Figure 2.3)
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Figure 2.3  ACh and norACh response in αL9’S muscle nAChR measured at varying pH.  Mean
whole-cell currents were recorded in response to 10 µM ACh and 100 µM norACh, then
normalized to the maximal current and are reported as the mean value (±SEM).
The whole-cell current peaked at pH 7.5 for both agonists, and no great difference
was observed between the behavior of tertiary and quaternary analogs.  It may be that the
binding-site environment shields agonists from buffer pH effects, but the lack of overt
variation with pH is perhaps suggestive that  the potential proton lability of norACh does
not account for the difference between its behavior and that of ACh.
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2.2.6 TMA dose-response
It also appears that weak agonism does not necessarily correlate with lack of a cation-
π interaction with α149, since data for TMA reported by Wenge Zhong show the
expected trend for cation-π interactions.19 Here, the EC50 for βδL9’S nAChR is
47.6±1.7µM, comparable to that of norACh.  There is a significant increase with F-Trp,
to 155.4±3.5µM, and additional linear increase to 312.7±8.0µM for F2-Trp and
788.6±22.7µM for F3-Trp.  Thus, the absence of a cation-πinteraction between norACh
and α149 cannot be explained by the low efficacy of norACh relative to ACh.  Nor is it
the case that cation-πinteractions are only observed with quaternary agonists, as primary
and secondary serotonin analogs undergo the interaction with the 5-HT3 receptor.
2.2.7 Serotonin binding to 5-HT3AR substituted with Fx-Trp series at W183
The position in the 5-HT3AR homologous to α149 in the mouse muscle receptor was
substituted with the series of fluorinated Trp analogs.  The results for W183 suppression
were obtained by Darren Beene and are reported in Table 2.5.  As was observed for the
nAChR, the other Trp side chain which aligns with the conserved residues of the
aromatic box was tested and showed no difference between Trp and F4-Trp.  Thus, it
appears that the behavior of residue 183 is unique.
2.2.8 Binding of tertiary and quaternary 5-HT analogs
In an effort to understand whether ammonium centers with differing degrees of
alkylation, such as those of nicotine and ACh, interact more or less strongly with
aromatic residues, a series of N-alkylated serotonin analogs was tested on the 5-HT3AR.
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In the usual fashion, the series of fluorinated Trp analogs was incorporated at position
183 and dose-response relations collected.  (Table 2.5)
2.2.9 Involvement of hydrogen bonding at W183 investigated
As in the case of the initial studies on the nAChR carried out by Wenge Zhong, we
were mindful of the fact that fluorination of the tryptophan side chain changes the
hydrogen bond donation ability of the indole nitrogen as well as the electrostatic
character of the aromatic portion of the molecule.1 As before, in order to verify that the
observed effects were not due to hydrogen bonding, a series of non-hydrogen bonding
analogs of tryptophan with similar calculated cation-π binding energy was tested at
position 183 by Darren Beene.  The results of these experiments are also reported in
Table 2.5.
Residue EC50±SEM (µM) Hill coefficient±SEM
5-HT
Trp 1.21±0.06 2.0±0.16
F-Trp 6.03±0.51 1.4±0.14
F2-Trp 37.7±2.96 1.9±0.23
F3-Trp 244±8.4 2.5±0.17
N-Me-5-HT
Trp 1.82±0.10 2.5±0.13
F-Trp 2.70±0.17 1.9±0.19
F2-Trp 23.1±2.73 2.6±0.22
F3-Trp 368± 2.0±0.10
5-HTQ
Trp 1.07±0.07 2.1±0.25
F-Trp 1.65±0.15 1.65±0.19
F2-Trp 12.8±0.95 1.8±0.19
F3-Trp 284±18.7 2.0±0.15
5-HT
1-Nap-Ala 30.4±1.75 1.6±0.10
2-Nap-Ala 32.0±2.30 1.6±0.12
N-Me-Trp 25.6±1.66 1.8±0.16
Trp 90
Trp 1.21±0.06 2.0±0.16
F4-Trp 1.01±0.049 1.6±0.09
Table 2.5 Serotonin and 5-HT analog dose-response data for oocytes expressing 5−ΗΤ3ΑR
suppressed with the indicated residue at position 183 and, where indicated, 90.
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2.2.10 Efficacy
The EC50 for a receptor is a composite measurement, comprising multiple elementary
steps.  Even in the most simplistic two-state model of channel opening, agonist binding to
the closed channel is followed by a conformational change to an open channel state.
Since the dose-response measurement fails to deconvolute these two steps, experiments
were undertaken to determine whether binding or channel gating accounted for the
observed alterations in EC50 in response to increasing Trp fluorination.  The efficacy of a
compound on a ligand-gated ion channel is reflected in the maximal current passed at
saturating agonist concentration under given electrophysiological conditions.25,26 Relative
efficacies of all nicotinic drugs were determined in ND96 medium in oocytes clamped at
a membrane potential of -80 mV at a concentration approximately five times the EC50 of
the compound.  (Figure 2.4)
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Figure 2.4 Efficacy measurements for oocytes expressing βγ L9’S nAChR suppressed with the
indicated residue at α149ACh, in response to saturating concentrations of the indicated agonist.
Mean whole-cell currents were obtained and normalized to the maximal signal elicited for each
oocyte.  Normalized data were averaged and are reported along with SEM.  Concentrations of
each agonist were ACh, 10 and 100 µM; N-Me-nicotinium, 10 and 100 µM; nicotine, 10 and 100
µM; norACh, 100 and 500 µM; and TMA, 250 and 500 µM.
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For the nAChR agonists considered here, there was no significant difference in efficacy
among them.  Nor was the relative efficacy observed to differ in receptors containing
fluorinated Trp analogs.  There are some small effects, such as the apparent drop in
efficacy of TMA with F-Trp and norACh with F3-Trp, although in both cases the sample
size was small and at least one oocyte showed uniform efficacy for all five compounds.
Also, the measurements were taken at high concentrations, in order to obtain maximal
current.  Particularly with fluorinated Trp residues, the potency of certain compounds is
sufficiently low that maximally efficacious concentrations begin to overlap with
concentrations which induce channel block.  Data for TMA and norACh were
particularly affected.  Additional data were collected at -40 mV, in an attempt to reduce
open-channel block by these agonists, although it differed little from that collected at -80
mV.
The process of channel gating is a complicated one and is postulated to involve
numerous elementary steps for the nAChR.  Thus, it is overly simplistic to conclude from
these efficacy experiments that the effects observed are due exclusively to binding.27
However, the fact that all compounds tested exhibit the same efficacy is somewhat
suggestive that the effects we observe are primarily relevant to binding.  The ability of
these compounds to initiate the conformational changes associated with channel opening
is not apparently affected by the presence of variously fluorinated Trp analogs in the
binding site.  Thus, the large effects that we see on potency probably arise due to effects
on agonist binding.
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2.2.11 Results from neuronal nAChR
Unlike the muscle-type nAChR, neuronal nicotinic receptors uniformly show higher
affinity for nicotine than they do for ACh.5 It would be quite interesting to know whether
these high-affinity nicotine receptors bind nicotine via a cation-π interaction with the
Trp149 homolog, which is conserved across all nAChR.  However, these receptors
proved not to be amenable to unnatural amino acid suppression.  Wild-type recovery in
the α4β2 receptor was possible, although injection of 25 ng of total mRNA in various
subunit ratios gave rise only to several hundred nA of whole-cell current at -80 mV in
ND96 under the most optimal circumstances.  Fluorinated analogs expressed even more
poorly, with less than 100 nA whole-cell current.  As a result, dose-response curves could
not be collected for α4β2 receptors. Chimeric constructs consisting of the extracellular
domain of neuronal nAChR α4, β2, and α7 and the transmembrane domains of the 5-
HT3R have been shown to express better than native nAChR in numerous cell lines.28-32
These constructs also failed to give substantial currents in wild-type recovery suppression
experiments.  Work to increase the expression efficiency of neuronal receptors in
nonsense suppression experiments in Xenopus oocytes is treated in further detail in
Section 2.4.
2.3 Discussion
The binding of a neurotransmitter to its receptor is a testament to the organizing
power of weak, noncovalent interactions.  Determining the impact these low-energy
interactions have on a dynamic process such as molecular recognition requires that the
analysis, involving physical organic chemistry,  be carried out on a functioning integral
membrane protein.  The technique of introducing synthetic amino acid side chains
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through in vivo nonsense suppression is one of the few methods available for performing
such analyses.  In the case of the nicotinic acetylcholine receptor, we have previously
proposed a unique role for Trp149 in the alpha subunit in the binding of the natural
agonist, acetylcholine.1 The cation-π binding ability of the side chain at this position was
subtly and serially altered by introducing a series of increasingly fluorinated tryptophan
derivatives.33,34 (Figure 2.5)
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Figure 2.5 The series of fluorinated Trp analogues, with the gas phase cation-π binding energy of
fluoroindoles (HF 6-31G**) in kcal/mol.33,34
The ability of ACh to trigger receptor opening decreased with decreasing cation-π
binding ability of the side chain at this position.  From this, we concluded that α149
participated in a direct cation-π interaction with the quaternary ammonium center of
ACh.  More recent structural work from other labs has confirmed our conclusion and
provided much greater detail as to the composition of the binding site.12 (Figure 2.6 and
Figure 2.7)
muscle       TWTYDGS----VVAI NPESDQPDLS-NFME SGEWVIKESRGWKHS VTYSCCPDTPYLDIT YHFVMQRLPLYFIVN
5-HT3A       SWLHTIQDINISLWR LPEKVKSDRS-VFMN QGEWELLGVLP--YF REFSMESSNYYAEMK FYVVIRRRPLF----
AChBP        SWTHHSR----EISV DPTTENSDDSEYFSQ YSRFEILDVTQKKNS VTYSCCPEA-YEDVE VSLNFRKKGRSEIL-
  PDLVLYNNADGDFAI VKFTKVLLQYTGHIT WTPPAIFKSYCEIIV THFPFDEQNCSMKLG
  PDILINEFVDVGKSP -NIPYVYIRHQGEVQ NYKPLQVVTACSLDI YNFPFDVQNCSLTFT 
  PDLAAYN-AISKPEV LTPQLARVVSDGEVL YMPSIRQRFSCDVSG VDTESG-ATCRIKIG 
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5-HT3A 
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93149 190 198
Figure 2.6 Sequence alignment of muscle nAChRα, 5-HT3AR, and AChBP.12,35,36 The residues
which comprise the aromatic box are indicated with arrows, with the exception of the Trp residue
contributed by the interfacial subunit, which is conserved among all members of the nAChR
receptor family and which is γ55 or δ57 in muscle nAChR.
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Figure 2.7 Diffraction data from AChBP showing the quaternary ammonium center (blue) of a
HEPES molecule from the crystallization buffer bound to the face of Trp143, the homolog of
muscle nAChR Trp149 and 5-HT3AR Trp183. The residues  of the aromatic box comprising the
nAChR active site are numbered according to the nAChR muscle numbering.  Trp55 is from the γ
subunit.
In the work presented here, we extend this technique to consider the binding of the
pharmacologically important nAChR agonist, nicotine.  In addition, the approach of
altering side chain electrostatics is complemented by modification of the ammonium
center of both ACh and nicotine.  Finally, related work by Beene on the ligand-gated
serotonin receptor, 5-HT3R, is introduced to support and further the analysis of results
obtained on the nAChR.
2.3.1 Anomalous behavior of nicotine
Probing nAChR containing variously fluorinated Trp derivatives with ACh gives a
very clear relationship between calculated cation-π binding energy and the measured
dose-response.1 However, this is not true at all with nicotine.19 As may be appreciated
from Figure 2.8, fluorination of Trp149 gives rise to a receptor with diminished
responsiveness to nicotine.  However, further fluorination does not further impact
nicotine's ability to open the channel.  Thus, it does not appear that there is a direct
electrostatic interaction between the ammonium center of nicotine and Trp149.  Nicotine
34
is a full agonist for the nAChR and would be expected by all conventional
pharmacophore models to share roughly the same binding mode as ACh.37-42
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Figure 2.8  Electrophysiological analysis of nicotine. Left panel:  Nicotine dose-response relations
for βγ L9’S nAChR suppressed with Trp (O), F-Trp ( ), F2-Trp (◊), F3-Trp (), and F4-Trp () at
α149. (b) Fluorination plot for ACh (O) and nicotine ( ) at the nAChR.
2.3.2 Similarity between ACh and serotonin
The linear response to fluorination seen with ACh is not a property peculiar to the
nAChR.  The introduction of a series of fluorinated Trp analogs at position 183 of human
5-HT3R provides clear evidence for a cation-π interaction between this residue and
serotonin, as had been suggested by earlier studies from the Lummis laboratory.43 This
interaction appears to be unique to Trp183.  Substitution of the fluorinated Trp series at
other aromatic residues in the binding site region causes no significant effects.
Interestingly, the slope of the plot relating EC50 to calculated cation-π binding energy is
rather different than for ACh binding to nAChR.  Inspection of Figure 2.9 shows that the
serotonin slope is markedly steeper.  However, the similarity between these two
completely different systems is much more striking than the difference, in light of
observations on two highly related agonists at the nAChR.
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Figure 2.9  Fluorination plots showing dependence of ACh ( ) and 5-HT (O) on Trp fluorination
at position α149 in βγ L9’S nAChR and 183 in 5-HT3AR.  Fluorination plot (log[EC50/EC50(wt)]
versus calculated cation-π binding ability for the series of fluorinated Trp derivatives) for 5-HT
data fit the line y = 5.37 - 0.17x and for ACh  fit the line y = 3.2 - 0.096x. The correlation for both
linear fits is R = 0.99.
2.3.3 Expected behavior  of primary, tertiary, and quaternary ammonium compounds
In comparing ACh, 5-HT, and nicotine, a very evident difference is the nature of the
cationic center.  ACh contains a quaternary ammonium group, nicotine a tertiary N-
methyl-pyrrolidinium, and serotonin a primary ammonium.  (Figure 2.10)  From the
standpoint of molecular recognition by aromatic residues, these differences are expected
to be significant.  The three methyl groups of ACh carry most of the positive charge, and
they distribute it relatively diffusely and symmetrically around the nitrogen center.  At
the opposite extreme, serotonin bears most of the charge of its protonated ammonium on
hydrogen atoms close to the nitrogen.  The relatively higher charge density of the primary
center makes it more attractive to the face of an aromatic amino acid side chain, such as
tryptophan.  Nicotine occupies a middle ground in terms of cation-π binding ability, but it
is important to note as well that the distribution of positive charge around the nitrogen in
nicotine is highly asymmetric.
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Figure 2.10 Agonists utilized in this study.  Top:  nAChR agonists with AM1 electrostatic
surfaces showing the overall geometrical similarity of the structurally distinct nicotinoid and
cholinergic agonists. Bottom:  5-HT3AR agonists, with AM1 electrostatic surfaces showing the
varying charge density around the nitrogen center. Electrostatic surfaces were calculated using
Spartan and correspond to an energy range of -5 to +160 kcal/mol, where blue is positive and red
is negative.
Indeed, all three of these compounds are not modeled at all accurately by considering
a spherical distribution of charge, as would be the case for a sodium or potassium atom.
As a result, high-level quantum mechanical calculations of the kind performed for
fluorinated indoles are not feasible for these cations.  The issue of geometry is too
important and too difficult to assign to permit any kind of quantitative analysis.
However, it is the case that the two molecules which exhibit the hallmark of a cation-π
interaction with the Trp homologous to 149 behave as expected from this analysis.  In the
case of nAChR, the slope of plot of log EC50 vs. cation-π binding energy is rather
shallow.
Ab initio calculations show that the surface of F4-Trp is essentially electrostatically
neutral.33,34  Thus, a comparison of F4-Trp and Trp provides a measure of the electrostatic
component of the cation-π interaction. The F4-Trp/Trp ratio reflects the energy cost of
removing the attractive electrostatics but maintaining the residue, as if the Trp were
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replaced by a hydrophobic residue of the same shape. This new residue maintains most
van der Waals and dispersion interactions but cannot experience a cation-interaction. For
ACh, the F4-Trp/Trp ratio is 54. For serotonin, the F4-Trp EC50 value is obtained by
extrapolation of the line in Figure 2.9, which leads to a F4-Trp/Trp ratio of 836. If these
are viewed as ratios of binding constants, then the implied energetics of a cation-π
interaction are 2.4 and 4.0 kcal/mol, respectively, for ACh and serotonin. These are
consistent with other estimates of the magnitude of the cation-π interaction10  Based on
these calculations, it would appear that the primary cation interacts more strongly with
the face of tryptophan.
2.3.4 Experimental behavior  of primary and substituted ammonium compounds
Examination of the results for a series of substituted serotonin analogs shows that this
simple explanation does not do justice to the complexity of the molecular recognition
problem.  An N-trimethyl version of serotonin has a very similar charge distribution to
that seen for ACh.  However, Figure 2.11 shows clearly that the slope for this compound
is more similar to that of serotonin than that of ACh.  Indeed, a secondary analog of
serotonin behaves even more like the quaternary version than it does like 5-HT, thus
ruling out the hypothesis that slope of this plot reports in a simple way on the strength of
the interaction.  However, all three of these compounds follow the general trend that we
associate with an electrostatic interaction with Trp183.  As electron density is withdrawn
from the face of the aromatic side chain, the drugs are less and less effective agonists.
The EC50 rises, in fact, in a fairly regular way with decreasing cation-π binding ability of
the aromatic.
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Figure 2.11 Fluorination plots for N-alkylated serotonin analogs showing variation in dependence
on Trp fluorination at 5-HT3AR position 183.  Agonists are indicated by 5-HT (O), N-Me-5-HT
( ), and 5-HTQ ().
At first glance, these data appear mutually incompatible.  On the one hand, EC50 can
be tuned by varying the attractiveness of the aromatic side chain to the cation.  On the
other hand, varying the cation-π binding ability of the other partner, the cation, shows no
such trend.  We interpret this to mean that comparing a series of fluorinated analogs for a
given agonist represents the impact of changing electrostatics on a given binding mode,
namely, one where the cation is brought within van der Waals contact with the Trp
analog.  Predictable alteration of the energetics of this interaction gives rise to a
predictable trend in EC50.  When considering different agonists, however, the comparison
is potentially negated by the fact that the binding modes may be different.  The distance
of the cation from the aromatic face may be different; the geometry may vary, since the
highest region of local charge density is probably pointing toward the face of the
aromatic; the energetic contribution of other kinds of interactions with other parts of the
molecule may differ; and the ability of different agonists to gate the channel may
contribute.
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2.3.5 Potential acidity of protonated nicotine
Additionally, there is the interesting fact that serotonin analogs differ in a
fundamental way from what we have seen with nicotine and ACh.  While all the 5-HT
analogs show signs of an electrostatic interaction with Trp183, nicotine apparently does
not interact in this way with Trp149.  Having learned from the 5-HT3R that cation-π
binding ability of the agonist is not a good predictor of dose-response change with
increasing fluorination, we considered another hypothesis for nicotine, namely the
possibility of deprotonation.  Presumably, deprotonation would render the compound
unable to bind at all, since no neutral agonists of ligand-gated channels are known.  This
is a special concern for nicotine, as the pKa of the pyrrole is decreased to 7.8, almost
physiological pH, due to the inductive effect of the pyridyl ring.  It is a possibility that the
microenvironment of the binding site is such that it buffers the nicotine.  This could
explain why there is an apparent leveling in the EC50 response to increasing fluorination.
Rather than reflecting an electrostatic interaction between agonist and receptor, it could
be that the assay is reporting on changes in active site basicity as a result of incorporating
fluorinated indole side chains.  To test this hypothesis, a quaternary derivative of nicotine
was analyzed.
2.3.6 Behavior of tertiary and quaternary nAChR agonists
As is readily evident from Figure 2.12, nicotine deprotonation is unable to explain the
line shape seen in the plot of log EC50 versus cation-π binding ability.  N-methyl-
nicotinium is incapable of being deprotonated, but it gives very similar results to nicotine
itself.  Certainly, there is no regular increase in EC50 with increasing fluorination that
characterizes a direct electrostatic interaction with Trp149.
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Figure 2.12 Electrophysiological analysis of nicotine and its quaternary analog.  Left panel:
Nicotine dose-response relations for βγ L9’S nAChR suppressed at α149 with Trp (O), F–Trp ( ),
F2-Trp (◊), F3-Trp ( ), and F4-Trp ().  Center panel:  Dose-response relations for N-Me-
nicotinium for βγ L9’S receptors suppressed with Trp (O), F–Trp ( ), F2-Trp (◊), F3-Trp (), and
F4-Trp () at α149.  Right panel:  Plot of log [EC50/EC50(wt)] for ACh (O), nicotine ( ), and N-Me-
nicotine ( ) at the nAChR versus the calculated cation-π binding energy of the series of
fluorinated Trp derivatives.
Indeed, nicotine does not experience such an interaction with any of the aromatic
amino acids comprising the binding site, as inferred from the AChBP crystal structure.
Figure 2.2 shows that substitution of γ55/δ57 with Trp analogs of radically different
electrostatic character gives very little difference in EC50.  Additionally, earlier studies
carried out on Tyr93 and Tyr198 do not show shifts characteristic of nicotine-tyrosine
cation-π interactions.16 Substitution of Tyr190 with even very modestly different
unnatural analogs proved impossible, however, so we are unable to rule out the
possibility that nicotine interacts with this residue.
Where does this leave us as far as comparing the means of molecular recognition in
the two receptors?  The expectation for 5-HT3R was that modulation of the charge
density of the cationic center would track with the slope of log EC50 versus cation-
πbinding energy.  It stands to reason that the more energetic the interaction between
cation and aromatic, the more binding would depend on it.  In the simplest case of gas-
phase binding of ions to a series of fluorinated Trp's, the slope for Li+ would be greater
than Na+, which would be greater than K+, and so on.10 Clearly, the situation in the
binding site is more complicated than this.
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Where alkali metal ions are approximately spherical, the charge density of serotonin
analogs is highly anisotropic.  In fact, shape selection is usually considered to be
extremely important in the binding of small molecules in hydrophobic protein active
sites.44 The 5-HT3R has evolved to bind serotonin, which is a primary amine.  Even
though 5-HTQ binds and gates with channel with identical potency and efficacy to 5-HT,
it is safe to assume that the binding site is optimized for the smaller serotonin cation.  The
fluoro-Trp-based assay may, in fact, be reporting on extremely subtle differences in
positioning, as the electrostatic interaction between cation and πsystem is strongly
distance-dependent.  In the case where the natural agonists are being compared, as in
5–HT with 5-HT3R and ACh with nAChR, it may well be the case that the comparison is
significant.  Here, the systems are comparable, in that the binding site has been optimized
for best fit.  The implication that the productive binding mode for 5-HT is more
dependent on the electrostatics of Trp183 than is ACh on Trp149 may well be taken to
mean that non-cationic interactions with the receptor play a greater role in nAChR.
This interpretation is in some ways consistent with what was observed for TMA by
Wenge Zhong.19 This very simple cation is an agonist of nAChR, but with very low
potency.  Of all agonists tested, in fact, its potency is the lowest.  However, it exhibits a
cation-π interaction with Trp149.  (Figure 2.13)  In other words, productive binding of
TMA involves the quaternary ammonium group nestled up against the face of Trp149.
From the perspective of the aromatic box, when TMA gets this close, it is quite similar to
ACh.  The acetyl component of ACh doesn't have room to fit in the box, and probably
extends out of the box altogether during productive binding.  If TMA looks so similar to
ACh at its ammonium head group, then, is it safe to conclude that the additional potency
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of ACh comes from interactions between the acetyl group and another part of the binding
site?  It certainly seems so.  This is also in accord with what is observed for nicotine and
its N-methylated derivative.
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Figure 2.13 Plot of log [EC50/EC50 (wt)] for ACh (O), norACh ( ), and TMA () at the nAChR
versus the calculated cation-π binding energy of the series of fluorinated Trp derivatives.
Like TMA, these compounds are significantly less potent than ACh.  But unlike
TMA, they do not appear to come quite so close to the aromatics of the box during their
productive binding mode.  Indeed, no cation-π interaction is detected with any part of the
aromatic box.  Nonetheless, the compounds are reasonably efficacious.  The conclusion is
that the channel can be opened by compounds relying on interactions outside of the
aromatic box.  The most surprising result of all, a priori, is probably the behavior of
norACh.  (Figure 2.13)  The backbone of this compound is identical to ACh.  Any non-
cationic interaction available to ACh should be equally available to norACh.  Indeed, the
cationic center of norACh is an even better cation-π binder than the quaternary
ammonium of ACh.  However, norACh is an agonist of amazingly low potency.  It is
tempting to conclude that the aromatic box of the nicotinic receptor has evolved to
accommodate a quaternary ammonium, and anything smaller is rejected.  Until a tertiary
compound is discovered which displays an unequivocal cation-π interaction, this
argument may even be maintained.
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However, it is important to note that nicotine certainly opens the channel without
apparently coming in van der Waals contact with the aromatic box.  And productive
binding is primarily what one is interested in, as far as understanding channel function.
The neuronal receptors, for which nicotine is a far more potent agonist than the muscle
receptor, will present a very interesting system for study.  It is tempting to speculate that
these receptors contain aromatic boxes which are more accommodating of nicotine's
pyrrolidinium cation and allow it to behave like ACh in all respects.  It is also the case
that there are hundreds of interesting nicotinic agonists which remain unstudied by this
method, including the secondary amine epibatidine.  It is highly likely that high-
resolution structural data of AChBP may be able to shed further light on the varieties of
agonist binding modes.
2.3.7 Conclusions
In conclusion, we have learned several things from these studies.  First of all, it is
clear that 5-HT experiences a unique cation-π interaction with Trp183.  Furthermore, the
binding site of 5-HT3R is such that it can accommodate significant increases in bulk
around the ammonium center.  Even the quaternary analog retains a direct electrostatic
interaction with Trp183 and is an effective agonist for the channel.  Second, we have
shown that nicotine differs in a dramatic way from ACh in its reliance on direct
electrostatic interaction with nAChR Trp149.  This finding may prove to be relevant for
future generations of nicotinoid drugs.  Finally, we have determined that the fluorinated
Trp series works well as a general technique.  The differences in slope between the EC50
vs. cation-π binding energy plots of ACh and serotonin that it reveals may reflect
interesting differences in how molecular recognition of neurotransmitters by their
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receptors is effected.  It remains unwise to generalize too much about the nature of
molecular recognition of neurotransmitters by their receptors.  The amount of structural
information is still too limited.  However, elucidation of the atomic-level details of these
interactions continues, and the importance of these molecules to biology is so great that
we are optimistic that answers will be forthcoming.
2.4 Attempts to introduce unnatural amino acids into neuronal nAChR
2.4.1 Motivation
As indicated above, any serious study of nicotine and its analogs should most
properly be carried out on the receptors on which these compounds act.  In animals, these
receptors are neuronal nAChR.5,7,8,45 Mice in which either the α4 or β2 nAChR subunits
have been genetically knocked out show severely diminished self-administration of
nicotine, suggesting that these receptors play a substantive role in the physiological
effects of nicotine.46,47 Additionally, binding studies on brain slices from rats have shown
that the majority of nicotine binding in the brain is accounted for by α4β2 and α7
receptors.48,49
2.4.2 Expression of α4β2 in oocytes
Literature reports on the expression of α4β2 in oocytes present a variety of EC50
values for these receptors.50-53  Frequently, these differences are attributed to
heterogeneity of subunit stoichiometry.  This heterogeneity is expected to be a difficult
variable to control in a suppression experiment, where the amount of suppressed subunit
is difficult to control or predict.  In order to assess the behavior of α4β2 receptors in
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oocytes, wild-type receptors were expressed prior to the initiation of suppression
experiments.
Both α4 and β2 from rat were available in the pAMV subunit, from earlier work in
the laboratory by Mark Nowak.  In addition to these subunits, mutants containing α L9’S
were obtained and expressed.  Initially, these receptors gave rather inconsistent results,
particularly with regard to dose-response relations.  However, it was discovered that
changing to pH 6.5 gave much more consistent, and apparently normal behavior.  An
EC50 of 0.99 µM was obtained for ACh from the wild-type receptor, in accord with most
published reports.50-53  (Figure 2.14)  The Hill coefficient for this experiment, 0.80, was
also in the range of typically reported values.50-53
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Figure 2.14  ACh dose-response for wild-type rat α4β2 nAChR.  Left panel:  Individual traces
from two-electrode voltage clamp of oocytes treated with the indicated ACh concentrations.  Right
panel:  Dose-response curve for a single oocyte, plotting normalized ACh response against log
[ACh] and fitted to the Hill equation.
Because of the presumed stoichiometry of two alpha subunits and three beta subunits,
the use of βL9’S subunits was expected to give receptors with a dramatically shifted
EC50, so α 9’ mutants were used instead.  Unfortunately, these receptors proved
troublesome to characterize, because of frequent ill effects on oocyte health.
Initial studies attempting to introduce Trp at position α184, homologous to α149 of
the muscle receptor, produced absolutely minimal measurable response.  Currents were
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notably higher for suppression of alpha9’ subunits, although these receptors proved
difficult to work with, as mentioned above.  As the need for optimization became clear,
human α4 and β2 subunits were obtained, on the grounds that work on the human
receptor would have more direct relevance to the clinical pharmacology of nicotine.
Here, the wild-type receptors were obtained from Jon Lindstrom’s laboratory in the
pSP64 vector.  The overall level of expression of both human and rat α4β2 nAChR was
noticeably less than that of the mouse muscle receptor, but whole-cell currents of 3-5 µA
were routinely obtained.
2.4.3 Initial attempts at wild-type recovery by nonsense suppression
As in the rat receptor, the human α4 W182TAG mutation corresponding to muscle
α149TAG was made.  Attempts to recover wild-type activity by suppressing with tRNA-
Trp were disappointing.  The maximum whole-cell currents obtained were on the order of
50 nA, with median values in the range of 20 nA.  Co-injection of TAG-containing
subunits with wild-type subunits in the absence of suppressor tRNA was performed to
test for dominant-negative effects, with no evidence of such an effect.  The other residues
corresponding the aromatic box of the AChBP were altered to amber stop codons and
suppressed with Trp.  It was observed that the best suppression efficiency was obtained at
α182.  After many months of optimization, sufficient currents were achieved to collect a
dose-response curve for suppressed hα4β2 nAChR.  (Figure 2.15)  This experiment gave
an EC50 value of 0.6 ± 0.1 µM, with a Hill coefficient of 1.2 ± 0.1.
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Figure 2.15  Trp suppression of hα4β2 at the indicated position in the alpha subunit.  Left panel:
Mean whole-cell current (±SEM) in response to 20 µM ACh from oocytes expressing suppressed
α4β2 nAChR.  Right panel:  ACh dose-response curve from a single oocyte suppressed with Trp
at position hα4-182.  In all cases, 30 ng total mRNA (50:1 hα4-W182TAG:β2) was injected, and
recordings made 48 hr post-injection in ND96, pH 6.5.
 However, such expression levels were not typical, and even these whole-cell currents
were barely adequate for obtaining dose-response relations.  It appeared that poor
suppression efficiency was characteristic of α4β2 nAChR.  Accordingly, a broad-based
program to boost expression was undertaken.
2.4.4 Increasing translational efficiency
2.4.4.1 Use of vectors optimized for oocyte expression
One possible reason for low expression is that the suppressed subunits are not being
efficiently translated.  Given the importance of heterologous expression in Xenopus
oocytes to ion channel biology, a number of expression vectors have been developed and
optimized for expression in this system.  A vector developed in the Lester laboratory,
pAMV, has typically given good results.  This vector contains a 3’ UTR from alfalfa
mosaic virus, which is thought to confer upon the mRNA the ability to bind relatively
well to free ribosomes, thus providing a competitive advantage over endogenous
mRNA.54,55  Another common strategy for vector design has been to flank the desired
gene with 5’ and 3’ UTR from a highly expressed gene, such as β-globin.56 A vector
48
containing a multiple-cloning site surrounded by Xenopus β-globin UTR was obtained,
along with several others which have been reported to produce high levels of expression
in oocytes.
Unfortunately, two of these vectors (pBSTAII and pNKS)56,57 proved difficult to clone
the hα4 and hβ2 subunits into, and another gave no expression at all (pSGEM).58  The
complete lack of expression with pSGEM gave reason to believe that the latter constructs
were faulty, although restriction digestion and sequencing of the gene region appeared
normal.  Some favorable results were obtained with pAMV, particularly where
expression was measured two days after injection.  (Figure 2.16)
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Figure 2.16  Comparison of pAMV and pSP64 vectors for wild-type hα4β2 expression.  Left
panel:  Mean whole-cell currents (±SEM) in response to 20 µM ACh.  Right panel:  Mean whole-
cell currents (±SEM) in response to 20 mM nicotine.  In all cases, 27.5 ng total mRNA (10:1
α4:β2) were injected.  Recordings were made 48 hr subsequent to injection, at pH 6.5.
Whether or not this advantage is germane to suppression experiments remains to be
tested.
2.4.4.2 Overexpression of elongation factors
Another strategy which may increase translation is to boost the level of proteins
associated with translation.  One translation factor which is considered a promising
candidate for such up regulation is EF-1α.59 This elongation factor binds to
aminoacylated tRNA.  There is some evidence suggesting that this binding stabilizes the
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charged tRNA toward hydrolysis, which would be desirable.60 In addition, it is the ternary
complex of EF-1α, GTP, and aminoacyl tRNA which binds to the A site of the ribosome
in translation.61,62 The oocyte isoform of Xenopus EF-1α has been cloned, but repeated
requests for these constructs were ignored.63,64 Adult Xenopus EF-1α was available, as the
control RNA in the Ambion mMagic mMessage kit routinely used in the laboratory to
produce mRNA in vitro, and was also obtained from Paul Krieg.65 The two isoforms are
quite similar, so experiments were carried out with the adult isoform.
In a typical experiment, mRNA coding for EF-1α was injected 24 hours prior to the
injection of oocytes with nAChR mRNA.  Co-injection was also attempted, as well as
injection at a variety of intervals prior to nAChR mRNA injection.  Both wild-type and
suppressed receptors were examined.  In no case was a significant difference observed
relative to control oocytes.
2.4.5 Promoting folding, assembly, and transport to the plasma membrane
2.4.5.1 Use of epitope tags as a diagnostic
In addition to possible translational inefficiency, it may be that poor expression
results from compromised folding of suppressed subunits, assembly of subunits into
functional receptors, or transport of receptors to the plasma membrane.  Whether folding
and assembly or trafficking is the primary problem may be addressed by biochemical
analysis.  Synthesis of receptor subunits may be detected through Western blotting, a
technique which is treated in much greater depth in Chapter 3.  In brief, a crude protein
isolate from oocytes expressing the desired receptor is prepared and subject to gel
electrophoresis.  The proteins are thus separated by size.  They may be transferred to
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nitrocellulose, which is probed by antibodies.  The use of antibodies which specifically
recognize an antigenic determinant introduced in an epitope tag results in specific
labeling of the protein containing the epitope tag.  This technique is of value here,
because membrane preparations from the plasma membrane of the cell may be compared
to those from the cytoplasm.  If receptors are being synthesized but improperly trafficked,
this will be evident from staining of cellular membranes but not those from the plasma
membrane.
The HA epitope tag was introduced into the hα4 subunit, in two places, a region in
the M3-M4 loop previously determined not to affect expression of the muscle-type
receptor, and at the extreme C-terminus of the subunit.  Whole-cell currents from these
two constructs were compared to those of oocytes expressing wild-type α4β2.  While
current was almost completely eliminated in the C-terminal receptor, only a modest
diminution was observed for the M3-M4 HA tag.  These results were corroborated by
Western blots, both with protein produced in vitro and from the plasma membrane of
oocytes expressing the two different constructs.
Whether or not the HA tag will prove to be a useful diagnostic in following
trafficking of suppressed receptors awaits introduction of the epitope tag into TAG-
containing subunits.
2.4.5.2 Co-expression of dominant-negative dynamin
The presence of receptors on the cell surface is the result of a dynamic equilibrium
between forward trafficking from the ER and removal from the membrane by
endocytosis.  A dominant-negative dynamin mutant is available which greatly reduces
clathrin-mediated endocytosis.66,67 In certain cases, disruption of dynamin activity in
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Xenopus oocytes has been reported to increase ion channel expression severalfold.68,69  In
experiments with α4β2, no increase was observed through co-injection with dominant-
negative dynamin, nor was suppression efficiency improved.
2.4.5.3 Overproduction of BiP
The folding of membrane proteins is thought to be assisted by a number of ER-
resident chaperones.  Probably the best-characterized is BiP, a soluble protein present in
the ER lumen.  This protein has been expressed in Xenopus oocytes by the laboratory of
Käthi Geering.70 The construct was obtained from her laboratory, and experiments similar
to those reported above for EF-1α were carried out.  As with the elongation factor
experiments, co-expression of wild-type and W182-suppressed hα4β2 nAChR with BiP
appeared to have little effect.
2.4.5.4 FAYENE insertion
A study on expressing potassium channels in oocytes has suggested that the sequence
FCYENE is a forward-trafficking signal for these channels, which increased expression
four- to fivefold in heterologous expression in Xenopus oocytes.71 The report also
suggested that transferring this sequence to other channels had a similar effect, and that
the sequence FAYENE was likewise effective.  In order to avoid any complications
associated with introducing a cysteine residue, the sequence FAYENE was introduced
into hα4 in the same M3-M4 position which had proven successful for the introduction of
the HA epitope.  Comparison of these modified receptors with wild-type hα4 revealed no
apparent benefit of this sequence on whole-cell expression levels.
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2.4.6 Alternative strategies for increasing expression
2.4.6.1 Chimeric receptors
An altogether different strategy for circumventing the expression problems of α4β2 is
the use of chimeric  subunits.  The increased expression of 5-HT3R relative to α7 nAChR
has been traced to its transmembrane regions.72 The discovery by Changeux that a
chimera between the extracellular domain of α7 and the TM domains of 5-HT3AR shows
the binding properties of the α7  AChR raises the possibility that binding-site studies
could be carried out on chimeric receptors.29 The α4/5-HT3 and β2/5-HT3 chimeras have
been generated in the laboratory of Neil Millar and have been reported to assemble,
although no functional studies have yet been carried out.31,32 Nonetheless, these constructs
were obtained and injected.  A 1:1 mRNA ratio was initially employed, as the
stoichiometry of this chimera between a heteromeric and homomeric receptors is difficult
to predict.  This initial experiment gave no observable whole-cell ACh current, nor did
any variation of the relative amounts of mRNA improve upon this result.  It may be the
case that these chimeras are simply non-functional.  No binding studies were undertaken,
as the ultimate purpose of the experiment was to obtain functional data.
2.4.6.2 Multiple injection
A conceptually simple and usually effective method for increasing expression in in
vivo nonsense suppression is to multiply inject oocytes, typically at 24-hour intervals.  It
was this technique coupled with the use of the pAMV vector which gave the best
suppression results to date in α4β2 nAChR.  (Figure 2.17)
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Figure 2.17  Individual traces from two-electrode voltage clamp of oocytes expressing hα4β2
suppressed with the indicated residue at position 182 of the α4 subunit.  Oocytes were double-
injected (t = 0, and t = 24 hr) with 25 ng total mRNA  (1:1 α4:β2) and recorded from 48 hrs after
the initial injection.  Currents are in response to 50 µM ACh, and red bars indicate the duration of
its application.
These whole-cell currents are of sufficient magnitude that dose-response curves could be
measured.  Disappointingly, however, currents this large were unable to be obtained for
any fluorinated Trp residue, precluding the desired characterization of cation-π
interactions in neuronal nAChR.
2.4.7 Conventional mutagenesis experiments
A final experiment was undertaken to attempt to shed light on the differing modes of
nicotine and ACh binding between muscle and neuronal receptors.  The affinity of the
muscle-type receptor for ACh is significantly greater than its affinity for nicotine, as
noted above.  For all neuronal receptors tested, this affinity is reversed.50-53  In addition,
the muscle alpha subunit is alone among all discovered nAChR subunits in having an
arginine residue at the 55 position.  Every other subunit contains a tryptophan at this
position.  Even though our results above do not indicate a special relationship between
γ55/δ57 and nicotine in the muscle receptor, the photoaffinity experiments of Cohen are
suggestive of such a relationship.20  As a result, this residue was targeted for alteration by
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site-directed mutagenesis, and the relative potency of ACh and nicotine were tested on
the resulting mutants.
In the muscle receptor, an αR55W mutation was made and in hα4, W88R.  The
whole-cell currents in response to a variety of ACh and nicotine concentrations were
measured, in hopes of observing an alteration of the usual pattern of ACh and nicotine
potency.  (Figure 2.18)  The potency difference between ACh and nicotine at the muscle
receptor may be seen from the behavior of the wild-type receptor in response to three
concentrations of each agonist, 1 µM, 10 µM, and 100 µM.  The αR55W mutant seems
to have diminished ACh affinity, but without a corresponding increase in that of nicotine.
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Figure 2.18  Conventional mutagenesis of the position homologous to α55 in muscle nAChR in
muscle (R55W) and hα4β2 (W88R). Whole-cell currents in response to 1, 10, and 100 µM ACh
and nicotine, as indicated, are shown after normalization to the response to 100 µM agonist.  In
cases where multiple experiments were performed, SEM is indicated.  Dotted line is a guide only,
not a fitting of the data.  Left panel:  Comparison of wild-type and αR55W muscle nAChR
response to ACh and nicotine.  Right panel:  Responses of wild-type and W88R hα4β2 to ACh
and nicotine.
The responses of wild-type hα4β2 to both ACh and nicotine were almost identical.
Likewise, the response of the mutant W88R receptors to both agonists is very similar.
For both, the apparent effectiveness has been decreased in the mutant receptor, but
without the predicted switch in potency.  It is possible that detailed dose-response studies
of these mutants may reveal some interesting trends.  This initial study utilized only three
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concentrations of agonist, and concentrations that lie in very different regions of the dose-
response curve for ACh and nicotine, both of which may mask small effects on potency.
However, no dramatic reversal of ACh and nicotine affinities was observed, suggesting
that the identity of this residue is not determinative of relative  affinity for ACh and
nicotine.
2.4.8 Future directions
In order to precisely establish the role of cation-πinteractions in agonist binding to
neuronal receptors, it is necessary to develop relatively robust methodology for
introducing unnatural amino acids.  Thus far, the usual methodology applied successfully
to so many other receptors in this laboratory has failed to yield sufficiently large whole-
cell currents to obtain the necessary dose-response relations for α4β2 nAChR.  Through
the use of the pAMV vector and multiple injections, useful currents can relatively
reproducibly be obtained for suppression of α182 with Trp.  Attempts to extend to
fluorinated Trp derivative have thus far been unsuccessful.  A number of directions could
be pursued to perhaps achieve this goal.
First, recent results from the work of Nivalda Rodrigues-Pinguet and Bruce Cohen in
the Lester laboratory suggest that a threefold increase in whole-cell current from α4β2-
expressing oocytes may be achieved by potentiation with 3 mM Ca2+.  Although careful
controls would be required to verify that this potentiation is not accompanied by any
alteration in agonist affinity, this may be a simple and useful means to obtain usable
currents via nonsense suppression.  Second, there is reason to believe that the four-base
suppression methodology of Sisido et al. may give greater suppression efficiency than
amber suppression.73  Indeed, generation of the requisite constructs and tRNA’s with
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four-base anticodons was planned and undertaken, but difficulties in preparing them
prevented this methodology from being tested.  Third, there is the possibility that alpha7
nAChR, also thought to be an important pharmacological target for nicotine, may be
more amenable to nonsense suppression in oocytes.  Hong Dang, in the Lester laboratory,
has made the TAG mutant homologous to Trp149 in the chimeric construct rα7V201/r5-
HT3-AMV.  However, somewhat contrary to expectation, this construct expressed very
poorly in his hands.  In addition, we have the ‘WT’ version of this construct as well as
rα7 and cα7, both in the pAMV vector.  Because of our success with suppression in
homomeric 5-HT3, there is perhaps reason to be optimistic that suppression will work
equally well in α7.  In addition, there is an interesting observation in the literature that
cocaine (a tertiary amine) is not an agonist of α7, while the quaternary cocaine
methiodide is a rather good agonist.74
In general, identification of the molecular details which account for the difference in
potency between nicotine and ACh for muscle and neuronal nAChR is an interesting
question.  The conclusions from the fluorinated Trp study on the muscle receptor could
be augmented by studies on neuronal receptors that do not rely on nonsense suppression.
For instance, despite the similarity noted above in the muscle-type receptor’s response to
nicotine and the perpetually charged N-methyl-nicotinium analog, it may be the case that
neuronal receptors respond differently to these agonists.  In addition to pharmacological
studies of this nature, there is the possibility that comparison of the sequence similarities
and differences among AChBP, muscle receptors, and neuronal nAChR may provide a
guide for future experimentation.
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2.5 Experimental methods
2.5.1 Electrophysiology
Stage VI oocytes of Xenopus laevis were harvested according to procedures approved
by the Institute.  Recordings were made 24-72 hours post-injection in standard two-
electrode voltage clamp mode.  Oocytes were perfused in calcium-free ND96 solution, as
previously reported.1  Nicotinic agonists were either synthesized as described earlier (N-
methyl-nicotinium),22 purchased from Sigma/Adrich/RBI ([-]-nicotine tartrate) or Acros
Organics (the tertiary ACh analog, 2-dimethyl aminoethyl acetate).  Serotonin and its
analogs were purchased from Sigma/Adrich/RBI.  All drugs were prepared in sterile ddi
water for dilution into calcium-free ND96.  Dose-response data were obtained for a
minimum of eight concentrations of agonists for a minimum of three different cells.
Curves were fit to the Hill equation to determine EC50 and Hill coefficient.
2.5.2 Unnatural amino acid suppression in muscle nAChR and 5-HT3AR
Synthetic amino acids were conjugated to the dinucleotide dCA and ligated to
truncated 74 nt tRNA as described.75  Deprotection of charged tRNA was carried out by
photolysis immediately prior to co-injection with mRNA, in the manner described.1,76
Typically, 25 ng tRNA were injected per oocyte along with mRNA in a total volume of
50 nL per cell.  mRNA was prepared by in vitro runoff transcription using the Ambion
mMagic mMessage kit.  Mutation to insert the amber stop codon at the site of interest
was carried out by standard means and was verified by sequencing through both strands.
For nAChR suppression, a total of 4.0 ng of mRNA was injected in the subunit ratio of
10:1:1:1 α:β:γ:δ.  In many cases, non-α subunits contained a L9’S mutation, as discussed
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below.  Mouse muscle embryonic nAChR in the pAMV vector was used, as reported
previously.  For suppression in homomeric 5-HT3R,  5 ng of mRNA were injected.
Experiments involving heteromeric 5-HT3A and 5-HT3B subunits employed a total of 4.0
ng of mRNA in the subunit ratio of 10:1A:B.77  Mouse 5–HT3AR was used in all cases, in
the pAMV vector.  Negative and positive controls for suppression were performed in the
following way.  As a negative control, truncated 74 nt tRNA or truncated tRNA ligated to
dCA were co-injected with mRNA in the same manner as fully charged tRNA.  At the
positions studied here, no current was ever observed from these negative controls.  The
positive control involved wild-type recovery by co-injection with 74 nt tRNA ligated to
dCA-Trp.  In all cases, the dose-response was indistinguishable from injection of wild-
type mRNA alone.
2.5.3 Molecular biology of α4β2
In the course of attempting to introduce unnatural amino acids into α4β2 nAChR,
numerous constructs were made and obtained.  They are listed in Table 2.6.  All pSP
constructs were linearized with AseI and then transcribed using the mMagic mMessage
SP6 kit.  pAMV constructs relied upon NotI/T7, in the usual fashion.  The pSGEM
constructs we made gave no expression at all.  Additionally, testing the integrity of
individual subunits by co-injection with partners of known integrity (pSGEM-α4 +
pAMV-β2 and pAMV-α4 + pSGEM-β2) failed to result in expression.  Sequencing of
the region of sub-cloning appeared normal.  The SfiI-linearized pSGEM DNA gave the
appropriate UV spectrum.  The mRNA produced by the T7 kit was analyzed by agarose
gel electrophoresis and appeared very similar in size to α4 and β2 transcribed from pSP
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and pAMV constructs.  Nonetheless, it is likely that these constructs were faulty in some
way.  In all of the above experiments, mRNA amounts were not well controlled.  The
quantities injected were estimated by comparing mRNA band intensity on agarose gels to
that of pSP-α4 and pSP-β2 mRNA, and then diluting to give similar band intensities, but
this is a rather rough measure.
Construct Comments Source
pSP64-hα4 Jon Lindstrom
pSP64-hα5 Jon Lindstrom
pSP64-hβ2 Jon Lindstrom
pAMV-hα4 GSB/LJT
pAMV-hβ2 GSB/LJT
pSP64-hα4/M3-M4HA contains HA epitope GSB/LJT
pSP64-hα4/CTHA contains HA epitope GSB/LJT
pSP64-hα4/W88TAG Trp55 homolog GSB/LJT
pSP64-hα4/W119TAG Trp86 homolog GSB/LJT
pSP64-hα4/W182TAG Trp149 homolog GSB/LJT
pSGEM-hα4 failed to express GSB/LJT
pSGEM-hβ2 failed to express GSB/LJT
BiP Käthi Geering
EF-1α Paul Krieg
pSGEM Andreas Karschin
pBSTAII difficult to clone into Ligia Toro
pNKS difficult to clone into Günther Schmalzing
pRK5-rα4/m5-HT3 Neil Millar
pRK5-rβ2/m5-HT3 Neil Millar
Table 2.6  List of constructs utilized in α4β2 suppression studies.
The BiP construct was linearized with BglII and transcribed using the SP6 kit.70  With
regard to Xenopus oocyte EF-1α, Jane Frydenberg never responded to our e-mail request
for this clone.  Andre Mazabraud and Herman Denis at CNRS, Gif-Sur-Yvette also failed
to reply.  In the end, Paul Krieg at the University of Texas, sent us a plasmid containing
the adult form of Xenopus EF-1α.65  The experiments performed with EF-1α, however,
utilized adult Xef1, which is included as a control plasmid in Ambion kits, because of its
robustness in in vitro translation.  The linearized plasmid is included, and was transcribed
using the T7 kit.  Neil Millar's α4/5-HT3 and β2/5-HT3 constructs were linearized with
KpnI and transcribed using the SP6  kit.31,32
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Suppression in hα4 was attempted with Trp at positions 88, 119, and 182
(homologous to 55, 86, and 149 in muscle), despite the fact that the TAG mutants were
all in the pSP construct.  Low, but perhaps usable expression was observed at 182.  In
some experiments, mean currents of about 250 nA were observed, with individual
oocytes giving as much as 500 nA.  The very mRNA mixes used in these experiments
had consistently given only 20 nA currents over a year previously.  It may be that this
increase in suppression resulted from improvements that James Petersson made during
this time in the arc lamp setup.  None of these experiments was rigorously controlled with
74mer, although whenever we did suppress with 74mer, we got no current at all.  In
addition, a methodical study of subunit amounts and ratios was not carried out.
Since reasonable currents were being obtained with the hα4β2 mRNA mixes, an
attempt was made to introduce the 5-CN- and 5-Br-Trp pair at position 182.  Both times
it was tried, no currents were observed.  However, it was also the case that Trp
suppression on both days was giving much less than 50 nA whole-cell current.  The
second time, all three amino acids (Trp, CN-W, and Br-W) were double-injected, but
these oocytes failed to express even WT nAChR.  In general, there were oocyte problems
throughout the laboratory concurrent with these experiments.
Nicotine experiments were performed at pH 6.5, as were most ACh experiments.  In
general, ACh in pH 6.5 Ca2+-free ND96 gave the same current as it did at pH 7.5, which
is the normal pH of recording solution.
2.5.4 Introduction of the HA epitope into hα4
The HA epitope was successfully introduced into pSP-α4, at a position in the M3-M4
loop [PPQQPLEAE*KASPHP] homologous to the traditional 347 position  (see Chapter
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3) in muscle alpha, and also at the C-terminus immediately before the TAA codon
[WLAGMI*].  By in vitro translation, both constructs gave intense staining at about 55
kDa in a Western blot with BAbCo anti-HA antibody, using the usual protocol.
Electrophysiologically, we saw absolutely no current with the C-terminal tag construct
and about 78% of WT current with the M3-M4 HA construct.  mRNA levels were
reasonably consistent among the three constructs, but it would be unwise to rely too
much on these experiments for quantitative current comparisons, which were not our
intent in this study.  Membranes manually dissected from the very oocytes used for the
electrophysiology showed absolutely no staining for the WT and C-terminal constructs
and very clear, intense staining at unusually large molecular weights (doublets at ~100
kDa and ~200 kDa) for the M3 construct.  However, all of these experiments were done
only once each.
During the course of various  experiments, we saw small but measurable currents
from an alpha subunit co-injected with non-coding mRNA (in one case, for instance, the
mRNA was run off from a β2 construct where we had ordered a faulty primer and
inserted a frameshift in the second amino acid).  This may be something to be careful of
in future experiments.
2.5.5 Planning for four-base codon suppression
The most successful reported four-base suppression in both E. coli and rabbit reticulocyte
extracts employed the codon CGGG.78  In addition, AGGT was reported to work well in E. coli
extracts.73  In Xenopus laevis, AGG is fairly common (12.3 occurrences per thousand), whereas
CGG is rather uncommonly used (6.0 per thousand).79  In E. coli, these numbers are 1.7 for AGG
and 5.4 for CGG.  Least common non-stop codons in Xenopus are UCG (3.9), ACG (4.6), GCG
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(4.7), and CCG (4.8).  Comparable numbers for E. coli are UCG (8.6), ACG (13.8), GCG (31.8),
and CCG (22.0).79  As a result, we chose to emulate the strategy of Sisido in employing AGGT,
but also in order to minimize competition with endogenous tRNA’s, we also chose a codon based
on the least-used coding triplet, UCG.  The fourth base was somewhat arbitrarily made a G,
giving TCGG.  The initial experiments were specifically intended to increase the suppression
efficiency of hα4-W182 relative to conventional amber suppression with TH73G-Trp.  Thus, we
planned to prepare two mRNA’s, namely hα4 W182 CGGG and hα4 W182 TCGG.
We also chose to utilize two different kinds of tRNA.  One followed the strategy of Sisido,
and the other was derived from what is known to work for suppression in Xenopus
oocytes.73,78,80,81 Sisido’s suppressor tRNA is based on yeast Phe, quite similar to our MN3.  We
planned to use a version where nucleotide 73 has been changed to A, referred to as YF73G.  In
addition, we designed a modified TH73G to recognize the above four-base codons.  In total, we
planned to prepare five tRNA’s, YF73G CCCG, TH73G CCCG, YF73G CCGA, TH73G CCGA,
and YF73G CUA.  Difficulties in preparing the above constructs prevented us from trying four-
base suppression, although it may be an interesting strategy for future attempts to suppress in
α4β2 nAChR.
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Chapter 3. Analysis of protein conformation
3.1 Introduction
In the work presented in the previous chapter, unnatural amino acids were used to
make more subtle side chain perturbations than are possible using conventional
mutagenesis.  However, the range of side chain substitution permitted by the ribosome
allows for unnatural amino acids which induce much more radical transformations.  In
this chapter, nonsense suppression has been used to chemically modify proteins both
dynamically and after isolation from the membrane.  In the first case, nitrophenylglycine
(Npg) was introduced in order to photolytically cleave the polypeptide backbone at the
site of the amino acid’s introduction.1 The second set of experiments examined the
possibility of site-specific photoinduced cross-linking mediated by the unnatural amino
acid benzoylphenylalanine (Bpa).2 In the third study, hydroxy acids were inserted into the
backbone by nonsense suppression.3-5 The resulting ester linkage is labile to treatment
with strong base, which allows for the incorporation of hydroxy acids to be used for
mapping protein connectivity.4 Finally, cysteine and tyrosine residues with bulky photo-
removable protecting groups were used to induce conformational changes in a sensitive
transmembrane region of the nAChR.6
3.2 Site-specific backbone cleavage in nAChR Cys loop using Npg
3.2.1 Site-specific nitrobenzyl-induced photochemical  proteolysis (SNIPP)
Site-specific proteolysis is a fundamental step in a wide variety of biological
processes.7 A number of them have become widely publicized because of their role in
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human disease.8 Protease inhibitors for angiotensin-converting enzyme and HIV protease,
for example, are highly successful drugs.9  Targeted proteolysis is typically used at the
protein level to activate an enzyme by removing a regulatory domain which holds the
proenzyme in check.10  Among the many examples of this kind of regulation are the
caspases, tightly regulated proteases which initiate and carry out the proteolytic steps
leading to apoptotic cell death.  At the peptide level, potent peptide hormones are
synthesized as much larger polypeptides and released by cleavage into their active
fragments.  As previously mentioned, angiotensin is released this way into the
bloodstream.  Proteolysis also has a role in certain kinds of pathology.  The apparently
pathogenic Aβ fragment in Alzheimer’s disease is produced by aberrant proteolysis of a
precursor protein.11  A final strategy for proteolytic regulation has been only recently
recognized.  The protease-activated receptors are thought to be involved in pain
pathways, and thus are an increasingly recognized target for clinical intervention.12 These
G-protein-coupled receptors are activated only upon cleavage of an extracellular N-
terminal domain.
The ability to site-specifically cleave DNA revolutionized the practice of modern
biology.  It remains to be seen whether or not site-specific protein cleavage will have
such a great effect.  The most widespread method of experimental site-specific cleavage
is to introduce a protease site into the primary sequence of the protein.  This strategy has
been used to good effect in structural biology, where proteins may be purified by attached
affinity tags, which can then be proteolytically removed to allow characterization of a
more native protein.13  However, in situ studies which rely on proteolysis are more
difficult, since the proteases responsible for inducing the cleavage can be only under
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partial experimental control, at best.  Attempts have been made to adapt strategies which
have been successful for nucleic acids.  Molecules which bind specific DNA sequences
have been conjugated to metals or photo-excitable compounds, so that radicals induced
by these adducts may cleave the polyphosphate backbone.14  A similar, though non-
specific, strategy has been employed by Daniel Jay to hydrolyze proteins in the vicinity
of an irradiated malachite green-conjugated antibody.15 This technique is known as CALI,
or chromophore-assisted laser inactivation.16 The laboratory of C. V. Kumar has recently
introduced a more specific technique for inducing proteolysis this way.17 Here, dyes are
used which bind, under some circumstances, specifically to a given region of a protein.
Photolysis of the complex may produce radicals which cleave the backbone.18,19
The first general strategy for dynamically cleaving peptide backbones in functioning
proteins was only recently introduced.  This approach relies on the incorporation of the
unnatural amino acid Npg via nonsense suppression.  Photolysis induces proton
abstraction from the alpha carbon of the amino acid, leading ultimately to hydrolysis.1
(Figure 3.1)
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Figure 3.1  Mechanism of SNIPP - backbone cleavage induced by the photolysis of a protein
containing a nitrophenylglycine (Npg) residue.1
In this initial report, both transmembrane regions and intracellular protein domains were
cleaved photolytically in functioning receptors in living cells.  A more recent, although
less generally useful, derivative of this technique has also been reported, wherein allyl
glycine is cleaved by the addition of iodine.20-22
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The experimental site-specific cleavage of a protein backbone may be used in two
general ways.  The first involves mimicking a natural process.  For example, introducing
Npg into the linker region of a protease-activated receptor would place the receptor under
direct experimental control. (Figure 3.2)  This system would have the additional
advantage of generating a signal upon photolysis, whereas the channels examined to date
with Npg show reduced current after irradiation.
ONOFF
thrombin
thrombin
cleavage
site
Figure 3.2  Signaling is initiated by proteolysis of the extracellular N-terminal domain of
protease-activated receptors.12
A second use of in situ backbone cleavage is to attempt to map functionally important
regions of a protein.  This mapping is especially valuable in highly dynamic proteins,
such as receptors, where binding of a small molecule induces a conformational change
which must be mechanically transduced through the protein.  By severing the backbone
in a variety of locations, it may be possible to trace the path of conformational changes in
the protein.  (Figure 3.3)
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Figure 3.3  Schematic showing how site-specific backbone cleavage may disrupt the pathway of
mechanical coupling between binding site conformational change and channel opening.
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The ability to target cleavage to a specific residue in a functional protein is obviously of
paramount importance to this technique, and this specificity along with the technique’s
compatibility with living cells represent two of the principal advantages of nonsense
suppression.
3.2.2 Previous results with Npg in the nAChR
We have seen in the previous chapter how acetylcholine and nicotine binding may be
modulated in the nicotinic acetylcholine receptor.  Here, we turn our attention to the
biological consequences of agonist binding.  The binding of two molecules of agonist to
the receptor triggers a conformational change which opens the transmembrane pore of the
channel.  Relating binding to gating, as this conformational change is called, is
fundamental to the process by which a chemical synapse works.  The binding of
neurotransmitters released by the pre-synaptic cell to ion channels on the post-synaptic
cell allows the entry of cations into the post-synaptic cell, thus accomplishing
propagation of an action potential from pre- to post-synaptic cell.  Understanding, in
precise molecule detail, how this conformation change occurs in a protein such as the
nAChR could have important consequences, such as the ability to design molecules
which affect neurotransmission.  However, there are no analytical means available to
directly answer such a question.  Not only is dynamic crystallography a field in its
infancy, but multi-subunit integral membrane proteins such as the nAChR are
intrinsically extremely difficult to characterize crystallographically.
Given this experimental context, the ability to introduce unnatural amino acids into
functioning nAChR may provide an opportunity for understanding the conformational
change associated with gating.  In the initial report on Npg, data were shown for
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incorporation of this photo-cleavable residue into the Cys loop of the alpha subunit.1 The
Cys loop is a characteristic amino acid sequence which defines the nAChR family of
ligand-gated ion channels.23  (Figure 3.4)
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Figure 3.4  Presumed location of Cys loop in the nAChR,24 based on antibody binding studies and
apparent glycosylation of Cys142.
At the time this initial study was undertaken, very little structural information on the
positioning of this loop was available.  An NMR solution structure of a peptide
corresponding to the Cys loop, with and without N-linked glycosylation at Asn142,
showed the probable structure of the loop itself.25 Antibodies which were thought to
recognize the Cys loop appeared to bind only after certain maturational processes had
taken place, probably dimerization of subunit pairs.  However, binding ability was lost in
the fully folded receptor, suggesting that the Cys loop was occluded in the pentamer.26
From these studies, it was surmised that the Cys loop was positioned at inter-subunit
interfaces.24,27  Inter-subunit interfaces were in turn thought to be of critical importance in
both making up the agonist binding site, and communicating conformational change from
the extracellular binding domain to the transmembrane pore region, some 50 Å away.
Cleavage of the Cys loop in the nAChR alpha subunits had a dramatic effect.  Upon
photolysis, 90% of the whole-cell current was eliminated.  This current reduction was
unrecoverable.  This experiment appeared to corroborate the prevailing view of the
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importance of the Cys loop.  An additional experiment in the beta subunit was undertaken
to examine the ability of the residue to cleave in a transmembrane domain and also to
examine the effects of such cleavage.  As with alpha Cys loop cleavage, the effect was
expected to be marked.  The 9’ position of the nAChR is highly conserved, with a leucine
residue in all known receptor subunits.28  It was believed that the Leu residues from all
five subunits formed a hydrophobic plug of the pore, which was released during the
gating process by subunit movement.29  In accord with this prediction, photolysis of Npg
at the beta9’ position led to a 50% decrease in whole-cell current, again in an apparently
unrecoverable fashion.
Other than affirming the importance of these two regions to receptor function, it was
difficult to know how to interpret the results.  Binding studies implied that photolysis of
the Cys loop left the receptor able to bind ACh, so the effect appeared to be on gating.
However, was it possible to further interpret the result in a mechanistic way?  Could the
relative amounts of current inactivation be explained?  In an attempt to gather more
information on these important questions, two lines of experimentation were undertaken.
3.2.3 Experimental design
First, Cys-loop cleavage in all four nAChR subunits was planned.  The alpha subunit
appears to have a special role in receptor  activity.  In addition to its stoichiometric
double representation, it was thought to largely contain the agonist binding site.
Functional receptors may have a variety of subunit compositions and stoichiometries, but
alpha subunits are absolutely essential.  However, by the time the conformational change
associated with binding has been transmitted to the channel pore, each subunit appears to
contribute equally.  The additive nature of each subunit to the gating process was
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established, in part, by previous work from this laboratory involving replacement of the
Lue9’ residue with unnatural amino acids.30,31 By analyzing the effects of cleavage in the
non-alpha subunits, it was hoped that the results would provide additional information to
help delineate the contribution of all five subunits to agonist binding and to help interpret
the 90% current reduction observed on alpha Cys-loop photolysis.
Second, attempts were made to extend the analysis of Npg cleavage from
electrophysiology to direct biochemical observation of cleavage.  The complete scission
of a protein should be easily observable by techniques such as gel electrophoresis.
However, it was not known whether the small amounts of protein produced by nonsense
suppression in oocytes would be detectable.  It was hoped, again, that direct confirmation
of protein cleavage would assist in the interpretation of results obtained with Npg.
3.2.4 Results
3.2.4.1 Cleavage in non-alpha subunits
The requisite mutations were introduced in the beta, gamma, and delta subunits at the
positions homologous to alpha132 and 133, where the initial Npg results were obtained.
(Figure 3.5)
α: 128Cys Glu Ile Ile Val Thr His Phe Pro Phe Asp Glu Gln Asn Cys142
β: 128Cys Ser Ile Gln Val Thr Tyr Phe Pro Phe Asp Trp Gln Asn Cys142
γ: 128Cys Ser Ile Ser Val Thr Tyr Phe Pro Phe Asp Trp Gln Asn Cys142
δ: 130Cys Pro Ile Ser Val Thr Tyr Phe Pro Phe Asp Trp Gln Asn Cys144
Figure 3.5  Sequence of the Cys loop in all four subunits of embryonic mouse muscle nAChR.
In these experiments, the expected result was rather difficult to predict. A reasonable
presumption would have been that the contribution of different subunits in the
extracellular domain would be different.  After all, the arrangement of subunits around
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the pore calls for different interaction, at the very least, with the important alpha subunits.
(Figure 3.4)  The gamma subunit, which forms two interfaces with alpha subunits, must
have its Cys loop packed against an alpha subunit, if this domain is indeed interfacial.
Meanwhile, either the delta or beta subunit must not pack against alpha, because of
obvious topological restraints.  Upon incorporation of Npg into the receptor, photolysis
gave a uniform result.  (Figure 3.6)
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Figure 3.6  Photolysis of nAChR containing Npg in non-alpha Cys loops leads to a consistent
50% reduction in whole-cell current.  Left panel: Representative traces from oocytes expressing
nAChR with Npg at the γ133 position, without (left) and with (right) photolysis. Right panel:
Whole-cell currents from oocytes expressing nAChR suppressed at the indicated position in the
presence and absence of irradiation.  Filled bars represent mean current (±SEM) in the absence of
photolysis.  Hollow bars represent mean current (±SEM) from oocytes photolyzed for 4 hr.
In each case, approximately 50% reduction in whole-cell current was observed.  The
interpretation of this result is by no means straightforward.
One observation which complicates the interpretation of Cys-loop cleavage in non-
alpha subunits is the presence of large amounts of background current.  Suppression in
the alpha subunit of the nAChR typically works very well, with respect to the null
control.  Co-injection of mRNA and non-aminoacylated tRNA usually produces no
observable whole-cell current.  In non-alpha subunits, this null control is capable of
giving rise to currents of 50% of the maximum suppressed current.  (Figure 3.7)
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Figure 3.7  Whole-cell currents from oocytes expressing nAChR suppressed with Npg show both
the significant background and clear effect of photolysis.  Mean currents(±SEM) in response to
200 µM ACh, 24 hr post-injection.
The reason for this difference in behavior is unclear, but there is always concern that
receptors with truncated non-alpha subunits or even with non-canonical stoichiometry
(α2βδ2, for example) may be functional.32  Alternatively, it may be the case that the
amounts of read-through (the term is used here to refer to the formation, by any
mechanism, of full-length protein which lacks an unnatural amino acid at the desired
position) are small, and that the requirement for two alpha subunits means that very little
functional protein is formed which has two alphas arising from read-through.  In any
case, the large currents seen with this control complicate the analysis.  Photolysis
generally brings the level of whole-cell current down to the level of read-through current.
Should photolysis then be scored as 90-100% for all subunits?  Or, is it rather the case
that the vast majority of functioning receptors on the surface of an oocyte injected with
charged tRNA arise from suppression, and that photolysis of non-alpha receptors gives a
50% current decrease?  One way to differentiate between these possibilities would be to
analyze the products of nonsense suppression with Npg by polyacrylamide gel
electrophoresis.
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3.2.4.2 Attempts to visualize proteolysis by PAGE
Since electrophoresis separates proteins by mass, photoinduced cleavage should be
very evident in PAGE.  Since cleavage requires the presence of Npg, it should also be
straightforward to distinguish between suppressed protein and full-length protein
produced by read-through.  Suppressed protein should be cleavable by irradiation,
whereas read-through protein will not be.  It should be noted that, in the absence of direct
evidence for cleavage, there is an additional difficulty in interpreting an experiment with
Npg.  Has the residue actually cleaved the backbone, or has some conformational change
occurred which produces the observed effect?  Thus, the ability to directly observe
cleavage would simplify analysis by reducing the number of formal possibilities that need
to be considered to explain a given result.
The first thing which needs to be established is whether or not protein from
suppressed oocytes can be detected by PAGE.  The three most common ways of
visualizing expressed protein are staining by dyes (Kumasi blue, silver, Ponceau, etc.),
detection with antibodies in Western blotting, and by radiolabeling the protein, usually
metabolically.  These three assays vary in both sensitivity and specificity.  Given that
oocytes are very large cells with large numbers of membrane proteins, as well as yolk
components and vitelline membranes, it was thought that Western blotting might provide
an appropriate level of specificity.  Sensitivity in a Western blot is largely governed by
the affinity of the antibody for its protein target.  A number of subunit-specific nAChR
antibodies exist which are competent to recognize the denatured protein present in
PAGE.  However, greater sensitivity may often be gained through the use of epitope tags,
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where epitopes for which very high-affinity antibodies exist are introduced into the
protein.
Figure 3.8 shows that nAChR from oocytes suppressed with Npg may be detected in
Western blotting with anti-nAChRα antibodies. Note also that large amounts of truncated
protein are detected in this assay.  The domain recognized by Mab 210 is in the
extracellular region of the protein, N-terminal to the introduced stop codon.33 The rather
large ratio of truncated to full-length protein illustrates the partial efficiency of the
suppression process.  In addition, the lack of signal for nAChRα suggests the need for a
more sensitive assay.
97.4
66
46
30
21.5
14.3
Npg dCA
Figure 3.8  Western blot of total membrane preparations from oocytes expressing nAChR
suppressed with Npg at position α132, using Mab210 as the primary antibody.33  Solid arrow
indicates full-length alpha subunit.  Hollow-headed arrow indicates protein truncated at the 132
position.
Initial attempts to introduce epitope tags into nAChR subunits focused on two widely
used tags recognized by the FLAG and HA antibodies.  Introduction of an epitope tag
potentially constitutes a significant perturbation of the protein’s structure.  The FLAG
epitope is a highly charged sequence of amino acids, optimally DYKDE.34  The HA
sequence is the nine-amino acid YPYDVPDYA.35,36  In order to determine whether or not
introduction of the epitope tag sequence was disruptive to the receptor’s function, the
79
sequences were introduced into a number of regions and the expression of the receptors
tested.  The FLAG tag had dramatic and negative effects, almost completely eradicating
whole-cell nAChR current in all four positions.  The HA tag was also highly disruptive at
one position in the M3-M4 loop and also at the C-terminus.  However, a site with
minimal effect on whole-cell current was identified.  In addition, it was verified that the
HA tag could be introduced at the homologous position in each of the four nAChR
subunits.  (Figure 3.9)  Non-alpha subunits were generally somewhat more tolerant, in
that C-terminal HA tags were accepted with little loss of expression.  However, for
general use the M3-M4 loop position which worked well for alpha was adopted for the
other subunits as well.  (Figure 3.9)  Finally, dose-response relations were found to be
unaffected for HA-containing receptors relative to their wild-type counterparts.
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Figure 3.9  Effect of the introduction of the HA epitope tag into nAChR subunits on whole-cell
ACh current in response to 200 µM ACh, 24 hr post-injection.  Left panel: Mean whole-cell
currents (±SEM) resulting from injection of 780 pg mRNA [2:1:1:1] containing an alpha subunit
with HA tag inserted at the indicated residue number.  Right panel:  Mean currents (±SEM) upon
injection of  nAChR subunit mRNA, where the indicated subunit contains the HA tag at the M3-
M4 loop position homologous to α347.
The ability of the epitope tag to render the subunits detectable in Western blots also
had to be tested.  Isolation of membrane proteins from Xenopus oocytes was undertaken
in two ways.  The first preparation relies on ultracentrifugation of homogenized oocytes,
to harvest all of the cell’s membranes.37,38  If sub-cellular fractionation of the various
internal membranes is required, this total membrane preparation may be subjected to
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sucrose-gradient centrifugation.39,40  This technique separates the membranes by density,
which differs as a result of the varying lipid and protein content of various membrane
compartments.  Figure 3. shows the results of membrane fractionation.  The direct
comparison of staining with the anti-HA and Mab210 antibodies shows the superior
signal strength of the antibody directed against the epitope tag.
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Figure 3.10  Isolation of nAChR from the surface of Xenopus oocytes by ultracentrifugation of
homogenized oocytes followed by sub-cellular fractionation by sucrose step gradient.  Fraction
number is indicated above each lane, and molecular weight is indicated to the left.  Left panel:
Staining with HA.11.  Right panel:  Staining with Mab210.  EP indicates a protein sample from
electroplax organs of the Torpedo ray (provided by Anthony West).
There are a number of enzyme activity assays which may then be carried out to identify
individual membrane fractions.  For example, the plasma membrane is the only oocyte
membrane to contain a Na+/K+ ATPase.  Thus, assaying the various fractions for this
activity uniquely identifies the plasma membrane.40 (Figure 3.11)
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Figure 3.11  Assay for the plasma membrane-resident Na+/K+ ATPase, showing that activity is
greatest in fractions 5 and 6, which are thus identified as containing the plasma membrane.40  The
assay is based on detection of inorganic phosphate and was carried out by Yan Dang.
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A second means of harvesting membrane proteins from oocytes involves physical
dissection of the cell.41  Unlike most cell types, Xenopus oocytes have an external
glycoprotein membrane known as the vitelline membrane, for its glassy appearance.
Unlike a lipid bilayer, this vitelline membrane retains a great degree of structural integrity
when isolated from the cell.42 This rigidity is exploited in a method which fuses the
desired plasma membrane with the hardier vitelline membrane.  Treatment of the oocytes
in a hypotonic solution effects this fusion, as the oocyte swells and the two membranes
come in contact.41  The dissection was found to be facilitated greatly if trace amounts of
detergent were present in the hypotonic solution.  Figure 3.12 shows membrane proteins
isolated from oocytes by physical dissection in the presence and absence of detergents.
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Figure 3.12  Epitope-tagged nAChR subunits isolated from the oocyte membrane and subjected to
Western blotting with anti-HA antibody.  Subunit which contains the HA tag is indicated above
each lane.  Note significantly more intense staining of alpha subunits.  Left:  Fraction 5 from
sucrose step gradient subsequent to whole-cell homogenization.  Right panel:  Protein isolated by
physical dissection of oocyte plasma membrane.  The non-specific staining in the βHA lane was
not typical.
The combination of these techniques to isolate membrane proteins and the use of the
HA epitope thus proved satisfactory for visualization of proteins containing unnatural
amino acids.  It should be noted that staining of non-alpha subunits by the HA.11
antibody is considerably less intense, a phenomenon which is ill-understood but highly
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reproducible. Given receptors which may be detected by Western blotting, the analysis of
photo-cleavage appeared very straightforward.
Oocytes were irradiated with light of the appropriate wavelength, and whole-cell
currents were measured to ascertain whether or not photolysis had occurred.  Cells for
which current reduction was observed were collected and their membranes harvested for
Western blot analysis.  In comparison to control oocytes which had not been irradiated,
no differences were ever observed.  (Figure 3.12)
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Figure 3.13  Western blotting of suppressed nAChR βHA L9’TAG and effects of irradiation on
Npg-suppressed oocytes.   Left panel: Demonstration of suppression at β9’TAG.  Lane 1:
Uninjected.  Lane 2: mRNA + tRNA-dCA.  Lane 3: mRNA + tRNA-Val.  Lane 4:  βHA standard.
Nine oocytes per lane.  Right panel:  Effect of irradiation of membrane fraction 3 from oocytes
expressing nAChR suppressed with Npg at β9’.  Lane 1:  Irradiated.  Lane 2:  non-irradiated.
Four oocytes per lane, whole-cell irradiation for 4 hr at 0 °C.
The explanation for this inability to detect protein fragmentation in response to irradiation
remains very unclear.  A number of factors complicate the ability to correlate the
intensity of bands on the gel to the electrophysiologically observable effect of photolysis.
3.2.4.3 Read-through gives background current and gel bands
It seems evident that there is some read-through of stop codons, as full-length
epitope-containing proteins may readily be detected in oocytes co-injected with
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uncharged tRNA.  The degree to which read-through is observed is rather variable, as
may be seen by comparing the relatively light band intensity in Figure 3.13 with the
currents observed in oocytes injected with uncharged tRNA in Figure 3.14.  Indeed,
during the course of these studies, an extremely surprising observation was made.  As
indicated earlier, the co-injection of mRNA with non-aminoacylated tRNA is a routine
null control.  These tRNA’s are ligated to dCA, so that they are treated in exactly the
same way as charged tRNA’s.  Typically, this 76 nt tRNA-dCA gives much larger
currents than mRNA injected alone, but much smaller currents than in cells injected with
aminoacylated tRNA carrying a natural or unnatural amino acid.  In attempting to
identify the source of full-length read-through protein, tRNA which had not been ligated
to dCA (i.e. 74 nt tRNA missing the critical CCA motif found at the 3’ end of all tRNA)
was co-injected with mRNA containing a stop codon.  To our great surprise, this 74mer
produced larger currents than tRNA-dCA, although still much smaller than those from
oocytes injected with charged tRNA.  A comparison of a number of tRNA constructs was
made.  (Figure 3.14)
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Figure 3.14  Whole-cell currents resulting from the co-injection nAChR mRNA containing
β9’TAG with indicated truncated and full-length tRNA.
Eukaryotic tRNA is, in fact, synthesized as a truncated transcript to which the final C, C,
and A nucleotides are added by the cytosolic CCA nucleotidyl transferase.  The Xenopus
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isoform has recently been identified.43  Thus, the 74mer tRNA may well be modified to
produce a translationally competent full-length (though uncharged) tRNA.  It is
presumably this activity which accounts for the ability of the 74mer to produce full-
length protein, although it should be noted that no explanation has yet been offered for
the exact mechanism of tRNA-mediated read-through.
3.2.4.4 Attempts to eliminate background current by removal of un-ligated 74mer
The fact that 74mer was capable of giving rise to such current led us to the hypothesis
that background current in suppression experiments could be eliminated if unreacted
74mer tRNA could be removed after enzymatic ligation of dCA to the 74mer tRNA.  The
efficiency of this ligation reaction was thought to be on the order of 75%, from the ratio
of stained bands corresponding to full-length aminoacylated and 74mer tRNA on
sequencing gels.  Thus, even when charged tRNA was being injected, a significant
amount of 74mer was introduced into the oocyte.  Removal of unreacted tRNA was
attempted in two ways.  First, the vicinal diol of adenine ribose from unreacted dCA was
oxidized with periodate.  Numerous studies have shown that treating uncharged tRNA
with periodate abrogates its ability to function in translation.44,45  Second, the enzyme
polyA polymerase was used in an attempt to add a string of A’s to any unreacted tRNA,
while charged tRNA would be substitutionally inert.45,46  It was thought that these polyA
tRNA’s could then be removed easily using oligo-dT beads, which are traditionally used
to capture polyadenylated mRNA from transcriptionally active cells.  Neither of these
treatments had a significant effect on the electrophysiology of oocytes injected with
tRNA subjected to the treatments.  One gel showed apparent addition of polyA, although
there was little change in the electrophysiology.  (Figure 3.)  These methods may be
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largely irrelevant in light of more recent studies which suggest that the ligation reaction
conditions may be modified in such a way as to drive the ligation reaction to
completion.47
76mer Val dCA74mer - Val dCA -
Untreated Treated
76 nt
74 nt
Figure 3.15 SDS-PAGE of ligated and un-ligated tRNA’s treated with polyA polymerase
subsequent to T4 ligase reaction.
3.2.4.5 Attempts to eliminate background current by tRNA modification
In order for un-ligated tRNA to generate read-through currents, it seems likely that
the tRNA must be completed by the nucleotidyl transferase mentioned above.
Modifications of the T-loop of tRNA have been reported to compromise the ability of
these enzymes to recognize and transfer the final C and A nucleotides to the 3’ end of
tRNA.48 TH73G tRNA was accordingly prepared with a G57C mutation.  This tRNA was
synthetically charged in the usual way by ligation to dCA-Val.  Read-through current was
indeed dramatically reduced, along with current from suppression.  It appears that these
mutations may also disrupt ribosome-tRNA interactions, such that the mutant tRNA’s are
no longer translationally competent.
3.2.4.6 Anomalous subunit trafficking
Another surprising observation which resulted from studies on gel bands resulting
from read-through has to do with the fate of nAChR subunits injected alone.  The
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conventional belief is that single subunits are translated in the ER, but that assembly is
required for proper trafficking to the cell surface.  Indeed, numerous studies with
mammalian cells in culture form the basis for this belief.49,50  Experiments in oocytes
injected with single epitope-tagged subunits suggested that oocytes may be more
promiscuous in their trafficking.  Harvesting of membranes from such oocytes followed
by Western blotting invariably led to detection of the subunits in the membrane fraction.
(Figure 3.16)
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Figure 3.16  Stripped membranes from oocytes expressing HA-tagged subunits either alone or in
the full receptor.  Left panel: α and β subunits.  Lane 1:  αHA – nAChR.  Lane 2:  αHA only.
Lane 3:  βHA – nAChR.  Lane 4:  βHA only.  Lane 5:  βHA standard.  Lane 6:  αHA standard.
Right panel:  γ subunit.  Lane 1:  γHA – nAChR.  Lane 2:  γHA only.
It should be noted, of course, that it is extremely difficult to guarantee that a
membrane preparation is pure.  Interior membranes, scaffolding proteins, and
cytoskeletal elements all adhere tightly to the plasma membrane.  It is clear during the
dissection process that  significant amounts of cytosolic tissue are removed along with
the fused plasma and vitelline membranes.  This difficulty in obtaining pure surface
membrane preparations is also a possible confounding variable in attempts to detect
photoinduced cleavage of receptors.  Although the irradiating light undoubtedly
penetrates the oocyte surface to a significant extent (consider the wavelength of 300 nm
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light relative to the 3 nm plasma membrane), these sub-surface receptors may not
contribute to the observed electrophysiological effects.  The apparent cleavage of
receptors that is detectable by a loss of whole-cell current may represent only a small
fraction of the total receptor protein observed on the gel.  Although this does not explain
why irradiated sub-surface protein is not photo-cleaved, it does perhaps suggest an
explanation for the discrepancy between the electrophysiological result and the result by
biochemical analysis.
3.2.4.7 Techniques for harvesting plasma membrane proteins
In an attempt to isolate the surface proteins which were responsible for the
measurable electrophysiological change observed upon photolysis, a number of surface-
isolation procedures were attempted.  The most typical method of this nature is to modify
cell-surface proteins with an impermeant reagent, such as an amine-reactive biotin
analog.  Then, isolation by streptavidin should yield only proteins which were on the
surface to be so modified.  Indeed, a biotin-based method for detecting oocyte surface
expression has been reported.51 This technique was used apparently successfully,
although it gave no better results than manual dissection in terms of visualizing cleavage.
(Figure 3.17)
Another surface isolation technique which appeared to be useful was the treatment of
the oocytes themselves with antibody, followed by immediate immunoprecipitation.52
(Figure 3.18)  Again, this technique did not allow us to observe fragmentation.
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Figure 3.17  Isolation of surface proteins by treatment of oocytes with NHS-biotin followed by
streptavidin beads.  Left panel:  Comparison of whole oocyte, dissected membranes, and
streptavidin beads.  Lane 1:  Uninjected – total membranes.  Lane 2: αHA – total membranes.
Lane 3: αHA – dissected plasma membrane.  Lane 4: αHA – streptavidin beads.   Lane 5:
Uninjected – streptavidin beads.  Right panel:  Capture with streptavidin after surface
biotinylation.  Lane 1:  Uninjected – no biotinylation, no beads.  Lane 2:  Uninjected – beads only,
no biotinylation.  Lane 3:  Uninjected –biotinylation, beads.  Lane 4: αHA – biotinylation, beads.
Lane 5: αHA – beads only, no biotinylation.  Lane 6: αHA – no biotinylation, no beads.  Lane 7:
αHA standard.
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Figure 3.18  Isolation of surface proteins by treatment of whole oocyte with antibodies, followed
by recovery with Protein G-sepharose beads.  Left panel:  Establishing methodology.  Lane 1:
Oocyte homogenate treated with PGS beads.  Lane 2:  Antibody-treated homogenate treated with
PGS beads.  Lane 3:  Mab210 and beads  only (no oocyte homogenate).  Right panel:  Testing
surface antibody treatment with intra- and extracellular epitope tags.  Lane 1: αHA – dissected
membranes.  Lane 2: αHA – surface recovery with Mab210.  Lane 3: αHA – surface recovery
with HA.11.  Lane 4: γ497HA – dissected membranes.  Lane 5: γ497HA – surface recovery with
Mab210.  Lane 6: γ497HA – surface recovery with HA.11.  Lane 7:  Uninjected – dissected
membranes.  Lane 8:  Uninjected – surface recovery with HA.11.  Lane 9: αHA standard.
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3.2.4.8 Use of immunoprecipitation to increase signal strength
Various immunoprecipitation protocols were used and/or developed, for two reasons.
First of all, we felt that we could use the techniques to concentrate the protein.  Secondly,
we were concerned that perhaps the cleaved fragments were being preferentially lost
during membrane isolation.  Photolysis of Npg-containing proteins captured on beads
would allow us to both irradiate a large number of proteins in a very small area and also
to analyze beads and supernatant directly after irradiation, to minimize any possibility of
protein loss.  As with the isolation of cell-surface proteins, we found that we were able to
immunoprecipitate suppressed nAChR, but this isolation did not allow us to detect any
effect of photolysis. (Figure 3.19)
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Figure 3.19  Immunoprecipitation protocols.  Left panel:  Immunoprecipitation from oocyte
homogenate with Mab210 and HA.11 affinity matrix, followed by Western blot with HA.11.
Lane 1: αHA, IP protocol without antibody.  Lane 2:  Uninjected oocytes,  IP protocol without
antibody.  Lane 3:  Uninjected, Mab210 IP.  Lane 4: αHA, Mab210 IP.  Lane 5:  Uninjected, IP
with HA affinity matrix.  Lane 6: αHA, IP with HA affinity matrix.  Lane 7: αHA standard.
Protein was eluted from the affinity matrix with HA peptide.  Note the very small amounts of
recovered αHA relative to antibody.  Middle panel:  Metabolic labeling with35S-Met followed by
immunoprecipitation with HA.11.  Lane 1: αHA, IP with HA.11.  Lane 2: αHA, dissected
membranes.  Right panel:  IP with HA.11 followed by Western with biotinylated HA.11 and
streptavidin-HRP.  Also, testing the effect of SDS on membrane dissection. Lane 1: αβγδHA,
dissected membranes.  Lane 2: αβγδHA, IP with HA.11.  Lane 3: αHA, dissected membranes
(using SDS).  Lane 4: αHA, dissected membranes (without SDS).  Lane 5: αHA subunit injected
alone, dissected membranes (with SDS).  Lane 6: αHA subunit injected alone, dissected
membranes (without SDS).
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3.2.4.9 In vitro photolysis experiments
Ultimately, protein containing Npg was generated from in vitro translation and
irradiated under non-physiological conditions.  The results from oocytes gave us
confidence that we could detect suppressed protein by Western blotting.  Even if we were
unable to recover cleaved protein from oocytes, we felt we should be able to make the
protein, irradiate it, and see that it gave rise to two bands on the gel.  Even this
elementary experiment failed, however.  The primary technical difficulty was a general
loss of protein upon photolysis.  Even recovery of wild-type protein was significantly and
adversely affected by photolysis in the arc lamp.  Pre-coating of the Eppendorf tubes in
which irradiation was taking place failed to ameliorate this problem.  Both BSA and
coatings such as silicone and polylysine were tested, with negative results.  In spite of the
reduction of protein levels, it was obvious nonetheless that a band corresponding to
cleaved protein was not appearing in the photolyzed samples.  It was hypothesized that
the alpha-keto acid formed as a photoproduct from the C-terminal cleavage fragment was
perhaps susceptible to attack  and thus cross-linking by nucleophilic residues on the N-
terminal fragment.  Photolysis in the presence of nucleophilic scavengers such as
semicarbazide was attempted,  again with negative results.
3.2.4.10 Cross-linking as a positive control for detecting chemical modification
The final kind of experiment that was attempted was a positive control to demonstrate
that some chemical modification of any kind could be observed with suppressed proteins.
A brief and unsuccessful attempt was made to treat oocytes with trypsin, to provide
evidence that cleaved proteins could be isolated and detected from oocytes.  More
thorough experiments were performed, using chemical cross-linking as the positive
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control for detectable chemical modification.  In these experiments, the results of
Schmalzing et al. on nickel bead-captured 7His-containing nAChR were used as a
model.53,54 Constructs were generated containing the C-terminal 7His tag and the HA
epitope in the M3-M4 loop.  Subsequent to capture on nickel-NTA agarose beads, protein
was treated with DMS, the cross-linking reagent employed by Schmalzing.53 This
experiment gave decidedly mixed results.  Higher-molecular weight density was
observable in the treated lanes, but under no circumstances were we able to reproduce the
discrete bands seen in the reported work.53 (Figure 3.20)
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Figure 3.20  Results from treatment of oocytes and nAChR captured on Ni-NTA with the cross-
linking reagent DMS.  Left panel:  Treatment of nAChR captured on beads with DMS, as in the
procedure of Schmalzing.53 Lane 1: αHA untreated.  Lane 2: αHA treated with DMS.  Lane 3:
αHA standard.  Right panel:  Western blot showing the lack of higher-MW bands from
membranes dissected from DMS-treated oocytes.  Lane 1: αHA untreated.  Lane 2: αHA treated
with DMS.  Lane 3: αHA standard.
The only substantive difference we could identify between the two experimental
protocols was the fact that we were using immunological detection, whereas their
protocol called for metabolic labeling with 35S.  Oocytes were accordingly labeled, with
more or less identical results to our Western blots.  Higher molecular-weight density
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could be again discerned  but not as discrete bands.  Another report whose results we
were unable to replicate was Hucho’s treatment of oocytes with DMS.55,56 In their
experiment, they observed a reduction in whole-cell current upon treatment of oocytes
with DMS.56 In our initial experiments, the treatment had no effect at all, either
electrophysiologically or by SDS-PAGE.  (Figure 3.20)
A number of different cross-linkers and conditions were used during the course of
these experiments.  Many of them gave encouraging results, but it was also observed that
artifactual aggregation which persisted during standard reducing SDS–PAGE conditions
could arise from certain purification steps.  (Figure 3.21)
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Figure 3.21  Apparent cross-linking is shown to be artifactual by heating gel samples prior to
loading.  Left panel:  Investigation of Ni-NTA recovery protocol and treatment of captured protein
with photo-crosslinking reagents.  Oocytes were injected with 500 pg total mRNA containing
alpha subunits that have both HA and 7His tags.  Lane 1:  Usual Ni-NTA protocol.  Lane 2:
Second imidazole elution from beads in usual protocol.  Lane 3:  Washing and elution of beads
using a spin column.  Lane 4:  Treatment of captured protein with DASD.  Lane 5:  Treatment of
captured protein with SANPAH in DMSO.  Lane 6:  αHA standard.  Right panel:  Same samples
as left panel, except treated by heating to 100 °C for 10 min.
Collecting and washing Ni-NTA beads by low-speed centrifugation in fritted
Eppendorf tubes is a very convenient procedure which results in high yields of protein.
However, it appeared to induce aggregation, which could be alleviated by heating
samples prior to loading.  Apparent cross-linking with covalent reagents was thus also
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revealed to be artifactual.  As this effort to achieve cross-linking was somewhat
peripheral to our interests, it was not pursued further.
3.2.4.11 Ni-NTA purification as a general technique
However, the ability to isolate pentameric nAChR by nickel-mediated capture of
receptors containing a C-terminal 7His tag is potentially useful for a variety of
biophysical studies.  An experiment was performed to determine where receptors isolated
from both oocyte homogenate and dissected membranes in the presence of the detergent
β-dodecylmaltoside (DDM) maintain their inter-subunit contacts.13 Oocytes were injected
with a mixture of alphaHA and alpha7His subunits.  The capture protocol should pull
down only those receptors with a 7His tag, whereas the Western blotting detection
protocol should only detect those with the HA tag.  If the alpha subunit may de detected
in a Western blot, the implication is that the two alpha subunits are captured as a non-
covalent complex.
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Figure 3.22  Determination whether dissection and Ni-NTA capture protocols with a variety of
detergents maintain nAChR in its pentameric form.  Lane 1: αHA:α7H – dissected membranes, no
detergent. Lane2: αHA:α7H –Ni-NTA, no detergent.  Lane 3: αHA:α7H – dissected membranes,
with DDM.  Lane 4: αH A :α7H – N-NTA, with DDM.  Lane 5: αHA:α7H – dissected
membranes, with SDS.  Lane 6: αHA:α7H – Ni-NTA, with SDS.  Lane 7: αHA:α7H – oocyte
homogenate, Ni-NTA, DDM.  Lane 8: αHA/7H – positive control, where alpha subunits contain
both HA and 7His tags, Ni-NTA, SDS.  Lane 9:  αHA standard.
94
The results of this experiment imply that the pentamers remain intact in the presence of
DDM, consistent with other studies on multi-subunit integral membrane proteins.13
(Figure 3.22)  In our work, SDS also appeared to maintain the intact receptor.  The Ni-
NTA isolation protocol was performed on dissected membranes, except in one case
where it was carried out homogenized oocytes (Lane 7).  In all cases, Ni-NTA results in a
more pure sample, but one where the signal is correspondingly diminished.  The negative
control, where non-His tagged subunits are used, generally results in very little
background, but there is also frequent variation between batches of oocytes, and such a
control in this experiment is probably necessary to support the conclusion that the
nAChR remains intact during isolation.  However, the results are encouraging.  In
addition, techniques which only require the labeled subunit to be isolated have been
carried out with these constructs in the work of John Leite.57 Whether or not Ni-NTA
purification will provide a means of purifying suppressed receptors remains to be seen.
3.2.5 Conclusions from non-alpha Npg cleavage
In summary, cleavage of proteins containing Npg was  never able to be directly
observed by PAGE.  However, the whole-cell current of oocytes expressing nAChR with
Npg in non-alpha Cys loops was reproducibly reduced to the level of dCA current.  In the
absence of biochemical evidence on cleavage, we were unable to determine whether this
effect corresponds to 90% cleavage of Npg-containing receptors, with nAChR arising
from read-through accounting for the residual current; or 50% cleavage of Npg-receptors,
with un-cleaved receptors accounting for the remainder of the current.
One experiment which may shed light on this question was the determination of the
dose-response pre- and post-photolysis.  A change in the EC50 of the receptor may imply
95
that receptors have been affected by photolysis, as we had already shown that the read-
through currents had the same EC50 as wild-type receptors.  In fact, the EC50 values of
receptors containing Npg in non-alpha Cys loops is identical before and after photolysis,
even in cells where a 50% reduction in whole-cell current was observed.  (Figure 3.23)
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Figure 3.23  Dose-response relations for oocytes expressing nAChR suppressed with Npg in the
indicated position, fit to the Hill equation.  Photolyzed oocytes are indicated in red and un-
photolyzed cells by blue.
Thus, interpretation of the results obtained by the photolysis of receptors containing
Npg in non-alpha Cys loops remains difficult.  A number of useful biochemical
techniques were developed during the course of the study, including the use of epitope
tags, methods for isolation of suppressed receptors from oocytes, detection of suppressed
receptors in Western blots, immunoprecipitation in oocytes, in vitro translation of
suppressed proteins using wheat germ extract, cell-surface labeling of oocytes, and
purification of suppressed proteins by Ni-NTA.
3.3 Site-specific photocrosslinking with Bpa
3.3.1 Introduction to site-specific crosslinking
Both the difficulties in structurally characterizing membrane proteins and the large
number of stoichiometries available to neuroreceptors have been mentioned above.  In
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addition, a great deal of active research is directed toward understanding the modulation
of ion channel activity by protein-protein interactions, the targeting of ion channels to the
cell surface by cytoskeletal interactions, and the localization of channels to membrane
rafts and the proteins associated with them.58-60 A general technique to identify the
interaction partners of ion channel subunits would be of great utility.  In addition, the
ability to identify regions of a particular protein or subunit which constitute an interaction
domain or protein-protein interface would be valuable for relating the primary sequence
of a protein to the structure-function relationships inherent in its domain organization.
A number of photoactive functional groups have been employed in the design of
photo-crosslinking reagents.  The most common types, aryl azides, diazirines, and
benzophenone-based molecules have been reviewed.61 The various chemistries have
advantages and disadvantages and are appropriate for different contexts.  Experiments
using diazirines introduced by nonsense suppression played an important part in
establishing the role of the translocon in membrane protein synthesis.62,63 However, some
work performed here and elsewhere suggested that benzophenone-based residues may
incorporate more efficiently under the conditions used in our laboratory.2,64 In
collaboration with Justin Gallivan, who had previously prepared dCA-Bpa, the work
described here was carried out using 4-benzoylphenylalanine (Bpa).64 (Figure 3.24)
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Figure 3.24  Schematic of the cross-linking chemistry of benzoylphenylalanine (Bpa).  Irradiation
of the residue leads to a biradical, which abstracts hydrogen from a neighboring side chain.  The
resulting covalent linkage may be an intrasubunit crosslink, or if the residue is interfacial, an
intersubunit linkage.
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Suppression was attempted with the photoactive residue in every position in the Cys
loop of the gamma subunit of the nAChR.  As indicated earlier, the belief at that time was
that the Cys loop constituted a portion of the intersubunit interface.  The position of
gamma between the two alpha subunits was seen as desirable, in that cross-linking to
alpha seemed probable.  In addition to the fact that the stoichiometry of the receptor
makes labeling both alpha subunits with the HA epitope tag trivially easy, it is also the
case that the sensitivity of alphaHA in Western blots is higher than that of other subunits.
After introduction of the Bpa residue, the oocytes were tested for expression in the
standard two-electrode voltage clamp configuration.  Suppression was achieved at a
number of sites, although several never gave appreciable current over background levels.
(Figure 3.25)  Additional data on the suppression efficiency is available.64
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Figure 3.25  Suppression of Bpa at selected sites which gave good expression in the nAChR
gamma Cys loop.  Mean whole-cell currents (±SEM) are indicated.
Oocytes giving measurable whole-cell currents were then photolyzed in batches for
four hours, using the same conditions as employed for Npg cleavage.  After photolysis,
the oocytes were recorded from.  In addition, the membranes were dissected away and
analyzed for high-molecular weight products arising from cross-linking between the
alpha and gamma subunits.  Both of these studies were in all cases negative.  No
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electrophysiological effects were ever observed to arise from photolysis.  Nor were
higher-molecular weight bands ever observed in Western blotting.  (Figure 3.26)
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Figure 3.26  Western blotting from irradiated oocytes containing Bpa at a variety of sites in the
gamma Cys loop, showing the lack of detectable cross-linking.  Left panel:  Irradiation of oocytes
containing nAChR γ129Bpa followed by dissection of plasma membranes.  Lane 1:  Uninjected
oocytes.  Lane 2:  γ129 Bpa.  Lane 3:  Uninjected, photolyzed 4 hr.  Lane 4: γ129 Bpa, photolyzed
4 hr.  Lane 5: γ129 Bpa, photolyzed in arc lamp.  Lane 6:  Uninjected, photolyzed in arc lamp.
Lane 7:  αHA standard.  Right panel: Irradiation of oocytes containing nAChR γ134-137Bpa
followed by dissection of plasma membranes.  Lane 1: γ134 Bpa.  Lane 2: γ134 Bpa, 4 hr hν.
Lane 3: γ135 Bpa.  Lane 4: γ135 Bpa, 4 hr hν.  Lane 5: γ137 Bpa. Lane 6: γ137 Bpa, 4 hr hν.
Lane 7:  αHA standard.
Thus, although site-specific cross-linking remains an attractive use of unnatural
amino acid mutagenesis, Bpa incorporation in the Cys loop of gamma appears in
hindsight to have had little chance of success.  The crystal structure of AChBP shows the
Cys loop to be rather ill-positioned for intersubunit crosslinking.65 (Figure 3.27)
However, the sequence of this loop is very different from the highly conserved Cys loop
sequence found in the family of ligand-gated ion channels, so it is possible that the
AChBP is not a reliable indicator of the position of the Cys loop in the full receptor.
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Figure 3.27  Two views of the AChBP crystal structure, showing the location of the Cys loop, in
red.65 Left panel:  View from what would be the intracellular side of the receptor, if the AChBP
contained transmembrane domains.  Right panel:  View from the side of the protein, where the
Cys loops would contact the membrane in a true receptor.   One subunit is rendered in dark gray to
emphasize the subunit interface.
It may be the case also that the project suffers from a fundamental difficulty, namely,
that introducing unnatural amino acids into interfacial regions of proteins is intrinsically
destabilizing.  This problem could potentially be surmounted by making a longer linker
between the peptide backbone and photoactive functional groups in the side chain.
Alternatively, serial incorporation of the unnatural amino acid into a contiguous sequence
may be able to identify those sites where substitution of the natural side chain for the
large hydrophobic Bpa residue is tolerated.  Now that a crystal structure exists for the
highly homologous AChBP, it may be possible to rapidly determine whether or not inter-
subunit cross-linking may be realized with Bpa. In addition, the advent of mass
spectrometry from ion channels expressed in oocytes raises the possibility that a more
sensitive assay than Western blots may be employed.57 Success of these proof-of-
principle experiments could then justify a more intensive attempt to identify interfacial
regions in less well-characterized channels using site-specific photocrosslinking.  Thus,
the efforts reported here should only be considered as the pioneering stage of a the
project and were carried out using what may prove to be highly inaccurate structural
assumptions.
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3.4 Using hydroxy acids to determine Cys-Cys connectivity of the P2X2 receptor
3.4.1 Experimental design
The unnatural amino acid Npg allows the protein backbone to be site-specifically
cleaved in a functioning protein.  Compared to this, it may appear that the ability to site-
specifically cleave a polypeptide subsequent to isolation of the protein is a rather paltry
achievement.  However, site-specific cleavage of isolated proteins is a useful technique
for solving a particular topological problem.  The three-dimensional connectivity of a
protein backbone is complicated by the existence of side chain-mediated contacts, namely
the disulfide bonds between cysteines.  In the absence of three-dimensional structural
data, there is no way of knowing which cysteine in a primary sequence may be bonded to
another.  However, a technique developed by Pam England in this laboratory provides a
means whereby site-specific cleavage may be used to determine this connecticity.4 In this
methodology, incorporation of hydroxy acids is used to introduce a specific site between
selected cysteine residues where the backbone is base-labile.3,4 (Figure 3.28)
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Figure 3.28  Schematic showing how introduction of a hydroxy acid (red) into the protein
backbone creates a base-labile linkage.
In general, when a cleavable residue is placed between two disulfides and the protein is
cleaved, two outcomes are possible.  If the cysteines do not form a disulfide, the protein
will be cut in two.  If the side chains are connected by a disulfide bond, however, the
backbone will be cleaved but the two halves of the protein will remain attached by the
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covalent bond between side chains.  This difference is easily observable by PAGE.
Additional information may be obtained by treatment with reducing agents during
electrophoresis.  If disulfide-reducing agents are present, the disulfide-bonded halves will
separate into two fragments, confirming that backbone cleavage has occurred.  (Figure
3.29)
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S-S
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SH
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Figure 3.29  Schematic showing how site-specific backbone cleavage may be used to determine
the disulfide connectivity of a protein.4 Targeted inter-cysteine backbone cleavage is followed by
comparison of SDS-PAGE mobility in the presence and absence of disulfide reducing agents .
The gel mobility of the cleaved protein reveals whether or not the cysteines on either side of the
cleavage site are in a disulfide.  Red arrows indicate treatment with both base and reducing agent.
Black arrows indicate treatment with base alone in the absence of  reducing agent.
It has been relatively recently appreciated that disulfides provide small proteins the
opportunity to create highly stable scaffolds.  A number of disulfide knot toxins have
recently been discovered, such as the snail-derived conotoxins.66,67 These small peptides
are able to form a relatively rigid binding domain with excellent complementarity to the
extracellular domains of ion channels.  The paralytic ability of conotoxins arises because
of this binding, which inhibits the nicotinic receptors that motoneurons rely upon to turn
synaptic signals into muscle movement.  However, toxins are not the only proteins to rely
upon disulfides to scaffold binding domains.  The primary structure of P2X channels has
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recently been determined and has shown these receptors to be extremely cysteine-rich.68
(Figure 3.30)
MVRRLARGCWSAFWDYETPKVIVVRNRRLGFVHRMVQLLILLY
FVWYVFIVQKSYQDSETGPESSIITKVKGITMSEDKVWDVEEY
VKPPEGGSVVSIITRIEVTPSQTLGTCPESMRVHSSTCHSDDD
CIAGQLDMQGNGIRTGHCVPYYHGDSKTCEVSAWCPVEDGTSD
NHFLGKMAPNFTILIKNSIHYPKFKFSKGNIASQKSDYLKHCT
FDQDSDPYCPIFRLGFIVEKAGENFTELAHKGGVIGVIINWNC
DLDLSESECNPKYSFRRLDPKYDPASSGYNFRFAKYYKINGTT
TTRTLIKAYGIRIDVIVHGQAGKFSLIPTIINLATALTSIGVG
SFLCDWILLTFMNKNKLYSHKKFDKVRTPKHPSSRWPVTLALV
LGQIPPPPSHYSQDQPPSPPSGEGPTLGEGAELPLAVQSPRPC
SISALTEQVVDTLGQHMGQRPPVPEPSQQDSTSTDPKGLAQL
Figure 3.30  Presumed structure and primary sequence of the ATP-binding receptor P2X2.
Extracellular cysteine residues are boxed in red.  Sites of stop codon introduction discussed below
are indicated with red text.
The predicted 283 aa ATP-binding extracellular region of these channels contains ten
cysteine residues.  Interestingly, the ATP-binding domain of the P2X receptors has no
apparent sequence homology to known ATP-binding folds such as the Walker or
Rossman motif.69-71 So, structural information on the connectivity of the cysteines in the
extracellular region of the P2X2 receptor may be a valuable in guide in designing
experiments to try to identify where ATP binds.
These experiments were carried out in collaboration with Baljit Khakh, who provided
the initial P2X2 constructs.  A FLAG epitope was introduced into the receptor at the
extreme C-terminus.  In these two-transmembrane domain receptors, both termini are
intracellular.  In addition, he introduced stop codons between all ten cysteine residues.
The sites of mutation were chosen based on rules established in the work of England et
al. for optimal cleavage of hydroxy acids.3,4  She found that there were sequence context
effects on the efficiency of hydrolytic cleavage of hydroxy acids introduced into proteins.
The sites chosen in the P2X2 receptor were selected for favorable cleavage.  Based on the
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work of England, hydroxy acids of valine and alanine were employed for suppression
experiments.
Protein isolated from oocytes subsequent to electrophysiological recording was
thought to have the best chance of reflecting the native structure of the receptor, an
important consideration for an ex vivo structural technique.  However, it had also been
found in the earlier studies of England that protein produced by in vitro translation could
be valuable for establishing cleavage conditions.3,4 Whether or not the receptor is being
folded correctly in wheat germ extracts may even be determined by comparison to its
cleavage behavior relative to that of isolated functional protein.
3.4.2 Results
Initial work in this receptor indicated that the specificity of the FLAG epitope in
Western blotting was dramatically inferior to that of the HA antibody.  In addition, the
overall level expression of the channel was rather low in suppression experiments with
hydroxy acids.  In order to correct both of these problems, the P2X2 gene was cloned into
pAMV and an HA tag inserted at the extreme C-terminus.  These changes resulted in
increased expression and much better staining in Western blots.  (Figure 3.31)
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Figure 3.31  Western blot analysis of P2X2 receptors showing the relative efficacy of C-terminal
FLAG and HA epitope tags.  Additionally, effects of PNGaseF on the receptor are examined,
along with potential dominant-negative effects from truncated P2X2 142TAG.  Left panel:
Western blot of C-terminally FLAG-tagged P2X2.  Lane 1:  Uninjected, dissected membranes.
Lane 2:  P2X2, wheat germ extract.  Lane 3: P2X2, wheat germ extract, treated with PNGaseF.
Lane 4:  nAChR αHA/FLAG, wheat germ extract.  Lane 5: nAChR αHA/FLAG, wheat germ
extract, treated with PNGaseF.  Right panel:  Dissected membranes from oocytes expressing Vah-
suppressed P2X2 V142TAG with C-terminal HA tag.  Lane 1: P2X2 142TAG, 74mer.  Lane 2:
P2X2 142TAG, Vah.  Lane 3: P2X2 142TAG, mixed with WT P2X2.  Lane 4:  P2X2 wild-type
receptor with C-terminal HA.  Lane 5:  αHA standard.
However, two rather knotty problems arose. First of all, wild-type P2X2-HA showed a
rather significant mobility shift upon treatment with ammonium hydroxide.  (Figure 3.32)
This may arise as a result of base-catalyzed hydrolysis of sugars post-translationally
added to the receptor.  Treatment of isolated wild-type P2X2 with PNGase F, an enzyme
which removes N-linked glycosylation showed little effect, though, so it may be that O-
linked sugars or some other base-catalyzed chemistry was responsible for this mobility
shift.  (Figure 3.31)
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Figure 3.32  Western blot of base-treated P2X2 containing Vah and wild-type residues, and
nAChR positive control for ester cleavage.  Left panel:  Effects of treating Vah-suppressed and
wild-type P2X2 with base.  Lane 1:  WT P2X2, treated with NH4OH and β-ME.  Lane 2:  P2X2
142Vah, treated with NH4OH and β-ME.  Lane 3:  WT P2X2, treated with NH4OH but not β-ME.
Lane 4:  P2X2 142Vah, treated with NH4OH but not β-ME.  Right panel:  Positive control for
NH4OH cleavage and identification of disulfide formation with β-ME, showing cleavage only in
the presence of disulfide reducing agent.  Lane 1:  nAChR α131Ser132Vah, treated with NH4OH
and β-ME.  Lane 2: nAChR α131Ser132Vah, treated with NH4OH but not with β-ME.
Secondly, incorporation of hydroxy acids worked at very few of the eight inter-Cys
positions.  (Figure 3.33)  This was a surprising result in view of the fact that the amide-
to-ester mutation is a rather slight perturbation, that it seemed unlikely that so many of
the sites chosen would have represented critical residues to protein function, and that the
work of England suggested rather great tolerance to hydroxy acids in the nAChR.3,4
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Figure 3.33  Electrophysiological and Western blot analysis showing the relatively low tolerance
of P2X2 receptor  to incorporation of Vah.  Left:  Mean whole-cell current (±SEM) for oocytes
suppressed with Vah at the indicated inter-Cys position.  Right:  Western blot of membranes
dissected from the Vah-suppressed oocytes shown in left panel.  Lane 1: WT.  Lane 2: 117Vah.
Lane 3: 127Vah.  Lane 4: 142Vah.  Lane 5: 148Vah.  Lane 6: 162Vah. Lane 7: 117Vah.  Lane 8:
240Vah. Lane 9: 253Vah.
106
When compared directly to the wild-type residue, receptors arising from suppression
at 142 had somewhat different PAGE mobility.  (Figure 3.32)  Although the sequencing
data from these constructs suggested that the region around the introduced mutation was
consistent with the expected sequence, the constructs may well have been faulty.  Even if
this were the case, however, electrophysiology and Western results confirm that
significantly greater current and staining intensity were observed upon supplying the cells
with hydroxy acid-charged tRNA.  Thus, by all standards currently employed, the
hydroxy acid was present in these receptors.  In no case was base-induced cleavage
observed, however, although altered gel mobility in the presence of base was seen for 142
as well as the wild-type construct.  Given the apparent lack of cleavage, a position which
gave good cleavage in the nAChR in the earlier work of England was selected for use as
a positive control.3,4 Indeed, cleavage was observed as anticipated.  (Figure 3.32)
3.4.3 Future directions
Because of the intractability of the P2X2 system, with both gel mobility of wild-type
protein induced by base treatment and no evidence of cleavage in hydroxy acid-
containing protein, this line of experimentation was abandoned.  Suggestions for the
future involve treatment of the receptor with the glycosidase EndoH, which removes both
N- and O-linked sugars, to attempt to resolve the mobility of WT receptor upon base and
β-mercaptoethanol treatment.  Additional sites of mutation could also be chosen, to
determine whether better suppression efficiency might be achievable elsewhere in the
receptor.
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3.5 Use of photo-labile side chains to induce dynamic conformational change
3.5.1 Experimental design
In the case of Bpa, a photoactive side chain was incorporated for the purposes of
cross-linking.  Side chains with photo-cleavable protecting groups may also be
introduced for the purposes of providing steric bulk which may then be removed by
irradiation.72,73 In this way, a conformational change may be induced experimentally.
Typically, this conformational change is rather small, and a sensitive region of the protein
is the best site for use of protected side chains for this purpose.  Such a region is the gate
of an ion channel.  As indicated above, a conformational change resulting from binding
of a ligand-gated ion channel’s agonist is communicated to the gate in the transmembrane
regions, resulting in channel opening.  In the nAChR, this gate is thought to be near the
L9’ position.28,29,31
In work conducted in collaboration with Ken Philipson, tyrosine and cysteine with the
alcohol and thiol, respectively, protected by a nitrobenzyl group, were introduced at the
9’ position.6 (Figure 3.34)
N
H
O
O
O
NO2 hν
N
H
O
O
OH
NO
H
O
+
N
H
O
O
S
NO2
hν
N
H
SH
O
O
NO
H
O
+
Figure 3.34  Schematic showing photolytic de-caging of Cys(ONb) and Tyr(ONb).
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In these experiments, the removal of the protecting group was examined as a possible
means of very rapidly controlling channel gating and gaining insight into the temporal
mechanics of the gating process.
3.5.2 Results
Suppression in the alpha subunit proved rather inefficient, although better results
were obtained in both beta and gamma subunits.  Gamma suppression is exclusively
considered below.  The first observation from application of this technique was that very
striking effects of photolysis were immediately evident.  (Figure 3.35)
Figure 3.35  Light-induced decaging of  Cys and Tyr analogs in the transmembrane region of
nAChR γ.  Left panel: Light-induced decaging of Cys(ONb). Current was first activated by the
application of ACh (20 mM) to an oocyte expressing the ACh receptor. The oocyte had been
injected with cRNA coding for wild-type α, β, and δ subunits and for the γ subunit with a
Leu260TAG (γ9’TAG) mutation. Suppressor tRNA charged with Cys(ONb) was co-injected.
Methanethiosulfonate ethylammonium (MTSEA; 0.35 mM) was included in the bathing medium
as indicated. Three pulses of ultraviolet light of 3 s duration each are indicated by arrows. Spikes
in current traces are artifacts due to switching of the bathing medium.  Right panel:  De-caging of
Tyr(ONb). Current was activated by the application of ACh (20 µM) to oocytes expressing the
ACh receptor. A Leu260TAG mutation was present in the γ-subunit (γ9’ position of M2). The stop
codon was suppressed by the co-injection of suppressor tRNA charged with Tyr(ONb). Two
pulses of UV light of 3 s duration each are indicated by arrows. The current transient induced by
the second flash is artifactual, as similar transients were sometimes also seen with the wild-type
channel.
With both tyrosine and cysteine, irradiation caused an immediate increase in current.
Continued 1 ms pulses of light reveal more and more current, with each flash activating
approximately 5% of the available receptors.  Detailed kinetic analysis showed that the
response to cysteine de-caging was more rapid than could be measured by the apparatus
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used.  Receptor response to tyrosine de-caging was rather slower, an effect perhaps
explained by greater steric perturbation resulting from the larger nitrobenzyl tyrosine
residue.  Apparently, conformational rearrangement must occur before the channel can
respond properly to ligand binding.  An alternative explanation might be that the
photochemistry is slower for nitrobenzyl tyrosine than nitrobenzyl cysteine, although the
efficiency of tyrosine photolysis appears greater than for cysteine.
An additional effect which was observed with tyrosine was that the presence of this
residue at the 9’position appeared to greatly enhance ACh open-channel block.  A cation-
π  effect was considered to explain this effect, with the residue being replaced
sequentially by Trp and F4-Trp.  In both cases, robust channel block was observed.
Substitution of the tyrosine with 4-methyl-tyrosine appeared to abrogate block, however,
suggesting that the tyrosyl hydroxyl may have an important role in this effect.
3.5.3 Future directions
The applicability of caged amino acids to transmembrane domains was demonstrated.
In order to know whether high-resolution kinetic information could be obtained with
these residues, it will probably be necessary to employ rapid electrophysiological
techniques, such as single-channel recording.  If nonsense suppression is able to be
achieved in mammalian cells, it is conceivable that that this technique might be used in
situations where ultra-fast control over ion channels is required.  Signaling processes
associated with conductance could be examined in this way, for example.
As will be seen in the following chapter, caged amino acid side chains may also be
used to control certain post-translational modifications.  Tyrosine will be considered in
depth in this regard in Chapter 4.  Numerous processes rely on the modification of
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cysteine side chains, such as protein lipidation, and they may be able to be subjected to
control by caged cysteine.  Thus, the demonstration that this residue is compatible with
nonsense suppression is in itself an important precursor to such experiments.
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Chapter 4. Unnatural amino acids with caged side chains
4.1 Introduction
4.1.1 Caged compounds
The use of masks is practically universal, from the Halloween celebrations of Europe,
to Malian chiwara dancers, the no¯  theater of Japan, and the False Face societies of the
Iroquois.  In the Americas, some of the most dramatic masks were carved by the people
of the Northwest Coast.  A particular specialty of the Kwakiutl is the intricately worked
transformation mask, which is worn over the head of a dancer.  At the climactic moment
of a dance, the mask is flung open along concealed hinges, effecting a startling
transformation of Raven into Sisuitl, a spirit represented by the face of a warrior flanked
by coiling serpents.  (Figure 4.1)
Figure 4.1  Kwakiutl transformation mask, which transforms Raven (left) into Sisuitl (right),
compared to the photochemical transformation of an unnatural aromatic amino acid side chain
(left) into serine (right).1
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The instantaneous transformation of one material into another is likewise the most
dramatic demonstration of chemical change.  No popular chemistry demonstration
concludes without a bang, a color change, a puff of smoke, a flash of light, a sudden
phase transition.  Instigating such a transformation with light for more serious purposes
has a rather long history in chemical biology.  Biologically active compounds may be
protected with photo-removable protecting groups, altering important functionality in the
molecule so as to block its biological efficacy.  The protected compound is often thus
referred to as being ‘caged’ or ‘masked.’  Irradiation of the system (‘de-caging’) removes
the protecting groups and restores the intrinsic efficacy of the molecule.
This nomenclature disturbs some chemists, as the term is reserved in chemistry to
describe solvation effects on reactivity, leading to the proposal that these compounds be
referred to as ‘phototriggered’ rather than ‘caged.’2  However, the term ‘caged’ is
superior grammatically and has found favor among biologists.  The term will be used
throughout this work, along with ‘masked’ and occasionally ‘phototriggered.’
Classically, caged compounds have been used in biology for rapidly initiating
processes which depend on small molecules.3-6 High-resolution kinetic information may
sometimes be obtained this way.  Caged compounds can also be used because of their
ability to bring small molecule-mediated processes under experimental control.  A system
dependent on a small molecule is primed by the diffusion of caged compounds into the
proximity of the active site.  Since the caged compounds lack the efficacy of the natural
substrate, the process under consideration is held up until experimentally initiated.  It is
mostly in this latter sense that the compounds described below will be utilized.
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4.1.2 Caged amino acids, particularly tyrosine
Caging drugs and bioactive small molecules has led naturally to the idea of caging
peptides, many of which have important regulatory roles.  Additionally, peptides offer a
number of possibilities for caging.  Both amines, such as the N-terminus of a peptide, and
carboxylates (C-terminus) may be masked by photoactive protecting groups.  Amino acid
side chains also offer a number of easily caged functional groups.  Caged serine,
threonine, and tyrosine have all been reported.7-9  Cysteine, methionine, aspartate,
glutamate, and lysine have also been caged.10-19  Given the wide range of possibilities for
introducing a photo-labile protecting group and the large number of systems where
peptide binding has an important role, it is not surprising that large numbers of caged
peptides and amino acids have been reported.
Caged tyrosine, in particular, has been employed in a number of studies.  Its earliest
reported synthesis was in 1996, where the suitability of nitrobenzyl-protected tyrosine for
solid-phase peptide synthesis was demonstrated.  In this work, caged neuropeptide Y  and
caged angiotensin II peptides were synthesized.  In the case of neuropeptide Y, the
presence of a single caged tyrosine residue severely compromised binding to cells
expressing the NK2 receptor, whereas no effect was seen for caged angiotensin II relative
to the wild-type peptide.9  More recent work by the laboratory of Jeffery Walker has used
caged tyrosine in solid-phase synthesis to generate caged peptides which interact with
calmodulin and the myosin light-chain kinase (MLCK).  Photolysis of the caged
inhibitory peptides in eosinophils caused contraction  of these cells, implying an
important role for calmodulin and MLCK in the motility of these immune cells.20
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4.1.3 Caged proteins
The advent of techniques to alter the amino acids of proteins has permitted the
consideration of ‘caged proteins,’ in which particular residues in a protein are provided
with photo-removable protecting groups.   A number of recent reviews have presented a
survey of this literature.21-23  Interesting experiments have been done with such caged
proteins, including a number of caged kinases whose activity is dependent on de-
caging.23,24  In addition, protein-protein interactions essential to actin polymerization have
been disrupted by caging a lysine on F-actin.15  The laboratory of Hagan Bayley has a
long-standing interest in caged proteins and has recently introduced a caged hemolysin
which only conducts ions subsequent to photolysis.25 A caged antibody which only binds
upon irradiation has been developed.26  Both enzymes, such as galactosidase, and proteins
involved in signal transduction, such as p21Ras, have been caged.27,28
The necessity in these experiments for forming the caged protein in vitro has meant
that investigation of real cellular processes has been difficult.  Additionally, of course,
techniques relying on modification of reactive side chains in the protein suffer from
limited specificity of caging, as differential reactivity of multiple nucleophilic residues
can be difficult to guarantee.  To solve the problem of specificity, proteins containing
caged amino acids may be synthesized through either solid-phase methods, or by semi-
synthesis followed by ligation of the unnatural amino acid-containing portion to the
remainder of the protein.  Still, experiments with these proteins may be performed in situ
only insofar as modified proteins can be introduced into the cell.  Although such
techniques are being continually improved, this limitation provides clear incentive for
this work to be done using unnatural amino acid mutagenesis, where the protein is
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synthesized inside the cell itself. 29  In addition, caging integral membrane proteins
remains a particularly challenging case for conventional methods, whereas unnatural
amino acid mutagenesis is increasingly well-established for membrane proteins.
4.2 Using nonsense suppression to introduce caged amino acids into proteins
4.2.1 Expression systems
The first requirement for introducing an unnatural amino acid into a receptor is a
viable expression system for that receptor.  The majority of experiments employing
nonsense suppression as a means of incorporating unnatural amino acids into proteins
have relied on bacterial extracts to produce the proteins of interest.  More recent efforts
have employed bacterial extracts modified to increase suppression efficiency or extracts
from eukaryotic systems.30,31 In vitro systems such as wheat germ and rabbit reticulocyte
extracts have been utilized for nonsense suppression of functional soluble proteins.32-34 In
our lab, wheat germ extracts are routinely used to generate full-length membrane proteins
for PAGE analysis.35,36 In principle, receptors containing unnatural amino acids could be
reconstituted into bilayers using such a system supplemented with microsomes 37.
However, there is no precedent for unnatural amino acid mutagenesis of an integral
membrane protein using a cellular extract.  Expression in Xenopus oocytes is the only
method to date that has been shown to be effective for incorporating unnatural amino
acids into functional receptors.38-42
4.2.2 Caging groups
The choice of caged side chain depends, of course, on the exact nature of the
information to be gained from the experiment.  The literature contains precedents for
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caged side chain hydroxyls (Tyr43-45and Ser46) thiols (Cys44), acids (Asp47), amines (β-
aminoalanine48) and amides (Npg49 in which backbone cleavage can be seen as photolytic
"decaging" of the peptide bond).  As mentioned above, the suppression efficiency of an
unnatural amino acid is related to the nature of its side chain, but in a complex fashion.
Most investigators have employed relatively small caging groups, because the charged
tRNA must pass through the ribosome in order for the amino acid to be incorporated into
the receptor.  As will be discussed further, it is difficult to predict whether one will
encounter problems in incorporating a particular amino acid.  Workers in the field have
generally reported that steric and especially charge conservation of the native side chain
help promote efficient expression.  In practice, there is no substitute for simply
attempting the suppression at the desired position with the desired unnatural amino acid.
The only caging groups precedented for unnatural amino acid suppression thus far are
nitrobenzyl (Nb)43-50 and nitroveratryl.50 Other photoactive protecting groups have very
attractive photochemical properties, but it remains to be seen whether or not these groups
can be incorporated by nonsense suppression.  There are several considerations in
choosing a caging group:  1) synthetic characteristics: the degree to which it is
synthetically accessible and compatible with coupling to pdCpA; 2) photochemical
characteristics: its action spectrum, quantum yield for photolysis, and speed of the dark
reactions that complete photolysis; and 3) reactivity in the system of interest: its stability
in water, and the possible reactivity of its photoproducts.
4.2.3 Side chain uncaging
Various types of photolysis apparatus have been employed for side chain decaging.
Experiments involving photoreactive unnatural amino acids such as diazirine, aryl azides,
120
and benzophenone32,51-55 are also relevant here, as are experiments with caged small
molecules in Xenopus oocytes.56,57  In general, methods of photolysis can be divided into
those performed on single oocytes and those performed on batches of oocytes.
An apparatus for real-time decaging in single oocytes (Figure 4.2) was designed for
the particular needs of these unusually large cells (~ 1 mm diameter).43-45,58  In most cases,
inexpensive arc lamps (either continuous irradiation or pulsed) are preferred  over the
much more costly lasers if one wishes to illuminate the entire oocyte.57
Schott UG-11 Filter 
Liquid light guide 
l = 1 m,   d = 3mm
Pyrex cover slip
passes 300 - 350 nm
break in scale
ORIEL
300 W Hg
Arc Lamp
Microscope 
50 mm quartz lens
H N
2
HO C
2
h ν
H N
2
HO C
2
OH
O
NO2
NO
H
O
300-350 nm
Perfusion
Oocyte
4
0
 m
m
E
le
c
tr
o
d
e
 
E
le
c
tr
o
d
e
 
Moveable mirror
GeneClamp 500
Amplifier
AXON
Figure 4.2  Protein decaging with real-time electrophysiological monitoring.  Apparatus for
simultaneous irradiation and electrophysiological recording from Xenopus oocytes.  The output of
the Oriel Hg arc lamp is passed through a 300 - 350 nm bandpass filter and focused onto a fiber
optic liquid light guide.  The light guide directs the beam onto the oocyte, which is clamped in a
standard two-electrode configuration.  A concave mirror can be moved into position above the
bath, reflecting some of the beam that has passed around the oocyte back to the shadowed upper
surface.  The mirror increases the overall flash intensity by ~50%.  The inset depicts the photolytic
de-caging of a caged amino acid incorporated into a channel with attendant response.  This
example indicates incorporation of Tyr(ONb) into an extracellular domain of the protein, where
removal of the caging group results in an increased number of active channels.
121
Methods for decaging proteins expressed in many oocytes at once are rather simpler.49
In the particular case of Npg decaging, oocytes were irradiated for 4 hours at 4 °C in
Pyrex vials with a 288 W Hg lamp equipped with a 360 nm band pass filter at a distance
of 15-30 cm.
4.2.4 Choice of receptor
Suppression has been demonstrated in the major classes of neuroreceptors and ion
channels.  Unnatural amino acids have been incorporated into a number of ligand-gated
channels, such as the nAChR (numerous subunits) and 5-HT3 receptors, a G-protein-
coupled receptor (NK1), GIRKs, and several potassium channels including Kir2.1 and
Shaker.38,39,42,43,45,49,59-61  In unpublished work from our lab, we have incorporated unnatural
amino acids into CFTR, a P2X receptor, and a neurotransmitter transporter.  Among these
are monomeric and multimeric receptors, both homomeric and heteromeric versions of
the latter.  We emphasize that heterologous expression of any novel protein is by no
means guaranteed, since it is uncertain whether the protein will be folded, assembled, or
transported properly.  However, our experience suggests that any protein that can be
expressed effectively in Xenopus oocytes will be amenable to incorporation of unnatural
amino acids by nonsense suppression.
4.2.5 Assay
Finally, a fundamental methodological requirement for unnatural amino acid
mutagenesis is an assay capable of detecting the effects of photolyzing a caged side
chain.  In fact, one of the reasons that receptors are such an attractive target for studies of
this nature is that electrophysiology may be employed for this purpose.
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Electrophysiology is exquisitely sensitive and therefore capable of detecting the very
small amounts of protein generated by nonsense suppression.  To date, only two-
electrode voltage clamp recordings have been made with receptors containing caged
amino acids; but single-channel recordings are in principle possible.  In addition,
electrophysiology has been successfully coupled with irradiation in a number of
experiments.56,57
Other methods may be employed to detect downstream effects of side-chain
decaging.  There is ample precedent for most biochemical methods on receptors
expressed in oocytes.62 However, given that small amounts of protein are produced in
nonsense suppression experiments, these methods often require some adaptation for use.
The literature is not terribly extensive, but there are examples on non-
electrophysiological techniques that have been successful in the analysis of the effects of
single side chain decaging, some of which are presented below.
4.2.6 Precedents for using nonsense suppression to introduce caged amino acids
Unnatural amino acid mutagenesis is an attractive technique for generating caged
proteins, because of its absolute site-specificity. The Schultz group was the first to
employ  the technique for this purpose, caging a critical active-site serine in T4 lysozyme,
bringing the activity of the enzyme under photocontrol.47 Caged aspartate was also used
by this laboratory to control protein-protein interactions important to the signaling protein
p21Ras.28  A final example from the Schultz laboratory is the use of caged serine to control
the intein splicing of a DNA polymerase.46  In vitro nonsense suppression has been used
to cage aspartate residues in an attempt to bring the dimerization of HIV protease under
experimental control.50 Again, these experiments are somewhat limited in scope by the
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fact that the caged protein would have to be introduced into a cell to truly examine a
biologically relevant interaction.
In vivo unnatural amino acid mutagenesis provides a means to solve both the problem
of specificity and biological context of the caged protein.  Experiments on nitrobenzyl-
protected tyrosine residues have been carried out in this laboratory on the nAChR.43
Particular tyrosine residues shown to be important in agonist binding were introduced
into the receptor by unnatural amino acid mutagenesis in Xenopus oocytes.  The presence
of the caging groups was shown to impair the response of the receptor to acetylcholine.
Upon removal of the protecting groups by irradiation of the oocyte, wild-type reactivity
was restored.  Using this system, important kinetic and optical parameters of caged
tyrosine in oocytes were able to be determined, although it should be noted that these
caged tyrosine residues were incorporated in an extracellular region of the protein.  The
experiments reported in Chapter 3 with incorporation of caged cysteine and tyrosine into
the M2 transmembrane domain of the nAChR are an example of caged amino acids
incorporated into membrane-resident protein domains.
The effectiveness of caged tyrosine in both of these contexts led to a consideration of
the use of caged tyrosine to control the accessibility of this particular residue in a
functioning ion channel.
4.2.7 Application of caged tyrosine to ion channels
Ion channels represent the first-line class of signal-transducing molecules.  They are
resident in the plasma membrane and are thus in intimate contact with the extracellular
environment.  In addition, of course, functioning ion channels are an imperative of
earthly life, as any non-viral organism must maintain an ion gradient to power its
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metabolic processes. As a result of these critical functions, ion channels are tightly
regulated.  All of a cell’s regulatory mechanisms are probably brought to bear upon ion
channels, including transcriptional control; translational control; RNA editing; post-
translational modification of all varieties; dynamic insertion into and removal from the
membrane; functional modulation by ligand binding, pressure, light, heat, interaction
with other proteins, changes in membrane voltage, proteolysis, etc.
Phosphorylation is a modification that is presumed to be central to ion channel
regulation.  Surprisingly, however, there is remarkably little evidence that a specific
residue in an ion channel under a particular circumstance at a given time has been
phosphorylated.  The technical barriers inherent in obtaining this information are steep.
Any assay to determine whether or not a single residue has been phosphorylated must be
extremely sensitive.  Since the phosphate linkage is biologically labile (due to enzyme
activity, if not metal-promoted hydrolysis), the analyte itself is delicate.  Ion channels are
integral membrane proteins, and isolating them for analysis is difficult, particularly under
the required conditions of sensitivity and gentleness.  Finally, the temporal sensitivity to
determine whether a functional effect is caused by phosphorylation of a single residue is
simply unattainable, although the following chapter will present a technique for perhaps
achieving it.
Despite all of this, there are numerous reports of the direct detection of ion channel
phosphorylation.63-68  There are a few which show serine or threonine phosphorylation,
but the bulk involve tyrosine phosphorylation.  Partly, this could be because tyrosine
phosphorylation may have unique importance in mediating protein-protein interactions.
But it also reflects the existence of antibodies against phosphotyrosine which do not exist
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for phosphoserine and phosphothreonine.  In the work presented in this chapter, tyrosine
phosphorylation will be the sole focus.
4.3 Incorporation of caged tyrosine into the potassium channel Kir2.1
4.3.1 Introduction
There is ample evidence to suggest that the activity of ion channels is modulated by
the same regulatory mechanisms which operate on other signal transduction pathways.
Generally speaking, modulation may be accomplished by modification of the channel
itself or through the interaction of other proteins with the channel.  Phosphorylation has
been mentioned, where a charged phosphoryl group is transferred to a serine, threonine,
or tyrosine side chain.  An example of the latter mechanism is endocytosis.  Through
endocytosis, channel activity may be regulated by removal of channels from the cell
surface, a process mediated through non-covalent interactions with proteins of the
endocytotic pathway.  These two fundamental kinds of mechanisms are by no means
exclusive.69-71  Covalent modification by phosphorylation induces conformational
changes, which may directly affect the conducting pathway.  Alternatively,
phosphorylation may regulate the binding of modulatory proteins to ion channels, as it
does with G-protein coupled receptors.72,73
As an example of the complications which arise from interaction among regulatory
pathways, endocytosis is an interesting case. The rules whereby membrane proteins are
targeted for endocytosis are not yet completely understood.  One targeting motif for
which there is a significant body of biochemical evidence is the tyrosine-based
endocytosis motif, YXXΦ, where X may be any amino acid and Φ is a hydrophobic
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amino acid, typically L, F, or M.74  Tyrosine, however, is a residue which may be
phosphorylated by tyrosine kinases.  It is likely the case that the phosphorylation state of
a channel governs whether or not it is able to be targeted for endocytosis.  Furthermore,
both phosphorylation and endocytosis are precedented in the literature as mechanisms of
ion channel modulation. It would appear, then, that the pathways regulating ion channel
modulation are likely to be tightly coupled. In order to determine the molecular-level
details of ion channel modulation, it is essential to be able to distinguish the contributions
of the various regulatory pathways.  We introduce here an experimental technique which
allows for making these distinctions.  A caged form of tyrosine, a residue which plays a
special role in recognition events leading to both phosphorylation and endocytosis, was
incorporated into a potassium channel known to be sensitive to tyrosine phosphorylation.
(Figure 4.3)
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Figure 4.3  General schematic depicting the caging of an intracellular tyrosine residue in the
potassium channel Kir2.1.  The tyrosine residue of interest is indicated in red, and the caging
group in blue.
Ion channels which have been found to respond to modification by tyrosine kinases
include the potassium channel Kir2.1, a member of the family of inwardly rectifying K+
channels with the important biological function of maintaining membrane potential.75,76
As the name implies, these channels pass potassium only in the inward direction.  They
are, in fact, always open and have no apparent gating mechanism, other than the voltage-
dependence of their rectification.  Their physiological role is often described by analogy
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to the latch on a drawer.  These channels do permit some outward K+ flow within several
mV of EK, which allow the cell’s membrane potential to approach EK.  However, once Vm
becomes more negative than EK, these channels no longer pass K+.  The latch having been
released, the cell’s Vm is free to change, with inward rectifiers’ ability to allow K+ into the
cell under hyperpolarizing conditions contributing to the return to resting Vm.  Kir2.1 is a
particular isoform of inward rectifier found in a variety of tissues in the periphery and
CNS.75  Kir2.1 currents have been found to be strongly inhibited by tyrosine
phosphorylation.  Mutation of a single tyrosine residue to phenylalanine abolishes this
inhibition.76 Interestingly, this intracellular C-terminal tyrosine (Y242) is also part of a
YXXΦ tyrosine-based endocytosis motif.  Such a motif has been demonstrated to regulate
the expression of the ENaC sodium channel in oocytes.77
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Figure 4.4  Schematic showing the chemistry whereby wild-type tyrosine is revealed by
photolysis of Tyr(ONb).
By the nonsense codon suppression method, we have introduced the caged tyrosine
analog O-nitrobenzyl tyrosine, Tyr(ONb), into Kir2.1 at the critical Y242 position.  As
introduced, the protected tyrosyl oxygen is incapable of acting as a tyrosine kinase
substrate.  Nor, based on crystallographic evidence, would it appear that tyrosine
protected in this way would permit binding by components of the clathrin-mediated
endocytotic pathway.78  However, UV irradiation of the protein releases the nitrobenzyl
protecting group, revealing the wild-type tyrosine residue. (Figure 4.4)  Restoration of the
native side chain, of course, permits both phosphorylation and/or recognition by the
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endocytotic machinery. This technique thus brings the initiation of phosphorylation and
endocytosis under some degree of experimental control.  The experiments reported herein
distinguish the contribution of phosphorylation from that of endocytosis, revealing
important details about an interaction which may be fundamental to the regulation of ion
channels in vivo.
4.3.2 Results
4.3.2.1 Kir2.1 currents are decreased by tyrosine kinase
Initially, we verified that the inwardly rectifying potassium channel Kir2.1 from Mus
musculus is modulated by tyrosine phosphorylation under the present experimental
conditions.76  Xenopus oocytes expressing Kir2.1 were voltage clamped at 0 mV in a
recording solution containing 96 mM KCl.  Potassium currents elicited by a voltage step
to a test potential of –80 mV were recorded.  Table 4.1 shows that oocytes expressing
Kir2.1 gave robust 13.3 ± 1.2 µA whole-cell potassium currents after 24 hours.  Oocytes
treated with the tyrosine phosphatase inhibitor phenylarsine oxide (PAO)79 showed no
reduction of current, giving whole-cell potassium currents of 13.1± 1.4µA.  However,
oocytes co-injected with v-Src gave an average current of 7.8±0.3µA, a 57% current
reduction relative to those injected with Kir2.1 alone.  This effect was enhanced by
treatment with PAO; oocytes co-injected with v-Src and treated with PAO gave average
currents of only 5.7±0.6µA.  Indeed, co-injection with v-Src alone did not always yield
significant current reduction.  This is consistent with results from other laboratories.80
Although there appeared to be no strict requirement for the presence of phosphatase
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inhibitors, the phosphatase inhibitor PAO was always added for consistency between
experiments.
Treatment Mean current (µA±SEM) n
- 13.3±1.2 5
PAO 13.1±1.4 5
v-Src 7.8±0.3 5
v-Src + PAO 5.7±0.6 5
PYK-2 12.8±0.5 5
PYK-2 + PAO 6.9±0.8 5
Table 4.1  Averaged whole-cell currents for Kir2.1.
The proline-rich tyrosine kinase PyK2 gave results similar to v-Src.  48% current
reduction was measured upon PAO treatment of oocytes co-injected with PyK2 (Table
4.1).  In this case, co-injection of the kinase without phosphatase inhibitor was not
sufficient to cause current reduction: oocytes co-expressing the channel with PyK2 gave
12.8±0.5µA.
Table 4.2 confirms that Y242 is critical for the effect of tyrosine kinases.  The
tyrosine residue at position 242 was changed to phenylalanine by site-directed
mutagenesis.  Oocytes expressing the Kir2.1-Y242F construct were unaffected by
treatment with the tyrosine phosphatase inhibitor PAO and/or tyrosine kinases.  For
instance, untreated oocytes expressing the Y242F construct gave average whole-cell K+
currents of 31.4±2.7µA.; oocytes co-expressing v-Src and treated with PAO gave
currents of 31.2±0.9µA.  The overall expression for the experiment depicted in Table
4.2 was higher than that for the WT Kir2.1, which represents imprecision in mRNA
quantitation or batch-dependent expression differences among oocytes.  There were no
consistent differences in expression level between the WT (WT) and Y242F constructs.
In other experiments on Y242F at expression levels comparable to those of Table 4.1, we
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confirmed that no combination of v-Src expression and PAO gave significant decreases
for this mutant.
Treatment Mean current (µA±SEM) n
- 31.4±2.7 6
PAO 34.0±2.0 5
v-Src 30.3±1.8 5
v-Src + PAO 31.2±0.9 4
PYK-2 34.3±2.1 4
PYK-2 + PAO 32.9±3.1 4
Table 4.2  Averaged whole-cell currents for Kir2.1 Y242F.
For both constructs, similar but less extensive results on the inhibition of K+ currents
were obtained with the tyrosine phosphatase inhibitor pervanadate substituting for PAO.
Similar data were also obtained when the v-Src cRNA injection was omitted but oocytes
were injected with TrkB, a receptor tyrosine kinase, and exposed to BDNF.  These data
suggest that several different activators of tyrosine phosphorylation can inhibit the
function of Kir2.1.
4.3.2.2 Photolytic decaging of tyrosine-242 leads to a decrease in current
In order to gain temporal control over the state of the tyrosine side chain at position
242, the unnatural amino acid Tyr(ONb) was incorporated into Kir2.1 at position 242.
The nonsense codon TAG was introduced using site-directed mutagenesis.  mRNA
encoding the Kir2.1-Y242TAG construct was generated by in vitro transcription.  This
message was co-injected into Xenopus oocytes along with the nonsense suppressor tRNA
which had been chemically charged with the synthetic amino acid Tyr(ONb).  In order to
verify that functional protein was produced by this procedure and to assess the effect of
decaging the caged tyrosine residue, oocytes were studied as in the experiments of Table
4.3.  As in most unnatural amino-acid experiments to date, current measurements show
that expression levels are rather lower—in this case by a factor of 5 to 10—than the
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levels for WT channel or for conventional site-directed mutagenesis (compare the
expression levels in Table 4.1 and Table 4.2 above).  UV light was delivered to oocytes
for 3 s.43  Figure 4.5 presents normalized current values averaged over several oocytes.
v-Src hν Percent decrease±SEM
- + 5.0±1.5
+ - 1.5±0.9
+ + 32±0.9
Table 4.3 Normalized average whole-cell current decrease of oocytes expressing Kir2.1
Y242TAG suppressed with Tyr(ONb) thirty minutes after initiation of experiment (n=5).
Control oocytes were injected with Kir2.1-Y242TAG mRNA and tRNA-Tyr(ONb)
but not with v-Src mRNA.  Current from these oocytes decreased by only 5.0±1.5%
over the 30 min interval, showing that irradiation itself had only a small effect on Kir2.1
currents.  In a second control, whole-cell currents were measured in non-irradiated
oocytes co-expressing Kir2.1 containing Tyr(ONb) and v-Src.  After 30 min, the average
current decrease was only 1.5±0.9%.  This is consistent with the supposition that while
the nitrobenzyl protecting group remains, the residue at 242 is unavailable as a substrate
for interaction with other proteins—either tyrosine kinases or adaptor proteins.
Importantly, oocytes co-expressing Kir2.1 and v-Src, treated with PAO, and irradiated
showed an average current decrease of 32.0±0.9% 30 min after irradiation.  This shows
that the decaging of Kir2.1-Y242 under conditions favoring tyrosine phosphorylation
leads to a large decrease in current.
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Figure 4.5 Inhibition of current in oocytes expressing Kir2.1-Y242TAG suppressed with
Tyr(ONb).  Averaged normalized data from batches of oocytes recorded at t = 30 min  Average
values (and ranges) for 100% current were 8.7 (5.5 to 13), 6.5 (4.5 to 10.4), and 6.6 (1.6 to 15.5)
µA for the three groups (left to right). Error bars indicate SEM, n = 4 to 6 oocytes.
Although these data qualitatively agree with the data for the WT and Y242F
construct, present limitations of the nonsense suppression technique prevent direct
quantitative comparisons.  First, suppression is incomplete, leading to a substantial
proportion of Kir2.1 subunits truncated at the 242 position.  To control for this effect, we
expressed the Y242TAG construct alone; there were no currents.  When we co-expressed
Y242TAG and WT channels, we saw currents whose modulation properties were like
those depicted in the experiment of Table 4.1.  Therefore, dominant negative effects due
to truncated subunits probably play no role in our experiments.  Second, read-through
may occur, so that natural residues would be incorporated at position 242.  It is therefore
possible that some channels would contain one or more Kir2.1 subunits with natural
residues.  Although we know that a channel with four Y242F subunits does not respond
to v-Src and PAO (Table 4.2), we do not know how modulation would proceed for
channels with varying numbers of subunits containing one or more of the other 18 natural
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amino acid residues.  In the unlikely event that read-through produces a channel with
tyrosine at position 242 in one or more subunits, the modification has presumably
occurred during the PAO incubation period (> 30 min).  We assume that the general
effect of read-through would be to decrease the modulatory effect of irradiation.
4.3.2.3 Decaging tyrosine-242 also causes a capacitance decrease
Importantly, Table 4.4 shows that the current decrease observed in oocytes expressing
v-Src and Kir2.1-Y242-Tyr(ONb) was accompanied by a significant capacitance
decrease.  The change in capacitance is a direct measure of net endocytotic activity of a
cell (i.e. exocytosis minus endocytosis).  In both control cases where irradiation of
oocytes caused no current inhibition, the capacitance remained essentially constant over
the length of the experiment.  Thus, the correlation between current and capacitance
decrease is clear.   (Figure 4.6)
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Figure 4.6 Decrease of capacitance in oocytes expressing Kir2.1-Y242TAG suppressed with
Tyr(ONb).  Average values (and ranges) for 100% capacitance were 190 (159 to 227), 187 (167 to
202), and 194 (132 to 234) nF for the three groups (left to right).  Error bars indicate SEM, n = 4
to 6 oocytes.
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Control oocytes that were irradiated without v-Src co-expression showed an overall
capacitance decrease of only 2.8±0.8% 30 min after irradiation.  The second control, in
which oocytes co-expressing Kir2.1 with caged tyrosine and v-Src were studied without
irradiation, also showed little capacitance decrease (3.0±0.4%) over the time course of
recording.  In contrast, oocytes expressing v-Src and Kir2.1 in which the Tyr(ONb)
residue at 242 is uncaged by irradiation, showed an overall decrease in membrane
capacitance of 14.1±1.9% over 30 min.  This decrease suggests that the membrane
surface area has decreased as a result of increased endocytotic activity.
v-Src hν Percent decrease±SEM
- + 2.8±0.8
+ - 3.0±0.4
+ + 14.1±1.9
Table 4.4 Normalized average whole-cell capacitance decrease of oocytes expressing
Kir2.1Y242TAG suppressed with Tyr(ONB) thirty minutes after initiation of experiment (n=5).
In additional controls, we found no decrease in capacitance when oocytes were
injected with v-Src cRNA, treated with PAO, and then irradiated.  Therefore the
capacitance change does not arise from possible photosensitive processes involving v-
Src.  In additional controls, oocytes were injected with tRNA-Tyr(ONb) and v-Src, and
then treated with PAO.  Again, irradiation produced no capacitance change, ruling out
possible suppression of stop codons in endogenous proteins as the source of the
photosensitivity.  Furthermore, there were no changes in capacitance associated with
decaging of tyrosine in our previous study of caged tyrosine at the nicotinic acetylcholine
receptor.  Therefore tyrosine decaging in general does not lead to membrane endocytosis.
Irradiated oocytes co-expressing wild-type Kir2.1 and v-Src showed no decrease over
the time course of the experiment.  Presumably, the wild-type channel is capable of
phosphorylation by v-Src and would perhaps be expected to show a current decrease
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upon application of PAO.  Under certain conditions, current reduction with wild-type
Kir2.1 could, in fact, be seen in response to PAO treatment.  Oocytes recorded from
shortly after addition of the phosphatase inhibitor showed significantly lower maximal
currents than those which were untreated.  This observation is consistent with the
existence of a dynamic equilibrium between kinase and phosphatase activity.  Under
typical conditions, no special effort was taken to record immediately after phosphatase
addition.  Consequently, equilibrium was established prior to recording, and oocytes
showed an apparent steady-state current.  With suppressed proteins, the caged tyrosine
provides a controllable switch to initiate a process which occurs on the native protein.
We compared the time course of the current decrease and the capacitance decrease by
normalizing to the decrease at 30 min, then interpolating the approximate time to half-
completion for this decrease.  The average values were quite comparable: 11.8 min for
current and 11.1 min for capacitance.  These data indicate that the capacitance change
and the current decrease followed similar time courses.  Nonetheless some of our
measurements suggest that the capacitance decrease begins after a delay of several
minutes.  This possible initial delay has not been investigated systematically.
4.3.2.4 Dominant negative dynamin eliminates capacitance decrease and partially
eliminates current decrease
Capacitance measurements may reflect the contribution of various mechanisms of
endocytosis. In order to test specifically whether clathrin-mediated pathways were
involved, experiments were performed with a dominant negative dynamin isoform.  If
Kir2.1 inhibition resulted from clathrin-mediated endocytosis, co-injection of oocytes
with dominant negative dynamin (dynamin-K44A) 81,82 at levels capable of blocking
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endogenous dynamin activity would eliminate both the current change and the
capacitance change.  Table 4.5 and Table 4.6 present data that distinguish between these
two events.
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Figure 4.7 Data for current and capacitance for oocytes recorded 30 min after irradiation (mean +
SEM, n=5).  Left-hand y-axis and full bars represent normalized current decrease.  Average values
(and ranges) for 100% were 4.1 (3.15 to 4.8), 3.1 (2.8 to 3.7), and 4.1 (3.0 to 5.7) µA for the three
groups (left to right).  Right-hand axis corresponds to hollow bars, representing normalized
capacitance decrease.  The rightmost column shows capacitance change of uninjected control
oocytes.  Average values (and ranges) for 100% capacitance were 197 (191 to 205), 225 (191 to
248), 189 (174 to 199), and 197 (190 to 209) nF for the four groups (left to right).  Error bars
represent SEM.
Figure 4.7 shows averaged current and capacitance data for three to eight oocytes and
also the capacitance change of uninjected control oocytes over the course of the
experiment.  Current change is indicated by filled bars and the left-hand y-axis.  When no
dynamin mRNA was co-injected, the average current decrease 30 min after irradiation
was 41.1±0.7%, which is reasonably consistent with the value of 32% obtained in the
experiment of Table 4.3 and Figure 4.5.  Co-expression with a WT dynamin isoform had
an insignificant effect on the current decrease: the average decrease was 46.5±5.7%.
Dominant negative dynamin affected the current decrease somewhat, but it remained
relatively large at 27.9±1.5%.  The hollow bars and right-hand axis of Figure 4.7
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represent the normalized capacitance decrease.  Without added dynamin, the average
capacitance change associated with decaging tyrosine on Kir2.1 in the presence of v-Src
was 17.7±5.8%, consistent with the average value of 14.1% reported in Table 4.4.
Injection of WT dynamin gave rise to an average capacitance decrease of 26.0±6.6%,
not significantly larger than that of oocytes containing only endogenous dynamin.  The
effect of the dominant negative K44A dynamin isoform, however, was dramatic.
Oocytes expressing dominant negative dynamin displayed an average capacitance change
of 4.4±0.7% over 30 min.  This degree of change is not significantly different from the
baseline capacitance change for uninjected oocytes (3.3±1.4%).
Channel Dynamin % decrease±SEM n
Kir2.1 - 41.1±0.7 3
Kir2.1 WT 46.5±5.7 5
Kir2.1 K44A 27.9±1.5 8
Table 4.5 Normalized average whole-cell current decrease of oocytes expressing Kir2.1Y242TAG
suppressed with Tyr(ONb) treated with the indicated dynamin thirty minutes after initiation of
experiment.
Channel Dynamin % decrease±SEM n
Kir2.1 - 17.7±5.8 3
Kir2.1 WT 26.0±6.6 5
Kir2.1 K44A 4.4±0.7 8
- - 3.3±1.4 5
Table 4.6 Normalized average whole-cell capacitance decrease of oocytes expressing
Kir2.1Y242TAG suppressed with Tyr(ONb) treated with the indicated dynamin thirty minutes
after initiation of experiment.
By combining current and capacitance measurements with the expression of dominant
negative dynamin, we have shown that significant current decrease occurs in the absence
of appreciable capacitance change.  The 26% current reduction in the absence of clathrin-
mediated endocytosis is smaller than the 41% or 32% reductions seen in cells where the
endocytotic machinery has not been perturbed.  Thus, clathrin-mediated endocytosis may
account for a portion of the whole-cell current reduction.  In addition, however, a non-
endocytotic mechanism reduces current after the decaging of Tyr242.
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4.3.2.5 Fluorescent labeling corroborates dynamin-mediated endocytosis
In order to directly observe loss of plasma membrane, and to complement the
electrophysiological data on current and capacitance change, we labeled and measured
surface proteins on the oocyte.  Oocytes expressing Kir2.1 were exposed to the
impermeant thiol-reactive fluorophore tetramethylrhodamine-5-maleimide.  Since the
reagent is not specific for Kir2.1, uninjected oocytes were also labeled as a control.
Oocytes treated in this manner displayed fluorescence at the cell surface.  Oocytes
expressing the channel displayed 65% greater  fluorescence intensity than uninjected
oocytes, suggesting that one or both of the two putative extracellular cysteines of Kir2.1
are labeled by the maleimide.  After 3 s of irradiation, fluorescence was measured at the
animal pole at 2- or 2.5 min intervals over a 30-min period.83  (Figure 4.8)
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Figure 4.8  Normalized, average fluorescence change at t = 30min for oocytes expressing Kir2.1-
Y242TAG suppressed with Tyr(ONb) and treated with PAO, then labeled with
tetramethylrhodamine maleimide.  The first column represents a control in which oocytes were not
co-injected with v-Src.  In all other columns, oocytes expressed the Kir2.1-Y242Tyr(ONB) along
with v-Src.  The second column represents a control in which oocytes were not irradiated.  In the
third column, no exogenous dynamin was added.  The fourth column shows oocytes co-expressing
WT dynamin.  The fifth column represents oocytes co-expressing dynamin-K44A.  Each bar
represents 6 or 7 oocytes.  The average values (and ranges) for 100% fluorescence were 5.76 (3 to
9.5), 5.74 (3.5 to 7.2), 6.45 (3.7 to 9.5), 5.60 (3.93 to 6.92), and 5.62 (1 to 9.7) V.
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Averaged data from six or seven oocytes are collected in Table 4.7.  In  oocytes
expressing Kir2.1 with Tyr(ONb) at Y242 but not v-Src, the fluorescence change at 30
min was similar to that of non-irradiated cells expressing v-Src, 0.4±0.4% and
0.2±0.2%, respectively.  Cells that expressed both channel and kinase without added
dynamin showed an average fluorescence change of 5.7±0.9% 30 min after irradiation.
The co-injection of WT dynamin increased endocytosis markedly: there was a 9.2±0.7%
change over 30 min.  As before, dominant negative dynamin suppressed membrane
turnover to the level of uninjected oocytes.  Oocytes co-injected with dynamin-K44A
showed only a 0.4±0.2% fluorescence change 30 min after tyrosine decaging.  Net
membrane internalization is revealed by decreased fluorescence, possibly because the
exciting and/or emitted light is partially shielded by intracellular pigment granules and
other structures.  Corroborating the capacitance measurements, irradiation leads to
internalization only in oocytes co-expressing v-Src, caged Kir2.1, and endogenous or
added WT dynamin under conditions favoring tyrosine phosphorylation.  Thus, both
capacitance and fluorescence measurements imply that dynamin is required for decaging-
induced endocytotic activity in the cell.
v-Src hν WT dynamin K44A dynamin % decrease±SEM
- + - - 0.4±0.4
+ - - - 0.2±0.2
+ + - - 5.7±0.9
+ + + - 9.2±0.7
+ + - + 0.4±0.2
Table 4.7  Normalized average surface fluorescence decrease of oocytes expressing Kir2.1
Y242TAG suppressed with Tyr(ONb) thirty minutes after initiation of experiment.
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4.3.2.6 Tyrosine phosphorylation decreases Kir2.1 conductance and decreases total
open channels per patch
In single-channel experiments on WT Kir2.1 at –80 mV and –100 mV, we found that
co-expression of v-Src and treatment with PAO had two major effects on channel
openings.  First, conditions favoring tyrosine phosphorylation decrease the conductance
of Kir2.1.  For instance, Figure 4.9 presents tracings and all-points histograms for oocytes
injected either with Kir2.1 alone, untreated with PAO, or with Kir and v-Src and treated
with PAO.  The single-channel conductances for control and Src and/or PAO oocytes
were 17.5 + 0.4 pS and 12.3  + 0.2 pS (mean + SEM, n = 8 and 5, respectively),
amounting to a 30% decrease in single-channel conductance.  We found no additional
substates, suggesting that the conductance decrease is not graded with the number of
affected subunits in a channel.  Thus at least part of the phosphorylation-induced decrease
in macroscopic currents derives from a decreased single-channel current.
Second, v-Src/PAO patches consistently displayed fewer active channels.  In a series
of recordings with tightly controlled pipette tip diameter, three of five untreated patches
occasionally displayed two simultaneous openings, and the other two displayed only a
single opening.  Therefore the average peak was 1.6 simultaneous openings.  On the other
hand, none of five Src/PAO patches displayed more than one simultaneous opening; and
two of these patches displayed no openings.  Therefore the average number of peak
simultaneous openings was 0.6.  These data show that v-Src/PAO decreases either the
number of active channels per patch or the open probability Popen.  We noted that Popen was
near 0.5 for both untreated and v-Src/PAO patches with only a single channel; therefore
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the probable basis of the difference is that v-Src/PAO patches contained fewer active
channels.
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Figure 4.9 Conditions favoring tyrosine phosphorylation decrease single-channel conductance of
WT Kir2.1. Left panel:  Traces showing exemplar single-channel currents from cell-attached
patches at –100 mV.  The arrows point to the closed states and to the open states for control
oocytes (left) and for oocytes co-injected with v-Src and treated with PAO (right). Right panel:
Normalized all-points amplitude histograms for exemplar patches.  Data from an oocyte injected
with Kir2.1 alone are shown as heavy lines, and data from an oocyte injected with Kir2.1 + v-Src
and exposed to PAO are shown as light lines.  The arrows show open-channel amplitudes from
Gaussian fits to the data, 1.69 and 1.15 pA  for the control and v-Src/PAO patches, respectively.
4.3.2.7 There Is No Direct Evidence for Tyrosine Phosphorylation of Kir2.1
Active tyrosine kinases decrease the activity of WT Kir2.1 (Table 4.1), are required
for the decreases in both current and membrane area after tyrosine decaging (Table 4.3
and Table 4.4), and produce decreases in active channel density per patch (Figure 4.9).
None of these effects is observed for the Y242F mutant channel. The most direct
interpretation of these data is that covalent modification of Y242 causes these effects, as
proposed in earlier work on this system. It is also possible that this tyrosine residue is the
interaction partner of proteins that must themselves be tyrosine phosphorylated for full
activity, as is the case for many of the proteins in the clathrin-mediated endocytotic
pathway.
Therefore, we sought evidence that Kir2.1 is phosphorylated at position 242 in the
presence of kinases and phosphatase inhibitors. The primary strategy used to detect
phosphorylation of Y242 was Western blotting with anti-phosphotyrosine antibodies. For
142
the purposes of immunoprecipitation and immunostaining of the channel, a Kir2.1
construct with the hemagglutinin (HA) epitope at the carboxyl terminus was generated.
We verified in electrophysiological experiments that functional expression and inhibition
by v-Src/PAO of Kir2.1-HA were similar to WT Kir2.1. In addition, a Y242F-HA
construct was made and shown to behave like the Y242F channel.
Also, a panel of anti-phosphotyrosine antibodies was examined to optimize sensitivity
under the present experimental conditions, with the result that 4G10 gave the highest
sensitivity, followed closely by PY72.  (Figure 4.10)
MW MW1a 1b 2a 2b 3a 3b 4a 4b 5a 5b 6a 6b
Figure 4.10  Comparison of anti-phosphotyrosine antibody affinities in a Western blot of positive
control extract  from EGF-stimulated cells (a = 2 µg, b = 0.2 µg total protein).  Lane 1:  Upstate
Biotech 4G10.  Lane 2:  Covance 2G8-D6.  Lane 3:  Covance 6G9.  Lane 4:  Covance 1G2.  Lane
5:  Covance PY72.  Lane 6:  Covance PY20.
To establish whether Western blotting with anti-PY antibodies was sufficiently
sensitive to detect tyrosine phosphorylation of integral membrane proteins expressed in
oocytes, control experiments were performed using the receptor tyrosine kinase TrkB.
This kinase undergoes auto-phosphorylation on tyrosine in response to the binding of its
ligand, BDNF. Plasma membranes from BDNF-stimulated oocytes expressing TrkB were
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isolated by physical dissection. Western blotting with an anti-TrkB antibody (Santa Cruz
C14) shows readily observable staining at the expected molecular mass (Figure 4.11). As
expected, uninjected oocytes show no anti-TrkB staining. Blotting with an anti-
phosphotyrosine antibody (4G10) detects numerous phosphoproteins in the oocyte
membrane, which is consistent with the effects of treating the oocytes with a tyrosine
phosphatase inhibitor. Oocytes expressing TrkB contain a tyrosine-phosphorylated
protein that co-localizes with TrkB and that is not present in uninjected oocytes.
Densitometry showed that the phosphorylated TrkB band is roughly as intense as the
nearby bands corresponding to endogenous phosphorylated proteins.
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Figure 4.11  Detection of phosphorylated TrkB serves as a positive control for the detection of
phosphorylated integral membrane protein from dissected oocyte plasma membranes.  Western
blot of membranes from BDNF-stimulated oocytes expressing TrkB shows positive staining with
both anti-TrkB and anti-PY antibodies.  The left panel was stained with Santa Cruz C14 anti-TrkB
antibody.  Lane 1:  Uninjected oocytes.  Lane 2:  TrkB-expressing oocytes.  The right panel was
stained with Upstate Biotech 4G10 anti-phosphotyrosine antibody.  Lane 1:  Uninjected oocytes.
Lane 2:  TrkB-expressing oocytes.
Comparable experiments were carried out with Kir2.1-HA constructs (Figure 4.12).
Kir2.1 constructs are clearly detectable by the anti-HA antibody (HA.11) at the
appropriate molecular mass. A protein produced by in vitro translation of Kir2.1-HA
144
mRNA from wheat germ extract confirms the assignment of monomeric Kir2.1 subunits.
The stained upper molecular mass bands presumably represent oligomers that are not
denatured, even under SDS-PAGE conditions. In contrast, staining Western blots with the
anti-phosphotyrosine antibody gives no convincing signal corresponding to Kir2.1
monomer or oligomer. Phosphoproteins are clearly present at a variety of other molecular
masses, which is consistent with the TrkB results and corroborates that the assay does
detect membrane phosphoproteins. That these phosphoproteins are also present in
uninjected oocytes treated with PAO confirms that they do not arise from Kir2.1. Any
staining in the region corresponding to monomeric Kir2.1 is <10% as intense as that for
nearby endogenous phosphorylated proteins.
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Figure 4.12  Failure to detect Kir2.1 phosphorylation in membranes dissected from oocytes
expressing the channel.  Western blot of membranes from oocytes expressing epitope-tagged
Kir2.1 shows positive staining with anti-HA antibody, but not with the anti-phosphotyrosine
antibody 4G10.  The left panel is stained with Covance HA.11.  Lane 1:  Uninjected oocytes.
Lane 2:  Kir2.1-HA.  Lane 3:  Kir2.1Y242F-HA.  Lane 4:  Kir2.1-HA prepared by in vitro
translation from wheat germ extract.  Lanes 1-3 contain protein from membranes dissected from
21-23 oocytes.
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In addition to these experiments, a number of other immunoprecipitation and
immunodetection schemes were examined. Immunoprecipitation of phosphoproteins
from oocyte homogenates with anti-PY antibodies followed by detection with anti-HA
antibodies was undertaken, as well as the reverse.  A completely different assay was also
attempted, namely, autoradiography. Even though this technique is often considered to be
more sensitive than Western blotting, it has the disadvantage of not distinguishing
between phosphorylation on tyrosine, serine, or threonine without phosphopeptide
mapping. Oocytes were supplied with 32P either by co-injection with mRNA encoding the
channel, or by incubation in γ-[32P]ATP. HA-tagged channels were immunoprecipitated
from whole-cell membrane preparations and from physically dissected membranes by
both anti-HA and anti-PY antibodies and subjected to SDS PAGE. No differences
between the Kir2.1-HA and Kir2.1-Y242F-HA channels were ever observed in 32P
autoradiography, and further mapping was not attempted. That we did not detect tyrosine
phosphorylation of Kir2.1 is not conclusive, but it leads us to the explanation that other
protein(s) may be phosphorylated.  Interactions among these proteins, or between these
proteins and Kir2.1, may lead to downregulation of K+ current and endocytosis after
Y242 is de-caged.
4.3.3 Discussion
4.3.3.1 Caged tyrosine allows study of ion channel modulation
Evidence for the regulation of ion channels by phosphorylation has become
increasingly difficult to ignore in recent years.84,85  In most cases, it has been impossible
to establish the molecular basis for this regulation.  In principle, phosphorylation could
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directly influence channel properties by inducing conformational changes in ion channel
proteins themselves.  Alternatively, phosphorylation may promote, inhibit, or alter
protein-protein interactions between the channel and other potential modulators of
channel function.  In the latter case, information about the kinetics of these events may be
useful preliminary knowledge in helping to identify what kinds of processes may lie
downstream of phosphoryl transfer.  The use of caged compounds for determining the
kinetics of cellular events is well-precedented.4-6  Through the use of nonsense
suppression to introduce unnatural amino acids, functional groups on the ion channel
itself may be caged.  The photolytic decaging of protected tyrosine has been
demonstrated in the nicotinic acetylcholine receptor, but for the study of ion channel
phosphorylation, caged tyrosine represents a new tool.43  A particular tyrosine is rendered
unsuitable as a substrate for phosphorylation until the moment it is released by UV
irradiation provided by the experimenter.
Here, Kir2.1 was chosen as an experimental system, because there is a clearly
detectable current reduction dependent upon a single tyrosine in the C-terminal
intracellular tail of the receptor, Y242.  Mutation of this residue to phenylalanine
abolishes the effects of tyrosine kinases on whole-cell channel conductance.76 (Figure
4.13)
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Figure 4.13 Whole-cell current from oocytes expressing Kir2.1 (left panel) and Kir2.1-Y242F
(right panel).  Data columns represent normalized currents (mean + SEM, 4-5 oocytes).  Where
indicated, oocytes were co-injected with cRNA for tyrosine kinases v-Src or Pyk2 and incubated
with 10 µM PAO for at least 30 min prior to recording.  100% corresponds to 13.3 µA for WT and
31.4 µA for Y242F.
When this tyrosine is replaced with Tyr(ONb), the channel becomes insensitive to the
activity of v-Src, in the same way that the Y242F mutant fails to respond to tyrosine
kinases.  However, irradiation reveals the wild-type residue, rendering the channel
sensitive to tyrosine kinase-mediated current modulation.  Over the course of the next
thirty minutes or so, the whole-cell current decreases by about 50%. (Figure 4.14)
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Figure 4.14 Inhibition of current in oocytes expressing Kir2.1-Y242TAG suppressed with
Tyr(ONb), shown by typical current traces from individual oocytes.  Left panel:  The effect of
irradiating an oocyte (3 s) that is neither co-expressing v-Src nor exposed to PAO.  Center panel:
Effect of co-expression of v-Src and exposure to PAO, but no irradiation of the oocyte.  Right
panel:  Traces from an oocyte co-expressing v-Src, exposed to PAO, and irradiated.  Oocytes were
clamped at 0 mV and stepped to -80 mV to elicit inward current.  Bath solutions contained 96 mM
KCl.  Time after irradiation is indicated.
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This time course seems slow for a conformational change resulting in altered channel
properties.  It is possible that current reduction results from protein-protein interactions
arising as a result of phosphorylation-induced conformational changes, however.  In
order to understand the nature of these interactions, it is necessary to consider the various
pathways which could account for the phenomenon.
As in any mutagenesis experiment on an integral membrane protein, it is difficult to
be certain that the conformation of the mutant protein is identical to that of the wild-type
protein.  The nitrobenzyl group adds steric bulk to the tyrosine side chain and prohibits
the tyrosyl hydroxyl from engaging in hydrogen bonding.  It could be the case that
photolysis simply allows the protein to adopt the wild-type conformation, perhaps
permitting the binding of another protein which is blocked by Tyr(ONb).  The caged
Kir2.1 behaves identically to the wild-type channel by most measures, and the necessity
for both a tyrosine kinase and a phosphatase inhibitor to induce current inhibition point to
a role for phosphorylation.  However, we cannot rule out the possibility that a
phosphoprotein which would normally bind to the C-terminal region of Kir2.1 and
decrease its current is able to do so after removal of the protecting group.
4.3.3.2 Kir2.1 current decrease could result from endocytosis
Another possibility to account for the current reduction we observe upon liberating
the tyrosine residue is that the tyrosine itself is an necessary component of some protein-
protein interaction motif.  In fact, the sequence in which Y242 occurs, YIPLD, is a
consensus sequence for clathrin-mediated endocytosis.  The motif YXXΦ, where X is any
amino acid and Φ is a hydrophobic residue, has been proposed as the recognition signal
for AP-2, an adapter protein which targets polypeptides to clathrin-coated vesicles.
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Crystallographic evidence confirms that the AP-2 µ subunit is able to bind peptides
containing the YXXΦ motif.74,86  A study of the ENaC channel in Xenopus oocytes has
demonstrated that a tyrosine residue in such a motif is functionally important in targeting
an ion channel for removal from the plasma membrane.77
An obvious explanation for the phenomenon we observed with Kir2.1 would be that
caged tyrosine protects Kir2.1 from incorporation into clathrin-coated vesicles.  Once
photolysis liberates the wild-type residue in a tyrosine-based endocytotic motif, however,
the channel is removed from the plasma membrane by a clathrin-mediated pathway.  This
would neatly account for the observed loss in current.  In addition, an endocytotic
mechanism could easily be regulated by the phosphorylation state of tyrosine.  For
example, negative regulation of endocytosis by tyrosine kinases could occur if
phosphorylation of the tyrosine in this motif precludes binding, as suggested by the
crystal structure of a YXXΦ-containing peptide bound to AP-2 and a number of
functional studies.78,87-89  Alternatively, endocytosis could be positively regulated by a
kinase if components of the endocytotic machinery required tyrosine phosphorylation for
full activity.
4.3.3.3 Current decrease is not due solely to endocytosis
In order to establish the relative contribution of endocytotic and alternative
phosphorylation-based mechanisms, experiments were performed to address the issue of
receptor turnover.  If Kir2.1 were being removed from the plasma membrane, this should
be detectable in a number of ways.  The two which we chose to examine are changes in
whole-cell membrane capacitance, which is related to cellular surface area, and changes
in surface fluorescence of thiol-labeled Kir2.1.  First of all, there is a decrease in
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membrane capacitance associated with current inhibition, as shown in Figure 4.15.
Oocytes which are expressing receptors for which there is no current reduction upon
irradiation also show no capacitance change.  Conversely, oocytes expressing Kir2.1
suppressed with Tyr(ONb) at position 242 show capacitance decrease if and only if they
are co-injected with tyrosine kinase, treated with a tyrosine phosphatase inhibitor, and are
irradiated to remove the nitrobenzyl protecting group.
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Figure 4.15 Inhibition of current and decrease of capacitance in oocytes expressing Kir2.1-
Y242TAG suppressed with Tyr(ONb).  Typical current traces from individual oocytes are shown.
Left panel: The effect of irradiating an oocyte (3 s at arrow) that is neither co-expressing v-Src nor
exposed to PAO.  Center panel:  Effect of co-expression of v-Src and exposure to PAO, but no
irradiation of the oocyte.  Right panel:  Traces from an oocyte co-expressing v-Src, exposed to
PAO, and irradiated.  Oocytes were clamped at 0 mV and stepped to -80 mV to elicit inward
current.  Bath solutions contained 96 mM KCl.
The second experiment corroborates this.  In this case, the oocyte surface was labeled
with a membrane-impermeant thiol-reactive fluorescent compound (Figure 4.16).  By
viewing the fluorescence decrease over time, a similar trend to that seen by capacitance
measurements was observed.  Although the time course of the capacitance change and the
extent are slower and not as great as those of the whole-cell current change, it appears
that endocytosis is stimulated by kinase-mediated events subsequent to uncaging a
tyrosine at position 242.
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Figure 4.16  Fluorescence analysis of membrane retrieval.  Left panel:  Confocal image of two
oocytes labeled with 10 µM tetramethylrhodamine-5-maleimide, a membrane-impermeant thiol-
reactive fluorophore.  The oocyte at left was injected with v-Src and Kir2.1-Y242TAG suppressed
with Tyr(ONb).  Oocyte on the right was not injected.  Right panel:  Fluorescence measurements
for individual oocytes co-expressing v-Src and Kir2.1 Y242Tyr(ONb) and exposed to PAO.
Oocytes were labeled with 10 µM tetramethylrhodamine maleimide for 30 min prior to recording.
Fluorescence is measured as PMT output voltage. As indicated, controls included omission of co-
injected v-Src and omission of irradiation.
Both of these experiments measured changes which would arise from any endocytotic
mechanism.  However, since the caged tyrosine makes up part of a tyrosine-based
clathrin-mediated endocytosis motif, experiments to further delineate the role of specific
endocytotic mechanisms are possible.  The assembly of clathrin-coated vesicles is driven
by the small GTPase dynamin.  Previous work in other labs has shown that a K44A
mutation in dynamin renders it unable to hydrolyze GTP.81,82  More importantly, for the
purposes of the experiments described here, this K44A dynamin is capable of exerting a
dominant negative effect over wild-type dynamin.  Indeed, dominant-negative dynamin
has been used in Xenopus oocytes to suppress the activity of endogenous dynamin and
largely shut down the clathrin-mediated endocytotic pathway.77  Co-injection of dominant
negative dynamin should render the tyrosine-based endocytosis motif of Kir2.1
ineffectual in removing channels from the plasma membrane.  If this is the primary
mechanism by which current is inhibited subsequent to the de-caging of Tyr(ONb) at
position 242, dominant negative dynamin should remove the observed current reduction.
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What was observed instead is that dominant negative dynamin diminishes the degree of
current inhibition, but does not abolish it. (Figure 4.17)
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Figure 4.17  Dynamin expression distinguishes inhibition of the channel from endocytosis.
Current and capacitance data from representative oocytes co-expressing v-Src and Kir2.1-
Y242TAG suppressed with Tyr(ONb) and treated with PAO.  Data were recorded 48 h after
injection.  Left panel:  An oocyte without co-injected dynamin cRNA.  Center panel: An oocyte
co-injected with 10 ng WT dynamin cRNA.  The capacitance decrease for this cell was unusually
large.  Right panel:  An oocyte co-injected with 10 ng dominant negative dynamin-K44A.
In these experiments, the mean current reduction with the clathrin-dependent pathway
intact was 41%.  When the pathway is shut down (as evidenced by the 4% capacitance
change, relative to 3% for uninjected oocytes), the current reduction was 28%.  (Table 4.5
and Table 4.6)  Thus, the current decrease appears to be partially dependent on
endocytosis.  Oocytes which are defective in their ability to remove membrane proteins
from the cell surface do not undergo the full extent of current reduction.  However, some
current reduction is seen, in spite of the fact that plasma membrane retrieval has been
practically eliminated by dominant negative dynamin.  The conclusion from this set of
experiments is that clathrin-mediated endocytosis is operative in reducing whole-cell K+
currents, but that it is not responsible for all of the current inhibition observed after de-
caging Y242.  A non-clathrin pathway has been reported for ligand-gated ion channel
endocytosis that operates even in the presence of dominant-negative dynamin.90
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Alternatively, pathways acting directly on the channel may operate along with clathrin-
mediated endocytosis.
In fact, endocytosis and phosphorylation are not completely independent phenomena
in these experiments.  Figure 4.15 shows that endocytosis appears to be stimulated by
phosphorylation in an interesting way.  Simply revealing the native YXXΦ endocytotic
motif by photolysis does not cause the whole-cell capacitance change associated with
endocytotic activity.  Apparently, the clathrin-mediated pathway is unable by itself to
cause endocytosis with its attendant change in membrane capacitance.  Only when the
tyrosine is revealed and tyrosine kinase is present is there an observable capacitance
change.  At present, it is difficult to know with certainty why native Kir2.1 and v-Src are
required for whole-cell capacitance decrease.  As indicated above, the crystal structure of
AP-2 µ co-crystallized with YXXΦ peptide suggests that phosphotyrosine would be
unable to make the requisite binding contacts.78 Thus, it would be expected that v-Src
might inhibit endocytosis.  There are a number of reasons which might explain why our
observation is at variance with this.  First of all, there is presumably some regulation of
AP-2 binding to tyrosine-based endocytosis motifs, which quite commonly occur
multiple times in a single protein.91  Kir2.1 contains two more C-terminal YXXΦ
sequences, YEPV from 326-329 and YSRF, comprising residues 340-344 as well as a
potential dileucine motif at 231-232.  (Figure 4.18)
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MGSVRTNRYSIVSSEEDGMKLATMAVANGFGNGKSKVHTRQQCR
SRFVKKDGHCNVQFINVGEKGQRYLADIFTTCVDIRWRWMLVIF
CLAFVLSWLFFGCVFWLIALLHGDLDTSKVSKACVSEVNSFTAA
FLFSIETQTTIGYGFRCVTDECPIAVFMVVFQSIVGCIIDAFII
GAVMAKMAKPKKRNETLVFSHNAVIAMRDGKLCLMWRVGNLRKS
HLVEAHVRAQLLKSRITSEGEYIPLDQIDINVGFDSGIDRIFLV
SPITIVHEIDEDSPLYDLSKQDIDNADFEIVVILEGMVEATAMT
TQCRSSYLANEILWGHRYEPVLFEEKHYYKVDYSRFHKTYEVPN
TPLCSARDLAEKKYILSNANSFCYENEVALTSKEEEEDSENGVP
ESTSTDSPPGIDLHNQASVPLEPRPLRRESEI
Figure 4.18  Primary sequence of Kir2.1 showing the presence of numerous endocytosis motifs.
The  motif including Y242 is indicated in red, the others in blue.
It may be that phosphorylation of Y242 positively regulates binding to the more N-
terminal endocytotic motifs.  Second, the method presented here relies on functional
interactions between a multiple-subunit, multiple transmembrane-domain integral
membrane protein in a living cell.  It could be that the evidence collected thus far for
downregulation of endocytosis via tyrosine phosphorylation represents only one of a
number of important interactions for regulating endocytosis via tyrosine-based motifs.
4.3.3.4 Phosphorylation is implicated in Kir2.1 modulation
In addition, phosphorylation state may well regulate endocytosis at the level of the
cycling of endocytotic vesicles.  Just as there is an equilibrium between kinases and
phosphatases, there must be an equilibrium between endocytosis and exocytosis.  The
signals by which integral membrane proteins are targeted to endocytotic vesicles are just
beginning to be discovered, and even less is known about the signals for retrieval.74,86
Progress in this area is likely to come from the study of G-protein coupled receptors,
where the role of internalization and recycling in causing agonist-dependent
desensitization is rapidly being elucidated.92  Based on this work, it seems possible, even
probable, that phosphorylation of ion channels determines whether they are recycled to
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the plasma membrane or targeted for degradation.  Since vesicle internalization and re-
fusion modulate whole-cell capacitance changes, the mediation of their targeting by the
phosphorylation state of their membrane protein contents could explain the apparent
requirement for Kir2.1 to be phosphorylated at Y242.   
4.3.3.5 Attempts to detect phosphorylation
Since the available evidence points strongly toward a role for tyrosine
phosphorylation in the observed current reduction of Kir2.1, it would be valuable to
know whether or not the channel is phosphorylated directly.  Both anti-phosphotyrosine
antibodies and 32P were employed in an effort to detect the presence of a phosphoryl
group on wild-type and de-caged Kir2.1.  These experiments failed to detect such
phosphorylation.  The oocyte system has been reported to be difficult to work with in this
way, so it is unwarranted to conclude that failure to detect phosphorylation implies that
the protein is not phosphorylated.  Experiments are ongoing to attempt to detect a role for
phosphorylation of Y242 in Xenopus oocytes.  Given the difficulty of biochemically
detecting phosphorylation, the alternative technique of introducing non-hydrolyzable
phosphotyrosine analogs at position 242 is being considered.  Progress toward this goal
will be discussed further in Chapter 5.
As noted earlier, a variety of tyrosine kinases are able to induce the current inhibition
we observed.  Since Y242 is unlikely to be a consensus phosphorylation site for all of
these kinases, the implication is that a downstream kinase is ultimately responsible for the
effect.  Identification of this kinase represents a long-term goal for studies on the
molecular detail of phosphorylation-mediated ion channel regulation.  Introduction of a
mechanism-based inhibitor as an amino acid side chain is a potentially useful method for
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trapping the kinase responsible for phosphorylation.  Alternatively, antisense mRNA to a
series of tyrosine kinases may reveal that the diminished activity of a particular kinase
ameliorates the current inhibition resulting from phosphorylation.
4.3.4 Summary
Active tyrosine kinases decrease the activity of WT Kir2.1, are required for the
decreases in both current and membrane area following tyrosine decaging, and produce
decreases in active channel density per patch.  None of these effects is observed for the
Y242F mutant channel.  Usually, these data would be interpreted to suggest that
phosphorylation of Y242 causes these effects, as proposed in earlier work on this system.
However, the involvement of tyrosine 242 in an endocytosis motif suggests an alternative
explanation.  All of these observations are consistent with tyrosine-based endocytosis of
the channel.  The requirement for tyrosine kinases could reflect the need for components
of the endocytotic machinery to be activated by tyrosine phosphorylation.  The
requirement for a native tyrosine at position 242 of Kir2.1 could be explained by the
apparent involvement of this residue in binding of adapter proteins targeting the channel
for endocytosis.  Thus, the question arises of whether our observations result from
phosphorylation of Y242 or from endocytosis of the channel subsequent to unmasking of
a tyrosine-based sorting motif.
Biochemical evidence that Kir2.1 is phosphorylated at position 242 in cells which
exhibit current decrease would permit a compelling claim that phosphorylation is the
mechanism responsible for channel modulation subsequent to photolysis.  We were
unable to obtain such evidence.  (Figure 4.12)  Unfortunately, failure to detect
phosphorylation is itself somewhat difficult to interpret.  As a positive control for
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tyrosine phosphorylation, the auto-phosphorylated receptor tyrosine kinase TrkB was
expressed in oocytes.  As expected, both the 4G10 anti-PY and the C14 anti-TrkB
antibodies show easily observable staining and co-localization under standard Western
blotting conditions.  (Figure 4.11)  It is evident that the technique is capable of directly
detecting tyrosine phosphorylation of integral membrane proteins expressed in Xenopus
oocytes.  However, there are complications in extending this result to the detection of
phosphorylated Kir2.1.  The level of expression of the two proteins, the extent of tyrosine
phosphorylation, the duration of protein phosphorylation, and the sensitivity of particular
phosphotyrosine residues to de-phosphorylation may well differ.  As a result, the
inference that Kir2.1 is not phosphorylated is not conclusive.
Any proposed mechanism to account for the decrease in whole-cell current and
capacitance subsequent to photolysis must take into account the following observations.
First, both a free tyrosine side chain at position 242 and tyrosine kinases are required.
(Figure 4.14)  Second, the presence of kinases and Y242 brings about decreases in whole-
cell current, membrane capacitance, and surface fluorescence.  (Figure 4.14, Figure 4.15,
Figure 4.16)  Third, dominant-negative dynamin blocks the changes in capacitance and
fluorescence and causes a partial block of current decrease.  (Figure 4.17)  Fourth, the
presence of v-Src and PAO decreases the number of channels per patch without affecting
the single-channel properties of individual channels.  (Figure 4.9)  Experiments by other
laboratories have suggested also that phosphotyrosine is not competent for recognition by
adapter proteins responsible for targeting membrane proteins for endocytosis.78,87-89
All of these observations (and our inability to detect phosphotyrosine) fit neatly with
a model in which the role of Y242 is in targeting Kir2.1 for endocytosis, with one
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exception.  This exception is that a significant component of current decrease is
insensitive to dominant-negative dynamin.  It is clear that dominant-negative dynamin
suppresses changes in membrane capacitance.  (Figure 4.7)  If current decrease were
solely a result of channel endocytosis, the predicted result of halting membrane
internalization would be to eliminate current decrease.  Since this is not the observed
result, it is tempting to speculate that multiple mechanisms of channel modulation may be
involved.  Cells almost certainly regulate channels through both phosphorylation and
endocytotic targeting.  However, both of these effects would have to be in the same
direction, have the same time course, and result in no alteration of single-channel
properties.  We therefore prefer a model in which interaction with the endocytotic
machinery is the sole regulatory mechanism acting on Y242, which is consistent with the
similarity of the observed kinetics in the presence and absence of dominant-negative
dynamin.
In this model, a protein-protein interaction which is responsible for targeting of the
channel to endocytotic vesicles occurs, even though the downstream pinching off of
clathrin vesicles may be prohibited by dominant-negative dynamin. Channels in these
invaginations are unable to contribute to the whole-cell current, possibly as a result of
restricted flow of the external high-potassium recording solution through the dynamin
collar which constricts the neck of the vesicle.  As a result, the whole-cell current
decreases even though  the cell's surface area and capacitance remain the same.  The
extent of current decrease may be less than before because the arresting of vesicles may
down-regulate the assembly of dynamin collars, or perhaps because some of the vesicle-
bound channels remain active.  As indicated above, it is difficult to exclude the
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possibility that Y242 may be phosphorylated.  In the absence of direct evidence, though,
we feel the most parsimonious explanation of the data is that presented above.
Undoubtedly, further details will be forthcoming on the modulation of ion channels
by both phosphorylation and endocytosis.  At the currently achievable level of molecular
detail, this study represents a delineation of the roles of these two processes in
modulating Kir2.1 current through the common intermediate of a C-terminal tyrosine
residue.  Because of the complexity of multiple regulatory processes involving a single
residue, we introduce in the next chapter a technique involving caged phosphoamino
acids.  Through the use of this methodology, we hope to control directly, for the first
time, the phosphorylation state of a particular residue in a functioning channel inside a
living cell.
4.3.5 Experimental methods
4.3.5.1 Chemical synthesis
The 4PO-protected amino acid Tyr(ONb) was prepared as reported.61  Briefly, L-tyrosine
was complexed with copper(II) to protect the amino and carboxyl termini.  To this
complex was added nitrobenzyl chloride under basic conditions, yielding Try(ONb).
Addition of 4-pentenoic anhydride gave the N-protected 4-PO-Tyr(ONb).  The amino
acid was coupled to the dinucleotide dCA by established procedures.93  In summary, the
carboxyl terminus was converted to the cyanomethyl ester by treatment with
chloroacetonitrile.  The active ester was condensed with dCA under basic conditions to
give the aminoacylated dinucleotide, which was enzymatically ligated to a 74-base tRNA
precursor with T4 RNA ligase.
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4.3.5.2 DNA / RNA constructs
tRNA THG73 was  modified from eukaryotic Tetrahymena thermophila tRNAGln(CUA)
as described and inserted into pUC19 giving the plasmid pTHG73.93  pTHG73 was
linearized by Fok I and  transcribed in vitro using the MegaShortscript kit (Ambion).
The tyrosine codon at position 242 of the mouse Kir2.1 cDNA in pcDNA I was
mutated to phenylalanine or to the nonsense codon TAG, giving two mutants called
Kir2.1(Y242F) and Kir2.1(Y242TAG), respectively.  Mutagenesis was carried out using
the QuikChange kit (Stratagene).  Mutations were verified by sequencing of both strands
through the affected regions.  The hemagglutinin antigenic sequence YPYDVPDYA was
added to the C-terminus of Kir2.1 using PCR amplification, giving Kir2.1-HA.  The
Kir2.1 plasmids were linearized by Not I.
The cDNA for v-Src kinase (a gift of Dr. I. B. Levitan), PyK2 (a gift of Dr. J.
Schlessinger), human WT dynamin I and dynamin-I-K44A (gifts of Dr. Alex van der
Bliek and Dr. Thomas Moss), and rat TrkB (gift of G. Yancoupolis) were linearized by
XbaI, SspI, SalI and SalI , and XbaI or NotI, respectively.  All mRNAs were transcribed
in vitro using the SP6 or T7 mMessage mMachine kit (Ambion) as appropriate.
4.3.5.3 Suppression of Kir2.1-Y242TAG with Tyr(ONB) in Xenopus oocytes
The 4PO-Tyr(ONb)-tRNA in 1 mM NaOAc, pH 4.5, was de-protected just prior to
injection by mixing with equal volume of a saturated aqueous solution of iodine (1.2
mM) for 10 min at ambient temperature.  10–15 ng of Kir2.1(Y242TAG) mRNA and 20-
25 ng of tRNA-Tyr(ONb) in a total volume of 32.2 nL per oocyte were co-injected into
stage V and VI oocytes by a Drummond automatic injector.  The cRNA for WT Kir2.1
cRNA, the conventional mutant Kir2.1-Y242F, or Kir2.1-HA were injected at 1
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ng/oocyte.  Oocytes were incubated in 50% L-15 medium supplemented with 7.5 mM
HEPES, 0.8 mM of glutamine and 10 µg/ml of gentamycin sulfate, pH 7.5, at 18-200C.
After incubation for 24-48 h, functional measurements were made.
4.3.5.4 Electrophysiology
For macroscopic recordings, oocytes were voltage clamped at 0 mV in a high K+
solution (96 mM KCl, 2 mM NaCl, 1 mM MgCl2, 1.5 mM CaCl2 and 5 mM HEPES, pH
7.5) with two electrodes (filled with 3 M KCl, resistance 0.5-3 MΩ) and then stepped to a
test potential of -80 mV using a GeneClamp 500 (Axon Instruments).  Membrane
capacitance was measured on oocytes clamped at 0 mV in response to a train of 10 mV
pulses delivered at 2.9 Hz with 50% duty cycle.  Voltage command signals  were
generated, and membrane capacitance measured, by the algorithms in pCLAMP 8.0
software (Axon Instruments).  In preliminary experiments, capacitance measurements
were verified manually by integrating the response to 10 mV test pulses.
For cell-attached single-channel recordings, the pipette solution and the bath
contained the same high K+ solution.  The patch channel of the GeneClamp 500 was
employed, with 2 kHz filtering.  The signals were recorded and analyzed using
FETCHEX, FETCHAN, and pSTAT in the pCLAMP 6 suite.
4.3.5.5 Decaging optics
The apparatus for Tyr(ONb) decaging was reported previously.43  Light from a 300 W Hg
arc lamp was filtered through a Schott UG11 filter to provide 300-350 nm light and was
focused through a 50 mm quartz lens (Oriel) onto a liquid light guide (Oriel, 1 m long
and 3 mm in diameter)  connected to the recording chamber.  At the chamber, the end of
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the liquid light guide contacted a Pyrex cover slip placed at the bottom surface of the
chamber, upon which the oocyte rested.  Miller et al. reported that 3 s irradiation was
sufficient for photolysis of over 90% of caged tyrosine on the oocyte surface.43
4.3.5.6 Fluorescence labeling and measurements
For non-specific labeling of the cell surface, oocytes were incubated in ND96 solution
(96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.5 mM CaCl2 and 5 mM HEPES, pH 7.5)
containing 10 µM tetramethylrhodamine-5-maleimide for 30 min at 20-22 °C.  The
labeled oocytes were then washed five times with ND96 solution to remove unbound
fluorescent dye.  The labeling intensity was examined at the animal pole.  Confocal
images were taken with a Bio-Rad MRC 600 microscope with a 10x objective lens, with
10 average scans.
Surface fluorescence from labeled oocytes was measured using an Olympus IX-70-
FLA inverted reflected-light fluorescence microscope.83  Exciting light was delivered
from a stabilized 100 W Hg lamp.  We used a 40X, NA1.3 objective lens.  A
photomultiplier tube (PMT) attached at the side port recorded the fluorescence.  To avoid
bleaching, a shutter in the excitation pathway was opened and the fluorescence was
measured for only 10 to 20 sec at intervals of 2 to 2.5 min.  The emitted signal, as voltage
from the PMT output, was appropriately amplified and filtered, then sent to an Axon
Digidata interface for collecting data by pCLAMP 7 (Axon Instruments, Foster city, CA).
4.3.5.7 Immunochemical detection
Oocytes were injected with Kir2.1-HA.  Plasma membranes were isolated by physical
dissection.  The hypotonic solution used to prepare the oocytes for dissection was
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modified to contain 5 mM PAO and 1 mM sodium orthovanadate, one EDTA-free
Boehringer Complete tablet per 40 ml, and 0.08% SDS (which expedites dissection).
PAO was dissolved in DMSO and stored at -80 °C.  Yolk and pigment granules were
removed by a 2 min 14,000 rpm spin at 4 °C and the supernatant dissolved in 15 ml 2x
SDS gel loading buffer.  Samples were boiled for 5 min or heated to 55 °C for 10 min
prior to loading.  SDS PAGE was performed using 10% polyacrylamide (40T:1C) gels or
10% Tris-Cl ReadyGels (BioRad, Hercules CA).
Proteins were transferred to nitrocellulose overnight at 30 V.  Blots were blocked for
1 hr in 1x TPBS [PBS containing 0.1% (v/v) Tween-20] and 5% (w/v) non-fat dried milk
(Carnation, Columbus OH).  Blots were exposed to primary antibody for one h in TPBS
with 5% milk, washed three times 10 min each in TPBS, then incubated one h in TPBS
containing 5% milk and secondary antibody.  Detection employed ECL reagents from
Amersham.
Primary antibodies included monoclonal HA.11 ascites fluid; monoclonal anti-
phosphotyrosine antibodies 2G8-D6, 6G9, 1G2, PY20, PY72 (Covance, Berkeley CA),
and 4G10 (Upstate Biotechnology, Lake Placid NY); and anti-TrkB antibody C14 (Santa
Cruz Biotechnology, Santa Cruz CA).  All Covance antibodies and 4G10 were diluted
1:1000 for Western blotting; C14 was diluted 1:200.  Of the phosphotyrosine antibodies,
4G10 had the highest affinity under our conditions.  PY72 also performed well.  HRP-
conjugated secondary antibodies included goat anti-mouse (Jackson Immunologicals) and
donkey anti-rabbit (Amersham), diluted 1:5000 and 1:200, respectively.
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4.3.5.8 Data analysis
The experimental data were analyzed using ORIGIN (Microcal Software, Inc.) and
CLAMPFIT 8 software (Axon Instruments,  Foster City, CA).
4.3.5.9 Reagents
BDNF was kindly provided by Dr. Andy Welcher (Amgen, Inc., Thousand Oaks CA).
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Chapter 5.  Caged phosphoamino acids
5.1 Introduction
One of the lessons of the work presented in the previous chapter is that the great
complexity inside a cell requires chemical tools to be as precise as possible.  Caged
tyrosine allows some control over the phosphorylation state of a particular side chain, but
the downstream activity of tyrosine kinases remains out of the hands of the experimenter.
By introducing caged phosphoamino acids, an additional degree of control may be
exerted.  Here, the phosphoamino acid is masked as a large, neutral residue.  Irradiation
itself reveals the wild-type phosphoamino acid, thus placing the phosphorylation state of
the protein under direct experimental control.  Needless to say, this phosphorylation may
be reversed through the activity of phosphatases once the wild-type phosphoamino acid
has been revealed.  This reversibility may prove to be a useful null control, in that
reversion to the non-phosphorylated phenotype can act as an intrinsic confirmation that
an observed effect is due to phosphorylation.  Indeed, the synthesis of non-hydrolyzable
mimics may provide important insight into the kinetics of phosphatases in vivo.  The
three unnatural amino acids discussed here, caged phosphorylatable residues, caged
phosphoamino acids, and caged non-hydrolyzable phosphoamino acid mimics, constitute
a complete set for analysis of phosphorylation of a particular side chain in a protein.
5.1.1 Design of caged phosphoamino acids
The most straightforward design for caged phosphoamino acids involves protecting
the phosphate oxygens with photo-removable protecting groups. (Figure 5.1)  This
chemistry has a relatively long history, as ATP has been a common target for caging.1-3
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Figure 5.1  Schematic for the design of a phosphoamino acid where the side chain is caged.
Photo-removable protecting groups are indicated as red spheres.
In addition to caged nucleotides, caged lipids have been widely reported, as has a caged
phosphate-containing drug.3-21  In addition to their synthetic relevance, a number of these
studies provide important information on de-caging rates and conditions.4,11,12,17-21  More
recently, caged phosphoamino acid analogs have been developed and introduced into
proteins and peptides.22-25  Additionally, an interesting study has reported a caged
mechanism-based inhibitor of tyrosine phosphatases, which is reversible only upon de-
caging.26  Solid-phase peptide synthesis using nitrophenethyl-caged phosphotyrosine,
serine, and threonine has been accomplished very recently.23  Although no application of
these peptides has yet been reported, the de-caging efficiencies in water were determined.
In the studies involving proteins, caging was performed by reaction of kinase-introduced
thiophosphoryl groups with electrophilic reagents.22,24,25  (Figure 5.2)
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Figure 5.2  A strategy which has been reported for the incorporation of caged phosphoamino acids
into proteins and synthetic peptides.22,24,25
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Because of the requirement that the peptide or protein be modified with exogenously
applied reagents, this technique is limited in both its specificity and in vivo application.
Semi-synthetic peptides and proteins containing caged phosphoamino acids require
transport into cells to be used to investigate signal transduction.
The introduction of caged phosphoamino acids by unnatural amino acid mutagenesis
has the advantages of both site-specificity and compatibility with usage in situ.  However,
it has the potential drawback that steric bulk may be incompatible with ribosomal protein
synthesis. It is encouraging that a number of very large residues have been incorporated
via unnatural amino acid mutagenesis, notably the large hydrophobic residues introduced
into streptavidin by the group of Sisido.27 Nonetheless, caged phosphoamino acids are
bulkier than any ribosomally incorporated amino acid.  (Figure 5.3)
Figure 5.3  CPK models of tyrosine, phosphotyrosine, caged phosphotyrosine, and caged tyrosine,
demonstrating the steric bulk of caged phosphotyrosine.
One potential solution to this problem of bulk would be to cage one, but not both of
the phosphate oxygens.  Indeed, in the studies cited above employed singly caged
phosphoamino acids.  However, the effects of phosphorylation are often successfully
mimicked by replacing a potentially phosphorylated serine or threonine with a
monoanionic residue, such as aspartate.  Thus, a more certain means of ensuring that the
caged residue is functionally equivalent to its non-phosphorylated form prior to
photolysis is to utilize the neutral, doubly caged phosphodiester.  By analogy to
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isopropylidene or pivaloyl protection of vicinal diols, it might be possible to design a
caged phosphate where both oxygens could be caged by a single photo-removable
protecting group.  Indeed, some compounds similar to this are known.28  (Figure 5.4)
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Figure 5.4  Possible solutions to the problem of caging group bulk. Two different mono-protected
phosphoamino acid strategies are compared to the known oxathiaphosphalane ring system.28
However, for the initial experiments, the doubly caged phosphoamino acids represent a
logical starting point.  There is a large number of caging groups which may be
utilized.2,29-36  In fact, a flexible synthetic route which permits incorporation of  a variety
of these groups is desirable.  The initial amino acid design relied on nitrobenzyl esters,
which are well precedented, have optical properties which are appropriate for use in the
oocyte system, and which are relatively sterically compact.
5.1.2 Non-hydrolyzable analogs
As indicated, another attribute which is desirable from a design perspective is
stability to enzymatic removal.  Phosphate groups are, of course, dynamically removed in
a cell by phosphatases.  Replacement of the O-P connectivity by a methylene unit is a
common strategy for circumventing hydrolysis.  The phosphonate which results from this
replacement has rather different acidity than the parent phosphate.  In order to more
accurately mimic the natural phosphate group, difluoromethylene units are often utilized.
(Figure 5.5)
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Figure 5.5  Values of phosphate pKa for phosphonate analogs containing fluorine.37
There is little question that the ionization state of difluorophosphonates more closely
resemble that of phosphates, in that they are dianionic at physiological pH.37-40  Whether
or not phosphonates or difluorophosphonates are more effective analogs of
phosphoamino acids, however, continues to be debated.  A rather extensive literature on
this subject suggests that context plays an important role.  In some experiments,
phosphonates have tighter binding, or are more effective than their difluorophosphonate
congeners, while in others, the opposite trend is observed.  (reviewed in Berkowitz)41  No
pattern has emerged such that an a priori evaluation may be made.  Thus, the synthetic
strategy for caged, non-hydrolyzable phosphoamino acid analogs should permit the
synthesis of both phosphonate and difluorophosphonate analogs.
5.1.3 Mechanism-based phosphatase inhibitors
While difluorophosphonates act as non-hydrolyzable phosphate mimics, singly
halogenated phosphonates have been shown to irreversibly inhibit phosphatases.42,43
Covalent linkage of unnatural amino acid-containing proteins to phosphatases which act
on them could provide a means for specifically identifying these phosphatases.  While
this methodology perhaps awaits the development of sensitive means for isolating and
assaying the relevant phosphatases, the design of such molecules is straightforward and
requires no great modification to the synthetic route to caged non-hydrolyzable
phosphoamino acid analogs.
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5.2 Synthesis of caged phosphoamino acids
The conversion of alcohols to phosphates has become a routine transformation, due to
its central role in nucleic acid synthesis.44  Phosphoramidites provide a mild, high-
yielding methodology to accomplish the conversion, which has been applied to both
phosphopeptides and to phosphate-containing prodrugs with labile phosphate
modifications.44-52  Bis(nitrobenzyl) phosphoramidite 1 is precedented, for the synthesis
of a nitrobenzyl-protected phosphotyrosine and a caged phospholipid.15,53  In both cases,
nitrobenzyl alcohol is added to commercially available diisopropyl phosphoramidous
dichloride.  (Figure 5.6)
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Figure 5.6  Synthesis of bis(nitrobenzyl) phosphoramidite 1.15,53
The resulting phosphoramidite 1 may be conjugated to either aryl (tyrosine) or alkyl
(serine or threonine) alcohols, catalyzed by 1H-tetrazole.  The resulting trivalent
intermediate is oxidized, to provide a mild, one-pot conversion of amino acid (e.g. 2) to
phosphoamino acid (e.g. 3).  (Figure 5.7)
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Figure 5.7  Synthesis of caged phosphotyrosine 6 from protected tyrosine 2 using bis(nitrobenzyl)
phosphoramidite 1.
Initially, it was feared that the 4-pentenoyl N-terminal protecting group would be
unstable to the periodate oxidation involved in the final step of the phosphoramidite
reaction.  Thus, the amino acid was protected as the Boc t-butyl ester 3, as shown in
Figure 5.7.  However, TLC experiments of 4PO-protected amino acids treated with
tetrabutylammonium periodate at the appropriate conditions showed no apparent loss of
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the protecting group.  Thus, an even simpler route was subsequently used to generate
caged phosphoserine 9 (Figure 5.8) and phosphothreonine 12 (Figure 5.9).
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Figure 5.8  Synthesis of caged phosphoserine 9.
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Figure 5.9  Synthesis of caged phosphothreonine 12.
5.3 Synthesis of caged non-hydrolyzable phosphoamino acid analogs
The synthesis of non-hydrolyzable analogs is substantially more complicated than
that of phosphoamino acid analogs.  Phosphono and difluorophosphono analogs of
tyrosine, serine, threonine, and histidine are all well precedented.54-66  The initial synthetic
routes to the fluorinated tyrosine compounds relied on fluorination using DAST.58,60,67  In
more modern routes, this methodology has been superceded by the milder, safer, more
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specific metal-catalyzed cross-coupling developed independently by Shibuya and
Burton.68-70  (Figure 5.10)
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Figure 5.10  Methodology of Shibuya and Burton for the synthesis of difluorophosphonates from
aryl iodides via copper(I)-catalyzed cross-coupling.69,70
For forming aliphatic carbon-phosphorus bonds, a number of methods exist.67,71-81  Most
of them are useful for generating phosphonates, although a number can be used to
prepare difluorophosphonates.67,71-81  The triflate displacement methodology employed by
Berkowitz and others was selected for the synthesis of serine and threonine analogs.41,61-
65,82-90 (Figure 5.11)
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Figure 5.11  Berkowitz route to alkyl difluorophosphonates by direct nucleophilic displacement.82
In most cases, the phosphates are protected as the diethyl ester, although Berkowitz has
reported benzyl- and alloc-protected difluorophosphonates.41,83
5.3.1 Difluorophosphonate intermediates
An important intermediate for the copper(I)-mediated crosslinking central to the
routes of Shibuya and Burton is the dialkyl bromodifluorophosphonate.  The diethyl
version 15 is available from Aldrich, suggesting the possibility of coupling to suitably
protected p-iodophenylalanine.  The ethyl phosphodiester may be de-protected under the
conditions of Rabinowitz, McKenna, and Jung (TMSI/TFA) to give the dianion.55,56
Conditions analogous to those used in peptide coupling have been reported to generate
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phosphodiesters.91 Thus, coupling to nitrobenzyl alcohol may be possible, as indicated in
Figure 5.12.
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Figure 5.12  De-protection and re-protection scheme to replace ethyl esters of phosphate with
nitrobenzyl esters.
Alternatively, the bis(nitrobenzyl) bromodifluorophosphonate 16 may be synthesized and
utilized directly in the cross-coupling with protected p-iodophenylalanine. (Figure 5.13)
The latter route, in fact, may be compatible with 4PO- (13) and cyanomethyl-protected
iodophenylalanine 14.
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Figure 5.13  Installation of nitrobenzyl-protected phosphate.
A one-step synthesis of diethyl bromodifluorophosphonate from ethyl phosphite and
CF2Br2 has been reported by the group of Savignac, following earlier syntheses of
Burton.81,92  Work by Mioskowski on the use of benzyl phosphites in the Arbuzov
reaction suggests the necessity of in vacuo removal of the benzyl bromide product as it
forms.78  (Figure 5.14)
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Figure 5.14  Proposed synthesis of bis(nitrobenzyl) bromodifluorophosphonate 16 following the
route of Savignac to diethyl bromodifluorophosphonate.81
Nitrobenzyl phosphite 17 is easily available from the condensation of nitrobenzyl alcohol
with PCl3.93  Pure material was re-crystallized from diethyl ether and fully characterized
by NMR, although the compound proved unsuitable for electrospray mass spectrometry.
However, nitrobenzyl phosphite appears to be significantly deactivated for Arbuzov
chemistry relative to ethyl phosphite.  The conditions of Savignac (60 °C, gently
refluxing THF), gave no reaction.  Heating the reaction to 100 °C overnight in a sealed
tube also failed to give the desired product.  The reactions were monitored by 31P NMR.
Because of fluorine-phosphorus coupling, the difluorophosphonate has a very distinctive
triplet signal.  (Figure 5.15)
     
Figure 5.15  Characteristic triplet (J= 92 Hz) arising from –CF2-P splitting (NMR of 15).
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The Aldrich diethyl bromodifluorophosphonate 15 provided an authentic sample in which
this triplet was observed.  Under the conditions of Savignac, the 134 ppm phosphite
signal was still observed after overnight reaction, suggesting no formation of pentavalent
phosphorus and, indeed, no reaction.  After the sealed-tube reaction, pentavalent
phosphorus signals were observed, although these could not be unequivocally assigned.
The formation of nitrobenzyl phosphonate is a likely outcome of this reaction, although
proton de-coupled phosphorus signals did not appear to correspond to the expected
pattern from a methylene-phosphorus interaction.
An alternative route to dialkyl bromodifluorophosphonates was utilized by Berkowitz
in a synthesis of bis(benzyl) bromodifluorophosphonoserine.41  Here, a benzyl H-
phosphonate is treated with sodium hydride or sodium HMDS and added to an
electrophilic substrate.  (Figure 5.16)
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Figure 5.16  Alternative route to difluorophosphonates, involving benzyl H-phosphate.41,74
In the case of the Berkowitz reaction, CHClF2 was used, and earlier reports show the
addition of benzyl H -phosphonate to CH2Cl2.41,74  To synthesize the
bromodifluorophosphonate, addition to CBr2F2 would be required.  As with nitrobenzyl
phosphite 17, nitrobenzyl H-phosphonate 18 was synthesized by simple modification of a
preparation for the benzyl compound.94 (Figure 5.17)
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Figure 5.17  Route for preparation of nitrobenzyl H-phosphonate 18 from nitrobenzyl alcohol and
phosphorus(III) chloride.94
The compound was re-crystallized from ethanol and characterized by carbon, proton, and
phosphorus NMR.  Again, it proved refractory to electrospray MS.  The H-P interaction
provides a very distinctive splitting pattern which was easily observed in proton-
decoupled 31P spectra.  (Figure 5.18)
Figure 5.18  31P splitting pattern (J = 711 Hz) arising from H-P coupling in nitrobenzyl H-
phosphonate 18.
However, base-mediated condensation of compound 18 with neither CF2Br2 nor CH2Br2
was observed.  Subsequent discussion with former group members confirmed the
experience that nitrobenzyl compounds are not typically compatible with strong base, as
an apparent result of increased acidity at the benzylic position relative to benzyl
compounds which lack the nitro ring substitution.95
5.3.2 Future prospects
The routes thus far adopted to generate the important bromodifluorophosphonate
intermediate 16  for direct installation of the caged phosphonate have proven
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unsuccessful.  Two strategies remain viable for further work in this area.  First, the de-
protection and re-protection strategy proposed above may be implemented to convert the
commercially available ethyl phosphodiester to the desired nitrobenzyl compound 16.
(Figure 5.)
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Figure 5.19  Generation of nitrobenzyl bromodifluorophosphonate 16 by de-protection of
commercially available ethyl ester 15 followed by re-protection with nitrobenzyl alcohol.
As indicated previously, the conditions of Burton and Shibuya are expected to provide a
mild and convenient synthesis of caged difluorophosphonotyrosine from this
intermediate.  (Figure 5.10)  Given the difficulties encountered in using strong base in the
presence of nitrobenzyl groups, the conditions of Berkowitz may prove incompatible with
the direct installation of protected difluorophosphonate.  One possible route is the use of
metal-catalyzed addition to an α,β-unsaturated carboxylic acid, as in the report of
Kawamoto et al.96  (Figure 5.20)
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Figure 5.20   Proposal to employ Kawamoto’s mild and selective metal-catalyzed
bromodifluorophosphonate coupling on a vinyl halide substrate to provide an important
intermediate for caged difluorphosphonoserine.96
In a second approach to synthesizing caged non-hydrolyzable phosphoamino acid
analogs, the difluorophosphonate may be installed in its protected form.  Subsequent de-
protection of the difluorophosphonoamino acid may be accomplished and the desired
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protecting group installed.  Note that an unavoidable feature of this approach is the need
for orthogonal protection of amine, carboxylate, and phosphate.  Thus, a convenient
means of simplifying this approach would be to synthesize a bromodifluorophosphonate
with protecting groups orthogonal to those traditionally used for amino acid protection.
An example is shown in Figure 5.21, where benzyl protection is utilized for formation of
the caged non-hydrolyzable phosphoserine analog.
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Figure 5.21  Proposed general scheme for synthesis of nitrobenzyl difluorophosphonoserine,
involving installation of the protected difluorophosphonate followed by de-protection and re-
protection with nitrobenzyl alcohol.
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The 2-(trimethyl)silylethoxy (TSE) protecting group is also useful to consider, and is
perhaps more desirable than benzyl because of its expected increased reactivity in
Michaelis-Arbuzov chemistry.97  This chemistry may be important in preparing
phosphonate analogs.  As indicated earlier, there is no good means of predicting whether
difluorophosphonates or simple phosphonates will prove to be more effective phosphate
mimics.  Thus, the importance of developing synthetic schemes which permit
phosphonate synthesis was cited.  In general, there are two convenient routes for tyrosine
analogs and one for serine or threonine analogs.  In the case of tyrosine, the method of
Shibuya and Burton could be used, employing a simple bromophosphonate.  (Figure
5.22)  Because the TSE phosphite is expected to be active in Michaelis-Arbuzov
chemistry, the bromophosphonate may be generated via its condensation with
dibromomethane, as in Figure 5.14.  If desired, this compound could be de-protected and
converted to a nitrobenzyl bromophosphonate by the Mitsonobu chemistry proposed
above.  (Figure 5.)
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Figure 5.22  Proposed synthetic scheme for preparation of caged phosphonotyrosine, employing
metal-mediated cross-coupling between an aryl iodide and bromophosphonate.
An alternative strategy for synthesis of tyrosine phosphonate would employ Arbuzov
chemistry directly on a benzyl bromide analog of tyrosine.53 (Figure 5.23)
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Figure 5 .23   Proposed generalized Michaelis-Arbuzov scheme for synthesis of
phosphonotyrosine.
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A similar route is available for serine phosphonate analogs.  (Figure 5.)
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Figure 5.24  Proposed route to the synthesis of caged phosphonoserine.
A final strategy which would ameliorate problems associated with the nitrobenzyl
group is to utilize different caging chemistry.  Phenacyl groups, for instance, should
behave more like benzyl substituents in both Arbuzov and dialkyl phosphate chemistry
than do nitrobenzyl groups.  (Figure 5.25)
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Figure 5.25  The p-methoxyphenacyl group, a synthetically tractable phototrigger for alcohols and
carboxylic acids, and a phosphotyrosine analog showing the use of phenacyl as a phosphate caging
group.34,36
To date, both phosphoserine and phosphothreonine have been synthesized as the
active, protected amino acids 9 and 12.  However, coupling to dCA has yet to be
performed.  One possible difficulty which may be anticipated is β-elimination of the
phosphate from the side chain.98-100  Such elimination was observed by Fahmi et al. with a
glycosylated serine derivative upon coupling to dCA, but the conditions of the coupling
were able to be altered in such a way as to permit formation of the desired product.98
Also, the solid-phase conditions for preparing peptides in the presence of singly caged
phosphoamino acids involve piperidine in DMF, to which the linkage was apparently
stable.23  If elimination is a complicating factor in dCA coupling, the switch to
acetonitrile from DMF reported by Fahmi will be employed in an effort to overcome the
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problem.98  If elimination persists, alternative coupling methodologies may need to be
investigated.
Attempts to circumvent the synthetic problems outline above and prepare caged non-
hydrolyzable phosphoamino acid analogs are ongoing.
5.4 Identification of appropriate biological systems for analysis by caged pAA
Both tyrosine and serine phosphorylation are highly important to the functional
regulation of ion channels.  Direct observation of phosphorylated side chains has been
difficult, as noted in Chapter 4.  The unequivocal introduction of a phosphorylated side
chain by the method outlined here presents a unique opportunity to study the regulation
of channels by serine, threonine, or tyrosine phosphorylation.  The initial experiments to
establish the proof of principle should target channels for which a very distinctive change
occurs upon phosphorylation.
5.4.1 Tyrosine phosphorylation
The work on Kir2.1 described in Chapter 4 makes this ion channel a very attractive
target for preliminary studies of tyrosine phosphorylation.  Revealing the wild-type
tyrosine residue at 242 results in current decrement with a time course of approximately
11 minutes.  It would be very interesting to observe the effect of uncaging
phosphotyrosine at this position.  An immediate decrease in current would imply that the
events taking place over minutes that are observed by uncaging tyrosine correspond to
phosphorylation itself.  If the kinetics of tyrosine kinases in a living cell could be
observed in this fashion, it would represent a unique kind of information that may be
obtained by this technique.  Alternatively, if the de-caging of phosphotyrosine results in a
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current decrease over a similarly long time course it may suggest that the kinetics of a
protein-protein interaction are being observed, although it is possible that a very slow
conformational change could be occurring.  In either case, suppression of Kir2.1 with
phosphotyrosine analogs provides a valuable test case for observing the effects of
tyrosine phosphorylation on ion channel activity.
5.4.2 Serine phosphorylation
Recently, a striking change accompanying serine phosphorylation has been observed
in the potassium channel KCNK2.101 Phosphorylation of a single C-terminal serine
residue causes the channel to acquire voltage dependence.  (Figure 5.26)  The presence of
a such a dramatic phenotype makes this channel an excellent system for studying
phosphoserine analogs.102
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Figure 5.26  Voltage dependence of KCNK2 upon introduction of negative charge at Ser348
[adapted from Bockenhauer, Nat. Neurosci. 4, 486 (2001)].  The effects of PKA were successfully
mimicked by mutagenesis of Ser to Asp at position 348.  The left panel illustrates the voltage
dependence of the S348D but not S348A channels expressed in Xenopus oocytes,  in response to
voltage steps in 100 mM external K+.  The right panel shows the dependence of channel open
probability on voltage for S348D (circles) relative to wild-type (squares) channels.101
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5.5 Progress toward controlling phosphorylation with unnatural amino acids
5.5.1 Tyrosine phosphorylation
One important prerequisite for the use of phosphotyrosine analogs to control tyrosine
phosphorylation is that they can be employed in suppression experiments.  Encouraging
results have been obtained in this regard in the nAChR.  Mouse muscle receptors
containing A122, I123, or F124TAG mutations in the alpha subunit were suppressed with
pTyr(ONb)2 and Tyr.  As shown in Figure 5.27, significant currents were obtained,
suggesting that the residue is competent for ribosomal translation.  However, suppression
efficiency of the caged phosphotyrosine was significantly diminished relative to the wild-
type residue, which produced five to ten times the current of pTyr(ONb)2 suppression at
these sites.
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Figure 5.27  Suppression at nAChR αΑ123, αΙ123, and αF124 with 74mer and pTyr(ONb)2.
Currents elicited by 200 µM ACh were measured 36 hr after the injection of 2 ng total mRNA in
the ratio of 10:1:1:1 α:β:γ:δ.
Early experiments in Kir2.1 provided little evidence for incorporation at Y242, even
though Tyr(ONb) was successfully suppressed at this position. (Figure 5.28) However,  it
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may well be the case that this situation may be remediated by optimization of suppression
conditions.
1 µA
100 ms
mRNA only tRNA-pTyr(ONb)2 tRNA-Tyr(ONb)
Figure 5.28  Attempted suppression at Kir2.1 Y242 with pTyr(ONb)2.  Currents were measured in
High K+ solution 48 hr after the injection of 12.5 ng total mRNA.
A final test that was performed with the phosphotyrosine analog involved recognition
of the residue by anti-phosphotyrosine antibodies.  A dot blot of 6 nmol of dCA-
pTyr(ONb)2 was performed.  Development of the blot with BAbCo PY72 anti-
phosphotyrosine antibody reveals that only irradiated dCA-amino acid is recognized by
the antibody.  (Figure 5.29)
pTyr + hν
pTyr – hν
pYIPLD
Figure 5.29  Dot blot of irradiated and non-irradiated dCA-pTyr(ONb)2 21  with the anti-
phosphotyrosine antibody PY72.  The right panel shows the pattern of spotting, where pYIPLD is
a positive control peptide.
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This experiment confirms that the residue, when caged, is inequivalent to
phosphotyrosine, but that the irradiated residue reflects the properties of native pTyr.
5.6 Synthetic methods
5.6.1 General experimental procedures
All reactions were run under positive argon pressure, except where indicated.  Anhydrous
solvents were obtained from BakerDRY™ drums and were used without further
purification.  Amino acids and most commercially available reagents were obtained from
Sigma-Aldrich.  Thin-layer chromatography was performed using Whatman glass plates
pre-coated with 60 Å silica gel. Nuclear magnetic resonance spectroscopy was performed
on divisional Bruker spectrometers at the following frequencies:  1H (300 MHz), 13C (75
MHz) 31P (121 MHz), 19F (282 MHz).  Mass spectrometry data were obtained from the
divisional facility.  Analytical and preparative HPLC was carried out using a Millipore
system with fixed-wavelength and diode-array UV detection fitted with a C18 reverse-
phase column.
5.6.2 Bis(nitrobenzyl) diisopropyl phosphoramidite 1
Diisopropyl phosphoramidous chloride (1 eq, 5 mmol) was thawed and dissolved in 4 mL
anhydrous THF.  In a flame-dried reaction vessel, nitrobenzyl alcohol (2 eq, 10 mmol)
and dry diisopropylethylamine (3 eq, 15 mmol) were combined in 10 mL dry THF.  The
flask was fitted with an addition funnel and cooled to 0 °C in a water/ice bath.  The
addition funnel was charged with the phosphoramidous chloride solution, and it was
added dropwise to the reaction flask.  After 30 min reaction at 0 °C, the ice bath was
removed and the reaction permitted to stir an additional 30 min at room temperature.
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TLC (1:1 ethyl acetate:hexane, Rf = 0.8) confirmed reaction, although some starting
nitrobenzyl alcohol remained.  Filtration of the precipitate in a coarse fritted funnel,
followed by washing with 25 mL ethyl acetate produced a clear, golden filtrate.  The
filtrate was washed with 25 mL saturated NaHCO3 and 25 mL saturated brine.  The
organic layer was dried over MgSO4 and concentrated to an amber solid by rotary
evaporation.  The residue was brought up in ether and purified by flash column
chromatography (1:20 triethylamine:ether, Rf = 0.9) to give a pale yellow solid in 70-75%
yield.  1H NMR (CDCl3) δ = 1.25 (d, J = 6.9 Hz, 12H), 3.75 (m, 2H), 5.17 (m, 2H), 7.44
(t, J = 9 Hz, 2H), 7.67 (t, J = 9 Hz, 2H), 8.10 (d, J = 8.1 Hz). 13C NMR (CDCl3) δ = 25.0,
25.1, 43.6, 43.7, 62.6, 62.9, 124.9, 128.0, 128.7, 134.0, 136.2, 136.3, 146.9. 31P NMR
(CDCl3) δ = 151.7. MS (ESI) Calcd for C20H27N3O6P (M+H)+: 436.16.  Found 458.2
(M+Na+)+, 474.2 (M+K+)+.
5.6.3 Boc-Tyrosine-OtBu 2
Commercially available Tyr-OtBu (1 eq, 3.46 mmol) was weighed into a flask and
dissolved in 25 mL dioxane:water (5:1).  Boc anhydride (1.2 eq, 4.16 mmol) was added,
which dissolved readily.  Triethlyamine (1.2 eq, 4.16 mmol) was added, without overt
effervescence.  After overnight stirring at room temperature, the reaction was monitored
by TLC (1:1 ethyl acetate:hexane, Rf = 0.6) and shown to be complete.  The reaction was
quenched by the addition of 50 mL of 1 M NaHSO4 and 50 mL CH2Cl2.  The reaction
mixture was then extracted thrice with CH2Cl2 (15 mL portions) and dried over Na2SO4.
After rotary evaporation, the crude product was dissolved in a minimum volume of ethyl
acetate:hexane (1:1).  Flash column chromatography (1:1 ethyl acetate:hexane)  gave the
pure compound in approximately 60% yield. 1H NMR (CD3CN) δ = 1.43 (s, 18H), 2.93
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(ABM, J = 25.2, 15, 7.8 Hz, 2H), 5.58 (d, J = 8.1 Hz, 1H), 6.78 (d, J = 6 Hz, 2H), 7.07
(d, J = 8.4 Hz, 2H). 13C NMR (CD3CN) δ = 27.5, 27.9, 28.3, 37.1, 56.2, 79.4, 81.6, 115.3,
115.5, 128.2, 130.5, 130.8, 155.7, 155.9, 171.4.
5.6.4 Boc-pTyr(ONb)2-OtBu 3
N- and C-terminally protected Boc-tyrosine-OtBu 2 (1 eq, 0.78 mmol) was combined
with freshly sublimed tetrazole (1.8 eq, 1.51 mmol) in a flame-dried flask fitted with a
stirbar.  Dry acetonitrile (10 mL) was added to solubilize the tetrazole, followed by 38
mL dry CH2Cl2.  The reaction vessel was cooled to 0 °C in a water/ice bath.  A solution
of bis(nitrobenzyl) phosphoramidite 1 (1.5 eq, 1.15 mmol, in 2 mL dry CH2Cl2) was
added dropwise via syringe.  After 5 min mixing at 0 °C, the ice bath was removed and
the reaction allowed to proceed 2.5 hr at room temperature.  TLC (1:1 ethyl
acetate:hexane, Rf = 0.7) revealed possible product formation.  Oxidation was performed
with tetrabutylammonium periodate (1.5 eq, 1.15 mmol) added in 5 mL dry THF.  After
10 min reaction at room temperature, TLC (1:1 ethyl acetate:hexane, Rf = 0.4) indicated
that the starting nitrobenzyl alcohol had been consumed.  The reaction was quenched
with 200 mL CH2Cl2 and washed twice (50 mL saturated NaHCO3, 50 mL saturated
NaCl).  The organic layer was dried over Na2SO4 and concentrated to a thin yellow oil
under reduced pressure.  Flash column chromatography (1:1 ethyl acetate:hexane) gave
the purified title compound in 93% yield.  1H NMR (CDCl3) δ = 1.36 (s, 18H), 3.05 (m,
2H), 4.42 (m, 1H), 5.1 (d, J = 12.9 Hz, 1H), 5.61 (d, J = 7.5 Hz, 4H), 7.17 (s, 4H), 7.52
(m, 2H), 7.7 (m, 4H), 8.13 (d, J= 8.1 Hz, 2H).  31P NMR (CDCl3) δ = -3.96.
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5.6.5 pTyr(ONb)2 4
Deprotection of N- and C-protected caged pTyr 3 was performed with TFA. Boc-
pTyr(ONb)2-OtBu (1 eq, 0.5 mmol) and p-methoxybenzene (6 eq, 3 mmol) were added to
a dry reaction vessel.  Dry CH2Cl2 (5 mL) was added to produce a clear yellow solution.
A 5 mL portion of trifluoroacetic acid was added.  The reaction was stirred 60 min at
room temperature,  resulting in a solution of variable color, ranging from salmon to
green.  TLC (1:20 triethlyamine:ether, Rf = 0.1, and 1:20 acetic acid:ethyl acetate, Rf =
0.2, developed with ninhydrin) revealed the removal of both protecting groups.  Volatiles
were removed under high vacuum, after which 10 mL toluene were added and the flask
returned to vacuum.  The resulting compound was taken on to the subsequent steps
without further purification or characterization.
5.6.6 4PO-pTyr(ONb)2  5
De-protected pTyr(ONb)2 4 was dissolved in 6 mL p-dioxane and 6 mL water.  Na2CO3
(1.4 eq, 0.67 mmol) was added.  Complete solubilization of reactants was achieved
through ad libitum addition of dioxane (approximately 10 mL).  4PO-anhydride (1.4 eq,
0.67 mmol) was added in one portion and reaction allowed to proceed 4 hr at room
temperature.  Starting material appeared completely converted by TLC (1:20 acetic
acid:ethyl acetate, Rf = 0.4).  The reaction was quenched with 25 mL of 1 M NaHSO4 and
25 mL CH2Cl2.  Extraction with CH2Cl2 (3x, 10 mL each) was followed by drying over
Na2SO4.  After rotary evaporation, the thin yellow oil was brought up in 1:20 acetic
acid:ethyl acetate and purified by flash column chromatography (1:20 acetic acid:ethyl
acetate).  Under the conditions used, a stiff gel formed in certain column fractions,
resulting in some loss of product.  Thus, the purified title compound was obtained in 31%
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yield.  1H NMR (CD3CN) δ = 2.22 (m, 4H), 3.06 (ABM, J = 50.6, 14.1, 4.8 Hz, 2H), 4.64
(m, 1H), 4.94 (m, 2 H), 5.58 (d, J = 7.8 Hz, 4H), 5.75 (m, 1H), 6.87 (m, 2H), 7.25 (m,
4H), 7.58 (m, 2H), 8.09 (d, J= 7.5 Hz, 2H). 13C NMR (CD3CN) δ = 29.6, 35.1, 36.5, 67.0,
68.0, 114.9, 117.6, 119.8, 120.3, 124.8, 125.6, 126.4, 128.1, 128.7, 129.0, 130.0, 131.3,
133.4, 134.5, 135.0, 135.5, 147.2, 149.2, 149.3, 172.8, 172.9. 31P NMR (CD3CN) δ = -
8.5. MS Calcd for C28H28N3O11P: 613.15  Found: (ESI+) 614.4 (M+H+)+, 636.4 (M+Na+)+,
652.0 (M+K+)+.  Found: (ESI–) 612.0 (M-H+)–.
5.6.7 4PO-pTyr(ONb)2 cyanomethyl ester 6
A dry flask was charged with 4PO-pTyr(ONb)2 5 (1 eq, 0.15 mmol), 1.5 mL dry DMF,
and 1.5 mL chloroacetonitrile (160 eq, 24 mmol).  Triethlyamine (3 eq, 0.45 mmol) was
added and the reaction stirred 8.5 hr at room temperature.  Progress was monitored by
TLC (1:1 ethyl acetate:hexane, Rf = 0.1 and ethyl acetate, Rf = 0.7).  The reaction was
quenched with 50 mL ethyl acetate and washed twice (25 mL saturated NaHCO3 and 25
mL saturated NaCl).  The organic portion was dried over Na2SO4 and the solvent
removed in vacuo.  Flash column chromatography (1:1 ethyl acetate:hexane) gave the
purified compound, typically in approximately 75% yield. 1H NMR (CDCl3) δ = 2.32 (m,
4H), 3.13 (d, J = 3.9 Hz, 2H), 4.75 (q, J = 35.7, 15.6 Hz, 2H), 5.01 (m, 2H), 5.63 (d, J =
6.0 Hz, 4H), 6.06 (d, J = 7.8 Hz, 1H), 7.18 (m, 2H), 7.53 (m, 2H), 7.66 (m, 4H), 8.14 (d,
J= 7.8 Hz, 2H). 13C NMR (CDCl3) δ = 29.6, 35.6, 37.1, 49.3, 53.1, 67.1, 67.2, 116.1,
120.5, 120.6, 125.3, 128.7, 128.8, 129.4, 130.9, 132.7, 134.4, 136.8, 170.3, 172.3. 31P
NMR (CDCl3) δ = -4.2. MS Calcd for C30H29N4O11P: 652.16.  Found: (ESI+) 653.2
(M+H+)+, 675.2 (M+Na+)+, 691.0 (M+K+)+.  Found: (ESI–) 516.0 (M-Nb)–.
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5.6.8 4PO-Serine 7
Serine (1 eq, 4.76 mmol) and Na2CO3 (1.4 eq, 6.66 mmol) were dissolved in 60 mL
water, 30 mL hexane.  A solution of 4-pentenoyl anhydride (1.4 eq, 6.66 mmol) in 15 mL
dioxane was added in one portion.  After 2 h at room temperature,  TLC (10:10:1 ethyl
acetate: hexanes: acetic acid, Rf = 0.7, developed with iodine and ninhydrin) revealed
complete conversion of starting amino acid.  Reaction was stopped by addition of 250
mL of 1 M NaHSO4 and 250 mL CH2Cl2.  After extraction with CH2Cl2 (3x, 100 mL
each), the aqueous layer was treated with 350 mL saturated NaCl solution and extracted
twice with 100 mL portions of THF.  The organic layers were combined and dried over
Na2SO4.  Solvent was removed by rotary evaporation and the residue brought up in
CH2Cl2.  Flash column chromatography (CH2Cl2 followed by 1:1 CH2Cl2:ethyl acetate)
was carried out, and the product isolated in nearly quantitative yield.  1H NMR (CD3CN)
δ = 2.38 (m, 4H), 3.89 (ABM, J = 26.7, 11.4, 3.9 Hz, 2H), 4.56 (m, 1H), 5.03 (m, 2H),
5.83 (m, 1H), 7.51 (d, J = 7.8 Hz, 1H).  13C NMR (CD3CN) δ = 29.8, 35.2, 54.9, 62.1,
115.3, 137.2, 172.4, 174.8.
5.6.9 4PO-Serine cyanomethyl ester 8
4PO-Serine 7 (1 eq, 4.5 mmol) was dissolved in 25 mL dry DMF.  To this solution were
added 25 mL chloroacetonitrile (88 eq, 395 mmol) and triethylamine (3 eq, 13.5 mmol).
Overnight stirring at room temperature  gave complete reaction (TLC in ethyl acetate, Rf
= 0.5).  Volatiles were removed under vacuum and the residue was dissolved in ethyl
acetate with a small amount of methanol.  Flash column chromatography (ethyl acetate)
gave the compound in 72% yield. 1H NMR (CD3CN) δ = 2.34 (m, 4H), 3.86 (dd, J =
23.4, 6 Hz, 2H), 4.56 (m, 1H), 4.84 (s, 2H), 5.05 (m, 2H), 5.86 (m, 1H), 7.25 (d, J = 7.8
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Hz, 1H).  13C NMR (CD3CN) δ = 29.7, 35.2, 54.2, 61.9, 115.2, 117.9, 137.6, 169.9,
173.3.
5.6.10 4PO-pSer(ONb)2 cyanomethyl ester 9
In a dry flask, 4PO-Ser cyanomethyl ester 8 (1 eq, 0.6 mmol) and tetrazole (1.8 eq, 1.08
mmol, used without purification) were combined.  Dry acetonitrile (7 mL) and dry
CH2Cl2 (30 mL) were added.  After complete dissolution, the flask was cooled to 0 °C in
a water/ice bath.  A solution of bis(nitrobenzyl) phosphoramidite 1 (1.5 eq, 0.92 mmol, in
2 mL dry CH2Cl2) was added dropwise via syringe.  The reaction was mixed for 5 min at
0 °C and then returned to room temperature.  After 2.5 hrs at room temperature, TLC (1:1
ethyl acetate:hexane, Rf = 0.3) confirmed that the starting material had been completely
converted.  After an additional 2.5 hr, the oxidant mCPBA (1.1 eq, 0.66 mmol, in 5 ml
dry CH2Cl2) was added and the reaction allowed to stir 15 min at room temperature.
After TLC (1:1 ethyl acetate:hexane, Rf = 0.2), the reaction stirred another 15 min and
was then quenched with 50 mL CH2Cl2 and washed twice (20 mL saturated NaHCO3 and
20 mL brine).  The aqueous phase was extracted with CH2Cl2 and the combined organic
phases dried over Na2SO4.  Rotary evaporation gave a yellow oil, which was purified by
flash column chromatography (1:1 ethyl acetate:hexane, to ethyl acetate after fraction 12)
in 27% yield. 1H NMR (CDCl3) δ = 2.35 (m, 4H), 3.99 (m, 2H), 4.47 (m, 1H), 4.81 (s,
2H), 5.51 (m, 4H), 5.79 (m, 1H), 7.06 (d, J = 7.5 Hz, 1H), 7.51 (m, 2H), 7.66 (m, 4H),
8.11 (d, J = 8,1 Hz, 2H).  13C NMR (CDCl3) δ = 29.5, 35.5, 67.1, 67.6, 67.7, 114.4, 115.9,
125.4, 129.0, 129.6, 129.9, 131.5, 134.4, 136.8, 147.0, 167.9, 172.9. 31P NMR (CDCl3)
δ = -0.52.
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5.6.11 4PO-Threonine 10
A reaction vessel was charged with threonine (1 eq, 4.20 mmol) and Na2CO3 (1.4 eq, 5.89
mmol) along with 60 mL water and 30 mL p-dioxane.  A solution of 4-pentenoyl
anhydride (1.4 eq, 5.89 mmol) was prepared in 15 mL dioxane and added to the reaction
vessel in a single portion.  TLC (10:10:1 ethyl acetate: hexanes: acetic acid, Rf = 0.7,
developed with iodine and ninhydrin) subsequent to 2 h stirring at room temperature
showed complete reaction.  The reaction was quenched (250 mL of 1 M NaHSO4 and 250
mL CH2Cl2) and extracted thrice with CH2Cl2 (100 mL portions).  Considerable amounts
of product remained in the aqueous layer, so it was treated with an equal volume of brine
and extracted twice with THF (100 mL each time).  The combined organic layers were
dried over Na2SO4 and concentrated.  A flash column was prepared in CH2Cl2 and the
residue re-dissolved in CH2Cl2.  Chromatography (CH2Cl2, followed by 1:1 CH2Cl2:ethyl
acetate) produced purified 4PO-threonine in 99% yield. 1H NMR (CD3CN) δ = 1.17 (d, J
= 6.3 Hz, 3H), 2.40 (m, 4H), 4.34 (d, J = 4.2 Hz, 1H), 4.51 (d, J = 6.3 Hz, 1H), 5.02 (m,
2H), 5.85 (m, 1H), 7.40 (d, J = 8.4 Hz, 1H). 13C NMR (CD3CN) δ = 19.7, 29.9, 35.2,
57.9, 67.7, 115.3, 137.3, 172.7, 174.6, 175.0.
5.6.12 4PO-Threonine cyanomethyl ester 11
To a flame-dried flask were added 4PO-threonine 10 (1 eq, 4.5 mmol), 25 mL dry DMF,
and 25 mL chloroacetonitrile (88 eq, 395 mmol).  After addition of triethylamine (3 eq,
13.5 mmol), the reaction was stirred overnight.  TLC (ethyl acetate, Rf = 0.6) indicated
complete reaction, and the solvent was removed under vacuum.  The residual solids were
brought up in a minimal volume of ethyl acetate with a few drops of methanol.  Flash
column chromatography (ethyl acetate) was performed and the compound isolated in
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68% yield. 1H NMR (CD3CN) δ = 1.16 (d, J = 6.3 Hz, 3H), 2.36 (m, 4H), 4.29 (m, 2H),
4.52 (dd, J = 8.4, 3 Hz, 1H), 4.83 (s, 2H), 5.05 (m, 2H), 5.87 (m, 1H), 7.06 (d, J = 8.4 Hz,
1H). 13C NMR (CD3CN) δ = 20.4, 29.8, 35.4, 50.3, 57.4, 67.3, 115.4, 117.8, 170.1, 173.6.
5.6.13 4PO-pThr(ONb)2 cyanomethyl ester 12
In a flame-dried flask, 4PO-Thr cyanomethyl ester 11 (1 eq, 0.77 mmol) was combined
with sublimed tetrazole (1.8 eq, 1.38 mmol).  By syringe, dry acetonitrile (10 mL) and
dry CH2Cl2 (34 mL) were added.  The flask was cooled to 0 °C in a water/ice bath after
the solids had completely dissolved.  A solution of bis(nitrobenzyl) phosphoramidite 1
(1.5 eq, 1.15 mmol, in 2 mL dry CH2Cl2) was slowly added.  After 5 min at 0 °C, the
reaction was allowed to warm to room temperature.  After 2.5 hrs at room temperature,
TLC (1:1 ethyl acetate:hexane, Rf = 0.3) suggested that reaction was complete.
Tetrabutylammonium periodate (1.5 eq, 1.15 mmol, in 5 ml dry THF) was added and the
reaction stirred 15 min at room temperature.  TLC (1:1 ethyl acetate:hexane, Rf = 0.2)
indicated complete conversion, and quenching with 60 mL CH2Cl2 was followed by
washing the organic layer (40 mL saturated NaHCO3 and 40 mL brine).  The combined
organic phases were dried over Na2SO4.  White needles were observed upon standing.
Rotary evaporation gave a yellow oil, which was purified by flash column
chromatography (7:3 ethyl acetate:hexane) in 30% yield. 1H NMR (CDCl3) δ = 1.23 d, J
= 6.3 Hz, 3H), 2.42 (m, 4H), 3.31 (m, 2H), 4.47 (m, 1H), 4.84 (s, 2H), 5.5 (m, 4H), 5.9
(m, 1H), 6.6 (d, J = 7.5 Hz, 1H), 7.6 (m, 2H), 7.8 (m, 4H), 8.2 (d, J = 8,1 Hz, 2H). 31P
NMR (CDCl3) δ = -0.62. Found: (ESI+) 590.8 (M+H+)+, 613.0 (M+Na+)+.
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5.6.14 Nitrobenzyl phosphite 17
In a 500 mL RBF, 1 mL PCl3 (1 eq, 11.4 mmol, Acros Organics) was added to 300 mL
dry ether.  The reaction was cooled to –78 °C and 4.95 mL triethylamine (3.1 eq, 35.5
mmol) were slowly added via syringe.  A small amount of white vapor was produced
during the addition.  After approximately 5 min stirring, a solution of 5.26 g nitrobenzyl
alcohol (3 eq, 34.3 mmol) in 60 mL dry ether  were added over 10 min through an
addition funnel.  Reaction continued for 2 hr at –78 °C, after which the reaction was
allowed to come to room temperature and stir overnight.  The copious cream-colored
precipitate was removed by filtration through a fine frit.  The solid was washed with ether
and the filtrate evaporated in vacuo to give 4.6 g yellowish solid with a single 31P
resonance (crude yield 82%).  Crystallization from ether gave 2.1 g of pure nitrobenzyl
phosphite as white crystals.  Only one crop was collected, then the filtrate was
rotovapped to recover the remaining crude product. 1H NMR (CDCl3) δ = 5.36 (d, J = 6.6
Hz, 6H),7.44 (t, J = 7.8 Hz, 3H), 7.63 (m, 3H), 7.77 (m, 3H), 8.06 (d, J = 8.4 Hz, 3H). 13C
NMR (CDCl3) δ = 61.8, 124.5, 129.6, 133.2, 135.0, 146.8. 31P NMR (CDCl3) δ = 143.13.
MS Calcd for C21H18N3O9P: 487.08.  Found: (ESI+) 488.2 (M+H+)+, 510.2 (M+Na+)+,
256.0 (M+K+)+.
5.6.15 Nitrobenzyl H-phosphonate 18
Similarly to the synthesis of nitrobenzyl phosphite 17, 1 mL PCl3 (1 eq, 11.4 mmol,
Acros Organics) and 3.34 mL triethylamine (2.1 eq, 23.9 mmol) were combined in 300
mL dry ether at -78 °C.  Nitrobenzyl alcohol was added (2 eq, 22.8 mmol, a solution of
3.50 g in 60 mL anhydrous ether) over 10 min via addition funnel.  The reaction was
stirred 2 hr at -78 °C and allowed to warm to room temperature overnight.  After
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approximately 12 hr total reaction time, 100 mL water were added and the reaction
stirred 30 min at room temperature.  The crystals were filtered out and washed with
water.  The filtrate was washed with 100 mL 5% K2CO3 and 100 mL water.  After drying
over Na2SO4, the ether was removed in vacuo to give 3.3 g orange solid (82% crude
yield).  Crystallization from ethanol gave 1.3 g pure nitrobenzyl H-phosphonate as off-
white crystals.  The remaining product was recovered from the mother liquor. 1H NMR
(CDCl3) δ = 5.53 (sept, J ≈ 6.2 Hz, 4H),7.14 (d, JP-H = 716.7 Hz, 1H), 7.75 (m, 2H), 7.68
(m, 4H), 8.09 (d, J = 7.2 Hz 2H). 13C NMR (CDCl3) δ = 64.5, 126.0, 128.0, 128.6, 129.6,
130.1, 132.2, 135.3, 146.8. 31P NMR (CDCl3) δ = 9.8 (m).  [H-coupled]:  9.3 (dquint, JP-H
= 711 Hz, J-CH-O-P = 8.3 Hz).
5.6.16 4PO-Tyrosine 19
Tyrosine (1 eq, 4.14 mmol) and sodium carbonate (1.4 eq, 5.7 mmol) were weighed into
a 250 mL round-bottom flask equipped with a stirbar.  A total of 60 mL water and 60 mL
dioxane were added, until both solids were nearly completely dissolved.  4-Pentenoic
anhydride (1.4 eq, 5.7 mmol) was added in a single portion and the reaction stirred at
room temperature.  Progress was monitored by TLC (1:20 acetic acid:ethyl acetate, Rf =
0.5, developed with iodine and ninhydrin).  After 4 h, 10 mL of 1 N HCl were added
(resulting in a pH of approximately 4.5) and the reaction stirred 15 min to hydrolyze any
pentenoyl ester formed from side chain reactivity.  The reaction was quenched with 100
mL of 1 M  NaHSO4 and 200 mL CH2Cl2.  The organic layer was removed, and the
aqueous layer was treated with 200 mL saturated NaCl and extracted thrice with 50 mL
portions of THF.  The combined organic layers were dried over Na2SO4 and solvent
evaporated in vacuo.  The crude mixture was re-dissolved in a minimal volume of ethyl
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acetate with a small amount of methanol and loaded on a silica gel column.  Flash
column chromatography (1:20 acetic acid:ethyl acetate) gave purified product in 75%
yield.  1H NMR (CD3CN) δ = 2.25 (m, 4H), 2.99 (ABM, J = 30.9, 14.1, 5.7 Hz, 2H), 4.62
(m, 1H), 4.96 (m, 2H), 5.7 (m, 1H), 6.75 (d, J = 6.6 Hz, 2H), 6.93 (d, J = 8.1 Hz, 1H),
7.06 (d, J = 4.5 Hz, 2H).
5.6.17 4PO-Tyrosine cyanomethyl ester 20
A solution of 4PO-tyrosine 19 (1 eq, 0.44 mmol) was prepared in 2 mL dry DMF and 2
mL chloroacetonitrile (107 eq, 31.6 mmol).  Triethylamine (3 eq, 1.32 mmol) was added
and the reaction stirred 6 h at room temperature.  TLC (ethyl acetate, Rf = 0.5) showed the
reaction to be complete.  Solvent was removed under high vacuum and the residue
dissolved in 10:1 CH2Cl2:ethyl acetate with a few drops of methanol.  Flash column
chromatography (ethyl acetate) produced the title compound in 56% yield. 1H NMR
(CD3CN) δ = 2.24 (m, 4H), 2.99 (ABM, J = 30.9, 14.1, 5.7 Hz, 2H), 4.64 (m, 1H), 4.77
(s, 2H), 5.00 (m, 2H), 5.8 (m, 1H), 6.74 (d, J = 4.8 Hz, 2H), 6.85 (d, J = 7.5 Hz, 1H), 7.06
(d, J = 8.7 Hz, 2H). MS Calcd for C16H18N2O4: 302.13.  Found (ESI–):  301.2 (M-H+)–,
337.0 (M+Cl)–.
5.6.18 dCA-4PO-pTyr(ONb)2  21
4PO-pTyr(ONb)2 cyanomethyl ester 6 (1 eq, 0.05 mmol) was dissolved in 0.8 mL dry
DMF in a flame-dried 5 mL conical flask fitted with a stirbar.  The dinucleotide dCA (10
mg) was added in one portion, and the reaction was allowed to continue 3 h at room
temperature.  The reaction was monitored by analytical HPLC (gradient: 25 mM
ammonium acetate, pH 4.5 to CH3CN).  The addition of tetrabutylammonium acetate was
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necessary to promote reaction.  Upon completion of the reaction, the pure compound was
obtained by preparative HPLC (gradient: 25 mM ammonium acetate, pH 4.5 to CH3CN).
MS (ESI) Calcd for C47H52N11O23P33: 1231.25. Found (ESI–):  546.0 (M-Nb)2–, 806.2 (M-
Nb-pdC)–.  Found (MALDI–):  1265.1 (M+Cl–)–.  Found (MALDI+): 1097.2 (M-Nb)+,
962.2 (M-2Nb)+.
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